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Introduction and scope of the thesis 
Introduction and scope of the thesis 
Lower urinary tract symptoms (LUTS) are accepted by most 
cultures as an inevitable consequence of aging.1-2 LUTS are suggested to 
be caused by benign prostatic hyperplasia (BPH) and are traditionally 
labelled as 'prostatism'. The term 'prostatism' implies both cause and 
remedy and has been in widespread usage for over two decades. This term 
regrettably does not describe what it implies.3 Therefore, Abrams sug­
gested that the terminology in this area should be redefined.4 BPH is a 
histological diagnosis that affects approximately 45 % of men at 60 years 
of age1 and has been shown by Berry et al to occur in 88 % of men aged 
over 80. 6 Although BPH is prevalent, it may not lead to the clinical diag­
nosis benign prostatic enlargement (ΒΡΕ) or to the urodynamical diagnosis 
benign prostatic obstruction (BPO). Similarly, even though BPO exists, the 
patient may not be troubled by LUTS.4 Consequently, prior to any treat­
ment one should be informed about the origin of the complaints. 
The incidence and clinical significance of LUTS have been increas­
ingly difficult to evaluate, since the indications for therapeutic intervention 
have shifted from attempts to preserve life in elderly patients to those 
improving quality of life of younger patients. Also, as we move into an era 
where alternatives to surgery are increasingly used, the time has come to 
consider which diagnostic criteria should be established before any phar­
macological, minimally invasive or invasive treatment can be recom­
mended. To assess patient's complaints, subjective variables can be used 
such as symptom scores and/or objective variables such as prostate 
volume and voiding studies. Most urologists agree that only patients with 
BPO should undergo surgical intervention but nevertheless, the decision for 
surgery is usually based primarily on the nature and severity of symptoms. 
Considerable controversy surrounds not only the initial evaluation 
of men with LUTS but also the most appropriate means of assessing 
response to treatment.8·7 In this thesis, in chapter 2-5, the significance of 
the aforementioned micturition variables in the assessment of patients 
with LUTS is investigated. Furthermore, in chapter 6-8, the impact of 
noninvasive, minimally invasive and invasive treatments on subjective and 
objective micturition variables is quantified and compared within groups 
with various degrees of bladder outlet obstruction (BOO). 
Evaluation of men with LUTS: Symptoms 
A significant advance in recent years has been the introduction of 
validated symptom questionnaires used by the majority of urologists.8 The 
most popular of these, the American Urological Association (AUA) symp­
tom index, later adopted by the World Health Organization as the Interna-
12 
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tional Prostate Symptom Score (l-PSS), has been demonstrated to have 
high test-retest reliability and to correlate strongly with the patients' 
degree of bother from their urinary condition.9"12 The total symptom score 
derived from this index can be divided into storage and voiding symptoms.4 
Storage symptoms are correlated with the filling phase of the urinary 
bladder and voiding symptoms with the voiding phase. Examples of 
storage symptoms derived from the l-PSS questionnaire are repeated 
micturition, urge, and nocturia. Examples of voiding symptoms are 
intermittency, weak stream and push or strain to begin micturition. 
Although the l-PSS is now widely used, there are several potential 
difficulties with its use in men with LUTS. First, the ability of men to 
translate their voiding characteristics accurately into a scoring index is 
unclear. Matzkin et al prospectively correlated the AUA symptom score 
with voiding patterns determined subsequently by a home uroflowmetry 
system in 42 men referred for the evaluation and treatment of LUTS.13 
They found that men overestimated daytime frequency and that the 
perception of intermittent and weak stream was poorly correlated with the 
results of uroflowmetry. Second, LUTS are nonspecific and may be 
attributed to physiologic changes in the aging detrusor,3 or even from habit 
and changes in lifestyle that commonly occur as men grow older. This is 
well demonstrated by the similar pattern and intensity of voiding symp-
toms seen in an age-matched female population.14 Third, symptom ques-
tionnaires have been validated in groups of patients with the clinical 
diagnosis of 'BPH', but in only one, the l-PSS, has the relationship 
between symptoms and clinical objective measurements including the 
urodynamic diagnosis of BOO been investigated.16"18 The relationship 
between symptoms and urodynamic findings of the l-PSS questionnaire 
appeared to be rather poor. Obviously, symptom scores measure the 
severity of symptoms but do not tell a physician the reasons for the 
symptoms. Fourth, the prevalence of symptoms in the community is 
greater than the number of men who seek medical or surgical help indicat-
ing that men do not always perceive that their LUTS cause them prob-
lems.1,11 The perception of LUTS seems to be a personal matter that could 
be dissimilar among men in different age groups and various environmental 
and socio-demographic circumstances. 
In 1991, the International Continence Society (ICS) started an 
international multicentre study in patients with LUTS suggestive of BOO, 
to validate a new questionnaire incorporating all urinary symptoms (22 
questions measuring 20 symptoms), related problems (from 19 symptoms) 
and quality of life issues that could be indicative of BPO, detrusor instabil-
13 
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ity and detrusor underactivity and other urinary conditions.18 The ICS-
'BPH' questionnaire differs from the AU A questionnaire in the number of 
questions and in the sequence of the problem questions. In the AUA 
questionnaire, the symptoms questions are the first that have to be 
completed. Hereafter, for each specific symptom question, the degree of 
problem that they cause is assessed. In the ICS-'BPH' questionnaire the 
degree of problem is assessed directly after each specific symptom 
question (example in chapter 3). The aims of the ICS-'BPH' study were: 1) 
to investigate the relationship between the results of urodynamic studies 
and a wide range of urinary symptoms; 2) to develop and validate an ICS-
'BPH' symptom score for use in research and clinical practice and 3) to 
compare pre- and post-treatment symptoms with the results of advanced 
urodynamic pressure-flow study evaluation, used as the 'gold standard' 
for the quantification of the degree of obstruction in elderly men20, in order 
to be able to define the characteristics of patients who will benefit from 
the currently used therapies. 
In chapter 2 and 3, the results of the ICS-'BPH' study are reported. 
In chapter 2, international differences in the reporting of LUTS, and related 
bother in patients with LUTS suggestive of BOO are investigated. In 
chapter 3, the relationship between a wide range of symptoms from the 
ICS-'BPH' questionnaire and the results of urodynamic pressure-flow 
studies is reported. 
Evaluation of men with LUTS: prostate volume 
Estimation of the prostate volume is an important variable in the 
assessment of patients with LUTS. Transrectal ultrasound (TRUS) of the 
prostate is now widely used to support the diagnosis and choice of 
treatment.21 TRUS currently provides the most accurate means of measur-
ing prostate volume and also demonstrates the true extent of transition 
zone (TZ) enlargement.22 According to McNeal's assumption of zonal 
anatomy of the prostate, the TZ is the major site for development of 
benign prostatic hyperplasia.23 The traditional theory is that with the 
enlargement of the adenoma, the adenoma compresses the outer part of 
the gland, the peripheral zone that is traditionally known as the surgical 
capsule. The relationships between symptoms and total prostate volume 
have been described by Ezz El Din et al who in 803 patients found no 
correlation.18 The correlation between urodynamic variables of obstruction 
and total prostate volume have been shown to be statistically significant 
but weak.24,26 The value of volumetric determination of the TZ was 
recently reported in several studies. Hammerer et al assessed the unique 
14 
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relationship of TZ tissue to prostate specific antigen (PSA) elevation and 
underscored the importance of considering the TZ as a source of false-
positive diagnosis of prostate cancer.26 Hence, determination of the whole 
prostate volume and TZ volume by TRUS may increase the sensitivity of 
PSA in detecting prostate cancer. Tempany et al analyzed differential zonal 
volumes and their changes after treatment with finasteride and concluded 
that the TZ was more affected by medical treatment than the peripheral 
zone.27 Using these ideas, some studies investigated whether separation of 
the peripheral zone volume from the adenoma would improve the correla-
tion with other clinical and urodynamic variables. Furthermore, the relation 
between the TZ and total gland volume, expressed as TZ index was 
reported to correlate better than total volume alone with other clinical and 
urodynamic variables.28 
Chapter 4 deals with the question if transrectal ultrasound 
measurement of the TZ of the prostate and the ratio between TZ volume 
and total prostate volume (TZ index) correlates better with the results of 
clinical and urodynamic investigations than total prostate volume alone. 
Evaluation of men with LUTS: Uroflowmetry 
For decades uroflowmetry has played a major role in the evaluation 
of LUTS. Urologists use measurements of uroflowmetry along with patient 
symptoms and other clinical findings to make decisions regarding the need 
for therapeutic intervention. Besides its diagnostic role, uroflowmetry has 
evolved as one of the most important investigations in the assessment of 
the efficacy of drug treatments and other therapies in patients with LUTS. 
It is a noninvasive measurement technique that is simple to perform, the 
results are readily available, and sophisticated flowmeters are easy to 
use.28 The most modern flowmeters allow the measurement of voided 
volume, maximum flow, mean flow, time to maximum flow, voiding time 
and flow time. Moreover, the flow pattern can be described. Among the 
many variables, maximum flow is regarded as the most useful to assess 
the degree of obstruction and to monitor treatment effects. Despite its 
popularity, uroflowmetry is hampered by several draw-backs including its 
inability to differentiate between bladder outlet obstruction and impaired 
detrusor activity,30 artifacts,31 reproducibility,32 circadian changes32'36 and 
intra and interobserver variation.38 
It is clear that in clinical trials, these draw-backs may have a 
negative impact on sample size requirements to achieve statistical 
power.31 In chapter 5, a computerized method of validation of 
15 
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uroflowcurves is described. This computerized method of validation of 
uroflowcurves was developed for clinical research purposes with the aim 
to part with the interexperts variation and to minimize the intraobserver 
variation and the variability of maximum flow rate by automatic artifact 
detection and correction. The results of this computerized method were 
compared with the results obtained after visual correction by the experts. 
Single uroflowmetry may not be sufficiently reliable for the determi-
nation of bladder outlet obstruction because many patients are unable to 
relax and void in the normal fashion while at the clinic. Therefore, Blaivas 
suggested that multiple samples are most efficient for enhancing an 
accurate assessment.37 For this reason, many units have developed urine-
flow clinics to obtain multiple uroflowmetry results. Although this 
approach increases the number of reliable measurements, it is still not an 
ideal situation, being time-consuming for both the patient and doctor, 
while the patient is still not voiding under 'normal conditions'. To over-
come these problems, several home-based systems of uroflowmetry have 
been introduced.32'34,38 In chapter 5, a new portable home-based 
uroflowmetry system designed and developed to provide reliable results, is 
easy to use by the patient at home, has quality-control of flow-measure-
ment, is hand-held for practical use, uses hygienic disposable beakers and 
from which the results are quickly and easily available, was used to 
investigate variability and circadian changes of uroflow. 
Evaluation of men with LUTS: Urodynamic pressure-flow studies 
During the WHO international consultation on BPH in 1993, it was 
advised that, if obstruction is the endpoint of the study, pressure-flow 
studies before and after treatment should be used in the evaluation of new 
therapies.38 A pressure-flow study is recognized as the gold standard in 
diagnosing bladder outlet obstruction.20 Urodynamic investigation is a 
physiologic study that determines the response of the bladder to filling and 
emptying. The investigation consists of artificial bladder filling; a 
cystometrogram and intravesical pressure recording. To evaluate bladder 
function during micturition the intravesical pressure is measured with 
simultaneous recording of uroflow. The analysis of BOO by means of 
urodynamic investigation with analysis of the ratio of pressure and flow 
during micturition will be discussed in detail in chapter 6 of the thesis. 
The current treatment modalities available for the patient with 
LUTS are diverse. Transurethral resection of the prostate is no longer the 
only treatment option available. Presently, watchful waiting and a variety 
of medical, minimally invasive and surgical approaches exist for the patient 
16 
Chapter 1 
with LUTS. With regard to medications, there are the σ1-adrenergic 
antagonists (alfuzosin, doxazosin, tamsulosin and terazosin) and the 5-σ-
reductase inhibitors (finasteride). The minimally invasive procedures that 
are now available include balloon dilatation of the prostate, urethral stents, 
transurethral thermotherapy, transurethral needle ablation, laser ablation of 
the prostate, transurethral incision of the prostate and there are a number 
of new approaches now under development and being investigated. All 
these treatment modalities have shown that they are able to improve the 
symptoms of patients with LUTS. However, there is a large placebo factor: 
more than one third of the patients with LUTS who remain untreated or are 
treated with a sham procedure or a placebo experience spontaneous 
improvement based on subjective criteria.40 The spontaneous improvement 
based on objective criteria is reported to be smaller than that based on 
subjective criteria.40 Pressure-flow studies enable us to investigate the 
relationship between subjective efficacy of treatment and objective voiding 
variables. 
Previously, when the therapeutic choice was limited to surgery or 
watchful waiting, pressure-flow evaluation was simply used to diagnose 
bladder outlet obstruction. Because new, less invasive treatment 
modalities are now available, precise grading of obstruction is increasingly 
important in the objective evaluation of treatment efficacy.4 1 The clinical 
nomogram used in our study has 7 obstruction categories, and is more 
detailed than a diagnosis of obstruction or no obstruction.4 2 Pressure-flow 
evaluation is able to provide a continuous numeric scale of obstruction 
and, therefore, is even more refined. 
Although the use of pressure-flow studies does lead to a more 
accurate diagnosis of BOO, the most important issue remains whether this 
improved distinction leads to a sufficiently better treatment outcome to 
justify its use.7 
In chapter 6-8, the impact of noninvasive, minimally invasive and 
invasive treatments on subjective and objective micturition variables is 
quantified and compared within groups with various degrees of BOO. 
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International differences in symptoms and related bother 
Abstract 
Purpose: We investigated international differences in the reporting of 
lower urinary tract symptoms (LUTS) and related bother in patients with 
LUTS suggestive of bladder outlet obstruction (BOO). 
Material and methods: Multiple logistic regression analysis has been used 
to evaluate international differences in the reporting of LUTS and related 
bother in 1271 patients from 12 countries who participated in the ICS-
'BPH' study. 
Results: Country of origin was significantly associated with the preva-
lence of a large number (10 out of 20) of lower urinary tract symptoms, 
even after adjusting for potentially confounding variables including both 
physical and socio-demographic factors. Country of origin was also signifi-
cantly associated with the reporting of bother, but for a much smaller 
number (2) of symptoms. 
Conclusions: In different countries, LUTS may be reported to different 
extents. Therefore, the results of studies in particular countries may not be 
generally applicable to other countries. It is likely that symptom scores will 
conceal this variation, necessitating either the consideration of individual 
symptoms (as in the ICS-'BPH' study) or the development of country-
specific scoring systems. An alternative would be to focus on bother, 
which appeared to be much less sensitive to international differences. 
Introduction 
Lower urinary tract symptoms (LUTS), traditionally labelled as 
'prostatism', are accepted by most cultures as an inevitable consequence 
of aging.1,2 The term 'prostatism' implies both cause and remedy, whereas 
in reality the condition results not only from infravesical bladder outlet 
obstruction (BOO) caused by the enlarged prostate gland, but also from 
motor or sensory abnormalities of detrusor and urethral function3, or even 
from changes in habits and lifestyle that commonly occur as men grow 
older. Race, food, country of origin and other environmental factors are 
reported to be related to the prevalence of LUTS, but epidemiological 
studies are subject to many pitfalls, and the data have to be interpreted 
with great caution particularly because a widely accepted definition of 
'clinical benign prostatic hyperplasia' ('BPH') has not been established.2,4S 
The reported international differences in the prevalence of LUTS may 
reflect true differences in the prevalence of 'BPH', but they may also be 
related to cultural differences in the perception of or in the willingness to 
report symptoms. The prevalence of symptoms in the community is 
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greater than the number of men who seek medical or surgical help, indicat­
ing that men do not always perceive that their LUTS cause them prob­
lems.16 The perception of LUTS seems to be a personal matter that could 
be dissimilar among men in different age groups, and various environ­
mental and socio-demographic circumstances. Recently, Abrams has 
suggested that the terminology in this area should be redefined.7 BPH is a 
histological diagnosis that has been shown by Berry et al to occur in 88 % 
of men older than 80 years.8 Although prevalent, BPH may not lead to the 
clinical diagnosis of benign prostatic enlargement (ΒΡΕ) or to the 
urodynamical diagnosis of benign prostatic obstruction (BPO). Similarly, 
even though BPO exists, the patient may not be troubled by LUTS.7 
Many questionnaires have been developed for use by patients with 
LUTS.9·10'11·12·'3 Four questionnaires 8·10·13·14 have been validated in patients 
with the clinical diagnosis of 'BPH', but to our knowledge none has 
investigated the relationships with the urodynamic diagnosis of BOO. 
In 1991, the International Continence Society (ICS) started an 
international multicentre study in patients with LUTS suggestive of BOO, 
to validate a new questionnaire incorporating all urinary symptoms, related 
problems and quality of life issues that indicate BPO, detrusor instability, 
detrusor underactivity and other urinary conditions. The aims of the study 
were: 1) to investigate the relationship between the results of urodynamic 
studies and a wide range of urinary symptoms; 2) to develop and validate 
an ICS-'BPH' symptom score for use in research and clinical practice and 
3) to compare pre- and posttreatment symptoms with the results of 
advanced urodynamic pressure-flow study evaluation, used as the 'gold 
standard' for the quantification of the degree of obstruction in elderly 
men16, in order to be able to define the characteristics of patients who will 
benefit from the currently used therapies. 
We investigated international differences in the reporting of LUTS 
and related bother in patients with LUTS suggestive of BOO. 
Patients and methods 
In the ICS-'BPH' study, 1271 patients over 45 years of age with 
LUTS suggestive of BOO who were well enough to undergo prostatic 
surgery, if appropriate, were recruited from general urology practices in 12 
countries (table 1). Patients were excluded from the study if they had an 
abnormal result of the mid-stream urinary specimen analysis or if they had 
significant other urological disease, such as prostate cancer, neurological 
disease or previous prostatic surgery, or if they were taking medication 
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active on the lower urinary tract. 
All patients were evaluated at baseline by medical history, including 
questions concerning the location of the patient's home (city/town centre, 
suburbs, village/rural), marital status (married/living as married, single), 
work situation (in active work, retired, unemployed), and the pre-operative 
anaesthetic risk as indicated by the physician (minimal, moderate/severe). 
Symptoms were evaluated by the ICS-'BPH' study questionnaire, which 
allows men to report the frequency of symptoms associated with the 
filling, voiding and post-voiding phases, and also to assess the degree of 
bother that they cause.14 The questionnaire also contains specific ques-
tions that focus on issues concerned with sexual function and the effects 
of symptoms on daily life. The ICSma/e questionnaire was developed in 
English and then professionally translated into 10 other languages. Each 
translation was then back translated and evaluated by a lay advisor or 
senior urologist from each country who was nominated as a national co-
ordinator for the ICS-'BPH' study.14 Donovan et al demonstrated that with 
the ICSma/e questionnaire it was possible to differentiate between men in 
clinical and community populations, and to detect the expected positive 
age gradient for most symptoms in the community group. There was 
reasonable agreement between relevant parts of the questionnaire, and the 
frequency and volume charts. Internal consistency was high, and overall 
the questionnaire demonstrated good test-retest reliability.14 Furthermore, 
patients underwent a physical examination, including digital rectal examin-
ation with estimation of the prostatic volume and an optional 
ultrasonographic examination of the prostate, three free urinary 
flowmetries with subsequent measurement of residual urine volume, the 
flow with the highest maximum flow rate being used for the analysis, and 
urodynamic pressure-flow studies. 
Statistics were used to describe the patient population, and to 
provide an overview of the reported prevalence of each symptom and 
related problem for each country. Differences across the countries in 
medians for quantitative variables, and differences in distributions for 
categorical variables, were tested with the Kruskal Wallis One Way 
analysis of variance and chi-square tests, respectively. The impact of 
country of origin was studied on the reported prevalence of symptoms and 
related bother by using multiple logistic regression analyses. 
Initially, international differences for each symptom and related 
bother were tested by entering country alone (represented by 10 dummy 
variables) into a logistic regression model. The second step was to deter-
mine if adjusting for confounding variables changed these results. The 
possible confounding variables included location of the patient's home, 
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marital status, patient's work situation and pre-operative anaesthetic risk 
as indicated by the physician (all categorical); age, maximum flow rate and 
prostatic volume (quantitative). 
The logistic regression analysis was carried out using data from 
977 patients for whom complete data were available. Odds ratios and 
9 5 % confidence intervals (CIs) were calculated for each country using the 
UK as the reference country. Given the number of significance tests 
performed in each analysis, statistical significance should be interpreted 
with caution. Applying the Bonferroni correction for multiple testing would 
imply a cutoff point of about 0.0025 for each individual ρ value to retain 
an overall 5% significance level. Since the symptoms were strongly associ­
ated with each other, such a correction would be conservative. Therefore, 
for the present analyses a cutoff point of 1 % was used, with significance 
between 1 % and 5% being regarded as marginal. 
Results 
Patients with a wide range of objective variables, such as maximum 
flow rate, voided volume and residual volume, were included in the study 
(table 1). When comparing age, voided volume, maximum flow rate, 
residual volume, estimated prostatic volume, marital status, location of the 
patient's home, type of house, work situation and pre-operative anaes­
thetic risk, significant differences (p < 0.02) were apparent for all of the 
variables, indicating that overall patients recruited from the various coun­
tries were different. 
This can be illustrated by the following factors. The largest group 
of patients from the UK were aged between 60 and 69 years (45%), lived 
in the suburbs (88%) and were retired (72%), while 2 4 % were in active 
work. In Germany equal percentages of patients were between 60 and 69 
years old (40%) and less than 60 years old (40%). German patients were 
more likely to live in a city (65%) and 7 7 % were retired, while 2 1 % were 
in active work. The largest group of patients in Italy were older than 70 
years (43%), lived in a village (50%), and 7 7 % of them were retired. 
Although the majority of Japanese patients (53%) were older than 70 
years, the proportion in active work was considerable (40%), while only 
6 0 % were retired. 
The prevalence of each of the symptoms and the proportion of men 
reporting problems among those who had the symptom for the various 
countries as well as in the entire study group are shown in tables 2 and 3. 
In the entire study group voiding symptoms tended to be the most fre­
quently reported, whereas the most bothersome were storage symptoms.18 
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The results of the logistic regression analysis are shown in tables 4-
7. After controlling for possible confounding variables, country of origin 
was strongly significantly associated (p<0.01) with the prevalence of 10 
of the 20 symptoms: terminal dribble, intermittency, hesitancy, urgency, 
repeated urination, postmicturition dribble, urge incontinence, burning, 
bladder pain and sitting to urinate (table 4). In addition, 5 symptoms were 
marginally significant (0.01 <p<0 .05 ) : nocturia, strain to continue, strain 
to start, incontinence of no apparent cause, and urinary retention. Only 
one symptom, stress incontinence, was significant before but not after 
controlling for confounding factors. On the other hand, hesitancy became 
more significant after adjustment. 
Table 5 presents odds ratios (95% CIs) for the symptoms listed as 
significant in table 4. All countries were compared to the UK. Results for 
Canada, Portugal, Australia and Israel should be interpreted with caution 
given the relatively small numbers. The patterns evident are different for 
each country but there were some similarities. For example in the Nether-
lands, Denmark and Germany, the symptoms of strain to continue, strain 
to start and sitting to urinate were considerably more prevalent than in the 
UK, whereas hesitancy was less prevalent. Urgency and repeated urination 
were both less prevalent in Italy, Sweden, Japan, the Netherlands and 
Germany than in the UK. In other respects a considerably different pattern 
of symptoms was evident in Japan. In Japan only urinary retention was 
more prevalent than in the UK, while terminal dribble, intermittency, 
hesitancy, urgency, repeated urination, post-micturition dribble, urge 
incontinence, burning, bladder pain, and incontinence of no known cause 
were all less prevalent. Interestingly, all countries had a greater prevalence 
of urinary retention than the UK. Overall there were marked variations in 
the symptomatology across countries. 
After controlling for possible confounding variables, country of 
origin was strongly significantly associated (p<0.01) with bothersomeness 
for only 2 of the 19 symptoms for which bothersomeness was assessed: 
hesitancy and strain to start (table 6). In addition, 4 symptoms were 
marginally significant (0.01 <p<0 .05 ) : terminal dribble, reduced stream, 
incomplete emptying and strain to continue. Three of these 4 symptoms 
had been highly significant before controlling for confounding factors, 
while strain to continue was unaffected by adjustment. Of the 13 symp-
toms not significant after adjustment only 3 were even marginally signifi-
cant originally (intermittency, urgency and bladder pain). 
Table 7 presents odds ratios (95% CIs) for the symptoms listed as 
significant in table 6. All countries were compared to the UK. Results for 
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Table 4. Statistica/ significance from logistic regression models of the associ­
ation between the prevalence of each symptom and country of origin 
before and after adjusting for confounding factors. 
Symptom Unadjusted ρ value for Adjusted ρ value for country 
country 
< 0.01 
0.51 
< 0.01 
< 0.01 
0.14 
< 0.01 
0.01 
< 0.01 
0.01 
< 0.01 
0.03 
< 0.01 
0.10 
< 0.01 
< 0.01 
0.03 
< 0.01 
0.15 
0.02 
0.56 
Canada, Portugal, Australia and Israel should be interpreted with caution 
given the relatively small numbers. Again, the pattern for Japan was rather 
different from the other countries, with all 6 symptoms much more 
bothersome than in the UK. In Germany, terminal dribble, reduced stream, 
hesitancy and incomplete emptying were also highly bothersome, whereas 
for the other countries, only Italy and Sweden had a suggestion of marked­
ly greater levels of bother than the UK for 2 symptoms each (terminal 
dribble and strain to continue). There was only 1 instance when 
bothersomeness was significantly less than in the UK - for strain to start in 
the Netherlands. 
terminal dribble 
reduced stream 
intermittency 
hesitancy 
incomplete emptying 
urgency 
nocturia г 2 per night 
repeated urination 
strain to continue 
postmicturition dribble 
strain to start 
urge incontinence 
frequency 2: 9 per day 
burning 
bladder pain 
incontinence no cause 
sitting to urinate 
stress incontinence 
urinary retention 
nocturnal incontinence 
< 0.01 
0.42 
< 0.01 
0.02 
0.07 
< 0.01 
< 0.01 
< 0.01 
0.02 
< 0.01 
0.02 
< 0.01 
0.12 
< 0.01 
< 0.01 
0.03 
0.01 
0.04 
0.03 
0.18 
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Table 6. Statistical significance from logistic regression models of the associ­
ation between the bothersomeness of each symptom and country of 
origin before and after adjusting for confounding factors. 
Bother 
terminal dribble 
reduced stream 
intermittency 
hesitancy 
incomplete emptying 
urgency 
nocturia it 2 per night 
repeated urination 
strain to continue 
postmicturition dribble 
strain to start 
urge incontinence 
frequency г 9 per day 
burning 
bladder pain 
incontinence no cause 
sitting to urinate 
stress incontinence 
nocturnal incontinence 
Unadjusted ρ value for 
country 
< 0.01 
< 0.01 
0.02 
< 0.01 
< 0.01 
0.04 
0.07 
0.23 
0.03 
0.57 
< 0.01 
0.93 
0.84 
0.31 
0.02 
0.75 
0.88 
0.93 
0.93 
Adjusted ρ value for country 
0.03 
0.04 
0.31 
< 0.01 
0.01 
0.14 
0.17 
0.17 
0.03 
0.66 
< 0.01 
0.33 
0.82 
0.25 
0.11 
0.33 
0.74 
0.96 
0.88 
Discussion 
Although international variations in the prevalence of specific LUTS 
were clearly demonstrated in this study, the evidence that related bother 
differed among countries was much weaker. However, it must be con­
sidered that in this study the participating countries contributed dissimilar 
groups of patients with respect to the investigated variables of age, voided 
volume, maximum flow rate, residual volume, estimated prostatic volume, 
marital status, the location of the patient's home, the patient's work 
situation and the preoperative anaesthetic risk as indicated by the phys­
ician. Since these confounding factors may explain some of the interna­
tional variations, we examined these variations after adjusting for poten­
tially confounding factors. It must be recognized that there are several 
other potential confounding factors for which data were not available, 
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such as financial status, religion, occupation, hobbies, linguistic problems 
and cultural differences in the perception of or willingness to report symp-
toms, as well as variations in decision making by general practitioners, 
variations in the availability of treatments for LUTS, underlying variations 
in the prevalence of benign prostatic enlargement and prostatic obstruction 
and differences in health care delivery systems. 
After adjustment, country of origin was significantly associated 
with half of the symptoms measured, including both storage and voiding 
symptoms of both high and low prevalences. Controlling for a range of 
potential confounding variables had little effect on these relationships. 
There are two possible explanations for this finding. It may be that insuffi-
cient allowance has been made for potential confounders, or there may be 
real international differences in symptom reporting among these men. 
However, these international differences may arise from a number of 
sources, such as patient selection, health care organisation and percep-
tions of symptoms. In particular, the wide differences noted in the 
prevalences of urinary retention support the suggestion that patient 
selection may be different in these countries. 
It is notable that there were not such marked differences for 
bothersomeness, although the symptoms for which there were interna-
tional differences were all voiding symptoms. For symptoms in which 
differences were evident, reported levels of bothersomeness clearly were 
much lower in the UK than elsewhere, whereas Japan and Germany 
reported the greatest levels of bothersomeness. For bothersomeness, 
controlling for the confounding variables had some impact on the pattern 
of relationships, in most cases reducing the significance of the variation 
across countries. 
These observations were different from the report of Burton et al, 
who assessed differences in attitudes to incontinence in different migrant 
groups in Australia. Some ethnic groups were very concerned about their 
incontinence but did not tell their family or seek help, while others were 
very active in seeking treatment. Some ethnic groups were ashamed to be 
incontinent, while others accepted it.17 
It has been shown that the most frequently reported symptoms are 
not necessarily the most bothersome.16 In the northern European countries 
UK, Denmark, the Netherlands and Sweden, the storage symptom of 
frequency appeared to be one of the most bothersome symptoms. In 
Canada, Germany, the southern European countries Italy and Portugal, 
Australia, Israel, and the Asian countries Japan and Taiwan, incontinence 
was the most bothersome symptom. This suggests that cultural differ-
ences in the perception of symptoms may be important. Generally, the 
most frequently reported symptoms were those associated with the 
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voiding phase and the most bothersome symptoms were those associated 
with the storage phase or incontinence.18 This appears to be true for the 
majority of individual countries. 
Conclusions 
Nevertheless, our study indicates that international differences are 
relevant in the reporting of specific LUTS and related bother. Inevitably, 
individual countries have different cultural backgrounds and specific health 
care delivery systems. Therefore, the results of studies in specific coun-
tries may not be generally applicable in other countries. In particular, it 
may be important to consider different patterns of reporting of symptoms 
and bothersomeness when interpreting the results of studies using com-
mon questionnaires. Of course, symptoms are extremely important for 
monitoring disease progression and outcome of treatment in individual 
patients. Many studies use symptom scores that amalgamate individual 
symptom differences into 1 overall measure, thus potentially concealing 
this variation. The ICSma/e questionnaire avoids these difficulties by 
considering each symptom separately. For studies that use symptom 
scores it may be necessary to evaluate the effectiveness, cost-effective-
ness, and influences on quality of life of treatments for LUTS in each 
country, or to develop country-specific scores. An alternative is to focus 
on bother, which appeared much less sensitive to international differences. 
In addition, the ICS-'BPH' study will allow the investigation both of 
the role of BOO in the symptomatic evaluation of therapy, and demon-
strate the ability of urodynamic and clinical parameters to predict response 
to new treatments. Thus, the association between urinary symptoms and 
BOO may be evaluated so that obstruction caused by the prostate gland 
can be differentiated from other conditions causing LUTS. 
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Relationships between LUTS and BOO 
Abstract 
Background: Despite the lack of evidence in the literature for close 
relationships between lower urinary tract symptoms and bladder outlet 
obstruction, the majority of urologists rely on symptomatology when 
selecting patients for prostatic surgery. We investigated the relationships 
between a wide range of symptoms from the \CSmale questionnaire and 
the results of urodynamic pressure and flow studies. 
Methods: We evaluated 933 patients with lower urinary tract symptoms 
suggestive for bladder outlet obstruction from 12 countries who partici-
pated in the ICS-'BPH' study with the \CSmale questionnaire and 
urodynamic pressure and flow studies. Spearman rank correlation coeffi-
cients were obtained between symptoms and measures of bladder outlet 
obstruction. 
Results: There was little or no correlation between a wide range of 
symptoms and the results of pressure and flow studies. 
Conclusions: From symptoms alone, it is not possible to diagnose 
bladder outlet obstruction. Pressure and flow studies and symptom profiles 
measure different aspects of the clinical condition that should be viewed 
separately in the evaluation and treatment decision of the patient present-
ing with lower urinary tract symptoms. 
Introduction 
Lower urinary tract symptoms (LUTS), traditionally labelled as 
'prostatism', are accepted by most cultures as an inevitable consequence 
of aging.1,2 The term 'prostatism' implies both cause and remedy, whereas 
in reality the condition results not only from infravesical bladder outlet 
obstruction (BOO) caused by the enlarged prostate gland, but also from 
motor or sensory abnormalities of detrusor and urethral function, or even 
from changes in habits and lifestyle that commonly occur as men grow 
older.3 
Despite the lack of evidence in the literature for close relationships 
between LUTS and BOO, over half of the UK urologists rely on 
symptomatology when selecting patients for prostatic surgery.4 The 
remaining urologists used urine flow studies, a commonly used objective 
method to measure the urinary stream and to quantify the effect of 
treatment. However, the reliability of this method is not optimal because 
there is a great variability in consecutive measurements.6 Furthermore, in 
up to 25 % of patients with LUTS, the poor urinary stream is not due to 
BOO caused by the enlarged prostate gland but to a hypoactive detrusor 
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muscle.3 Conversely, about 10-28 % of the patients with normal flow rate 
are obstructed.8,7 Urodynamic investigation with pressure and flow analy­
sis is used as the 'gold standard' for the quantification of the degree of 
obstruction in elderly men.8 Precise grading of obstruction is becoming 
increasingly important in the evaluation and comparison of new treatment 
modalities in the treatment of patients with LUTS and BOO. Based on this 
precise grading of obstruction, stratification of therapeutic options has 
recently become available.9,10 
Besides the assessment of objective voiding parameters, the 
development and use of a valid symptom questionnaire are prerequisites in 
both the evaluation of patients' symptoms and the measurement of 
outcome in clinical studies. In the past decades, at least 6 symptom 
questionnaires have been introduced and employed in patients with 
LUTS.11'18 In 4 of these, the reliability and validity have been assessed in 
groups of patients with the diagnosis of 'clinical benign prostatic 
hyperplasia' (BPH),11·12·16·18 but in only one has the relationships between 
symptoms and clinical objective measurements including the urodynamic 
diagnosis of BOO been investigated.1719 
Recently, Abrams has suggested the following redefinition of 
terminology.20 BPH is a histological diagnosis that has been shown by 
Berry et al. to occur in 88 % of men aged over 80. 2 1 Although BPH is 
prevalent, in some patients the gland enlarges and this is then termed 
benign prostatic enlargement (ΒΡΕ). In approximately half of the patients 
with ΒΡΕ bladder outlet obstruction (BOO) results. BOO due to ΒΡΕ is now 
termed benign prostatic obstruction (BPO).20 
In 1 9 9 1 , the International Continence Society (ICS) started an 
international multicentre study of patients with LUTS suggestive of BOO -
the ICS-'BPH' study, The aim was to validate a new questionnaire incor­
porating all urinary symptoms, related problems and quality of life issues 
that could be indicative of BOO, detrusor instability and detrusor 
underactivity. The aims of this study were: 1) to investigate the relation­
ships between the results of urodynamic studies and a wide range of 
urinary symptoms; 2) to develop and validate an ICS-'BPH' symptom 
questionnaire for use in research and clinical practice and 3) to compare 
pre- and post-treatment symptoms with the urodynamic confirmation of 
BOO in order to be able to define the characteristics of patients who would 
be more likely to benefit from currently used therapies. 
In this paper, the relationships between a wide range of urinary 
symptoms and BOO were investigated. 
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Patients and methods 
In the ICS-'BPH' study, 1271 patients over 45 years of age 
attending urology departments in 12 countries with LUTS suggestive of 
BOO completed the ICS/na/e questionnaire between January 1992 and 
December 1994. Patients were excluded from the study if they had an 
abnormal result of the mid-stream urinary specimen analysis or if they had 
significant other urological disease (such as prostate cancer), neurological 
disease, previous prostatic surgery, or were taking medication active on 
the lower urinary tract. Among these, 933 patients had évaluable pressure 
and flow studies. 
All patients were evaluated at baseline by medical history. LUTS 
were evaluated by the ICS/na/e questionnaire, designed to be patient-
completed. The ICS/na/e questionnaire contains 22 questions measuring 
20 urinary symptoms, with 19 also assessing the degree of problem that 
they cause, as well as 7 condition-specific quality of life questions and 4 
items concerning sexual functioning.22 The majority of questions have five 
possible ranked responses from 1 to 5 (figure 1), 1 indicating the least 
severe and 5 the most severe. The problem questions have four response 
categories, ranging from 'not a problem' to a 'serious problem' (see figure 
1). The questionnaire was developed in English and then professionally 
1 During the day, how many times do you urinate, on average? 
1 lo 6 times I I 
How much of a problem Is this for you? 
7 to 8 times I I 
9 to 10 times Π 
11 to 12 times • 
13 or more times | | 
not a problem PJ 
a bit of a problem Γ ] 
quite a problem PJ 
a senous problem • 
2 During the night, how many times do you have to get up to urinate, 
on averag·? 
none | | 
o n e r j 
t w o r j 
three p j 
lour or more | | 
How much of a problem Is this for you? not a problem p j 
a bit of a problem p j 
quite a problem p j 
a senous problem p j 
Figure 1 . Example of the ICS/na/e questionnaire. 
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translated into 10 other languages. Each translation was then back-trans-
lated and checked by a lay advisor or senior urologist from each country 
who was nominated as a national co-ordinator for the ICS-'BPH' study. 
Patients were also evaluated by physical examination including digital 
rectal examination with estimation of the prostatic volume and an optional 
ultrasonographic examination of the prostate. Each patient had up to three 
free urine flow measurements including ultrasonic estimation of residual 
urine (the highest maximum flow rate being used for the analysis), fol-
lowed by a pressure and flow study according to the ICS standards.23 
Patients' bladders were filled at 50 ml/min; both intravesical (pves) and 
intra-abdominal pressure (pabd) were measured. Detrusor pressure (pdet) 
was derived by electronic subtraction (pdet = pves - pabd). From the 
voiding phase, the maximum urine flow rate and the detrusor pressure at 
maximum flow were recorded. These data were plotted on a Schäfer linear 
passive urethral resistance relation (L-PURR) nomogram to quantify the 
obstruction from grade 0 (no obstruction) to 6 (severe obstruction).24 
Spearman's rank correlation coefficients were calculated between 
each separate symptom question and the following urodynamic measures: 
linear passive urethral resistance relation classification, detrusor pressure 
at maximum flow and maximum free flow rate. The statistical significance 
of these correlations was ascertained with a two-sided ρ value. In addition, 
to remove any confounding effect of age on these relationships, partial 
rank correlation coefficients were calculated. Specifically, each correlation 
between symptoms and urodynamic measures were recalculated partialed 
for age. 
Furthermore, using chi-squared tests the prevalence of each 
symptom was compared between patients who were obstructed (linear 
passive urethral resistance relation 3 or more) and those who were not 
(linear passive urethral resistance relation less than 3). Similarly, symptom 
prevalence was compared between those with a residual urine volume 
after free flowmetry of below and above 100 ml, and between those with 
a calculated bladder capacity (voided volume + residual volume) of below 
and above 300 ml. 
Results 
Table 1 and figures 2 and 3 present descriptive statistics of the 
urodynamic variables for the study patients. For the maximum free f low 
rate (figure 2) and detrusor pressure at maximum flow, the means are 
higher than the medians (table 1), indicating that the distributions of these 
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Figure 2 . Histogram of maximum urinary flow rates for the study patients. 
values are skewed to the right. The prevalence of each of the reported 
symptoms have been presented previously.26 
Table 2 presents the Spearman rank correlation coefficients and ρ 
values for the relationships between each symptom question and the 
urodynamic measures. Although a substantially greater number of these 
correlations achieve statistical significance than would be expected by 
chance alone, the largest coefficient is about 0.20, and even those of 
magnitude 0.10 are highly statistically significant, due to the large sample 
size involved. Considering combinations of symptoms within the groups of 
storage and voiding symptoms did not lead to stronger associations with 
BOO than for the individual symptoms. The relationships between each 
symptom question and urodynamic measures were recalculated after 
Table 1. Descriptive statistics of the urodynamic parameters of the study 
patients. 
Mean ± s.d. Median (range) 
Free maximum flow (ml/s) 
Detrusor pressure at maximum flow 
(cm water) 
L-PURR 
12.3 ± 6.3 
68 ± 30 
3.0 ± 1.4 
11.0 (1.0-55.01 
63 (15-2001 
3.0 (О-в) 
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Table 2. Spearman rank correlation coefficients and their significance levels 
for each symptom with pressure and flow measurements. 
Free maximum Detrusor pressure L PURR 
flow at maximum flow obstruction class 
terminal dribble 
reduced stream 
intermittency 
hesitancy 
incomplete emptying 
urgency 
nocturia 
repeated urination 
strain to continue 
postmicturition dribble 
strain to start 
urge incontinence 
frequency (times) 
burning 
bladder pain 
incontinence no cause 
sit to urinate 
stress incontinence 
urinary retention 
nocturnal incontinence 
strength of stream 
frequency (intervals) 
r 
< 0.01 
-0.19 
-0.09 
-0.16 
-0.02 
-0.03 
-0.09 
-0.02 
-0.06 
0.09 
-0.03 
0.02 
-0.07 
-0.04 
-0.02 
-0.02 
-0.11 
0.07 
-0.10 
-0.01 
-0.21 
0.07 
p-value 
0.97 
< 0.01 
< 0.01 
< 0.01 
0.52 
0.33 
< 0.01 
0.57 
0.04 
< 0.01 
0.32 
0.53 
0.03 
0.20 
0.52 
0.50 
< 0.01 
0.02 
< 0.01 
0.71 
< 0.01 
0.02 
r 
0.02 
0.04 
< 0.01 
0.02 
< 0.01 
0.17 
0.07 
0.04 
<-0.01 
-0.01 
-0.02 
0.15 
0.03 
0.09 
0.05 
0.04 
0.02 
0.01 
0.08 
0.02 
0.05 
-0.09 
p-value 
0.46 
0.19 
0.81 
0.60 
0.80 
< 0.01 
0.03 
0.24 
0.78 
0.71 
0.55 
< 0.01 
0.33 
< 0.01 
0.15 
0.19 
0.53 
0.66 
0.01 
0.59 
0.10 
< 0.01 
r 
0.02 
0.06 
0.02 
0.05 
0.02 
0.14 
0.07 
0.03 
< 0.01 
-0.02 
< 0.01 
0.11 
0.05 
0.10 
0.07 
0.03 
0.02 
<-0.01 
0.10 
0.01 
0.09 
-0.10 
p-value 
0.53 
0.06 
0.47 
0.10 
0.63 
< 0.01 
0.02 
0.41 
0.81 
0.48 
0.83 
< 0.01 
0.15 
< 0.01 
0.04 
0.36 
0.45 
0.92 
< 0.01 
0.66 
< 0.01 
< 0.01 
adjustment for age. The results were not noticeably different when 
compared to the correlation coefficients in table 2, indicating that age has 
little or no confounding effect on these relationships. 
Table 3 shows the results of the comparison of the prevalence of 
each symptom between the groups with (n = 563) and without bladder 
outlet obstruction (n = 370). The prevalence of urge and urge inconti­
nence were significantly higher in the groups with bladder outlet obstruc­
tion. This is in accordance with low (albeit statistically significant) correla­
tions presented in table 2. In addition, the prevalence of urinary retention 
was marginally significantly (0.01 < ρ < 0.05) higher in the group with 
bladder outlet obstruction. 
Table 3 also presents the results of the comparison of the preva­
lence of each symptom between the groups with (n = 300) and without 
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Figure 3. 
0 1 2 3 4 5 6 
LIn-PURR obstruction category 
Histogram of linear passive urethral resistance relation (L-PURR) for 
the study patients. 
(n = 622) a residual volume of at least 100 ml after free uroflowmetry, 
and between the groups with (n = 450) and without (n = 471) a calcu­
lated bladder capacity of at least 300 ml. The prevalences of hesitancy, 
urgency, repeated urination and strain to start were significantly higher in 
the group with a larger residual volume. The prevalences of intermittency 
and burning were marginally significantly (0.01 < ρ < 0.05) higher in the 
group with a higher residual volume. The prevalence of burning was 
significantly higher in patients with a larger calculated bladder capacity. 
The prevalence of urge incontinence was marginally significantly (0.01 < 
ρ < 0.05) higher in the group with a smaller calculated bladder capacity. 
Discussion 
The present study has investigated the associations between the 
various questions from the ICS/na/e questionnaire and the results of 
pressure and flow studies. For only one of the published questionnaires 
has the relationships with urodynamic measurements been investigated17' 
1 9
, specifically, the relationship of the AUA-7 index (the sum of the specific 
answers) with the grade of obstruction. No correlations were found for the 
AUA-7 index in relation to maximum free urinary flow rate, linear passive 
urethral resistance relation obstruction category and detrusor strength. 1 β · 2 β 
Using the AUA-7 symptom index, the severity of LUTS correlated well 
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with overall health status but not with free urinary flow rate, prostate size, 
degree of bladder trabeculation and the amount of post-void residual 
urine.17 This is not surprising because the AUA-7 questions are a hetero-
geneous group of storage and voiding symptoms (frequency, intermittency, 
urgency, nocturia, weak stream and hesitancy and the feeling of incom-
plete bladder emptying). Combining symptoms within the storage and 
voiding groups made no difference to the results of the study reported 
here. 
The main finding of the present study was that there is little or no 
correlation between the various symptoms and either the data from the 
pressure flow study or from the maximum free flow rate. This is in agree-
ment with a previous study which investigated the correlation between the 
diagnosis of BOO and individual symptoms of the International-Prostate 
Symptom Score (l-PSS) - a symptom score that is the same as the AUA-7 
questionnaire but with the addition of an extra question on the overall 
quality of life.1* Although this previous study concluded that there was a 
statistically significant correlation between the specific questions of the I-
PSS and objective grade of obstruction, the clinical significance of this 
finding is doubtful because none of the Spearman rank correlation coeffi-
cients was above 0.23, indicating very weak correlations. Furthermore, 
there was considerable overlap of symptom scores between patients with 
different grades of BOO.19 
The impact of age on the prevalence of symptoms has been 
described before. For instance, although an increasing trend was observed 
with increasing age in a population based study,27 the present group of 
patients exhibited a broadly negative correlation between the prevalence of 
symptoms from the ICSma/e questionnaire and increasing age.26 Possible 
explanations put forward for these observations were that the selection 
process of the patients is of considerable importance and that the toler-
ance of LUTS may increase with age. To correct for the possible con-
founding effect of age on the relationship between the prevalence of 
symptoms and urodynamic measurements, the correlation coefficients 
were adjusted for age. In the event, the confounding effect of age on the 
relationship between each symptom and the urodynamic measures was 
negligible indicating that the relationships are independent of the age 
pattern. 
In conclusion, there are objective methods which quantify both 
urine flow rate and BOO. In addition, there are valid and reliable methods 
to quantify the presence of LUTS. These methods measure different 
aspects of the clinical condition that should be viewed separately in the 
evaluation and treatment decision of the patient presenting with LUTS. 
Since earlier studies have indicated that inclusion of pressure flow data in 
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the preoperative evaluation and patient selection for interventional ther-
apies such as transurethral resection of the prostate and transurethral 
microwave thermotherapy may improve the overall clinical results,8,10,2e the 
conclusion from the present study is that symptoms alone should not be 
used as the main indication for surgical management. 
Future analyses of the ICS-'BPH' study will provide vital informa-
tion on the relative potential of symptoms, urodynamic and other clinical 
parameters to predict a favourable response to current and innovative 
treatments. Only then can the treatment of LUTS be individualized accord-
ing to the pathophysiology, symptomatic complaints and expectations of 
the patient. 
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Relationships between symptoms, urodynamics and 
prostate (transition zone) volume 
The correlation between prostate volume, transition zone volume, 
transition zone index and clinical and urodynamic investigations 
in patients with lower urinary tract symptoms. 
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Correlation between prostate volume and micturition variables 
Abstract 
Objectives: To determine if, in patients with lower urinary tract symp-
toms, transrectal ultrasound measurement of the transition zone (TZ) of 
the prostate and the ratio between TZ volume and total prostate volume 
(TZ index) correlates better with clinical and urodynamic investigations 
than total prostate volume alone. 
Methods: A total of 150 consecutive patients with lower urinary tract 
symptoms were subjected to a standardized screening program including I-
PSS, physical examination, transrectal ultrasound of the prostate, and 
urodynamic investigations with pressure-flow studies. Total prostate 
volume as well as TZ volume was assessed ultrasonographically using the 
ellipsoid formula. Spearman's rank correlation coefficients were calculated 
between different prostate volume measurements and specific sympto-
matic and urodynamic parameters. 
Results: The relationships between specific l-PSS symptoms, symptom 
scores and the investigated prostate volume measurements were not 
statistically significant except for one question, nocturia that appeared to 
be statistically significantly correlated with TZ index (r = 0.25). The 
correlations for free f low, pressure-flow parameters and prostate volume 
measurements were stronger but only moderate at best. The highest 
correlations were between TZ volume and L-PURR obstruction category, 
urethral resistance factor and detrusor pressure at maximum flow (r = 
0.43, 0.44 and 0.40, respectively). The differences between the correla-
tions of prostate volume and TZ index and these parameters were small (r 
= 0.39, 0.38 and 0.37, respectively for prostate volume and r = 0.38, 
0.40 and 0.33, respectively for TZ index). 
Conclusions: There were very small differences between the correlations 
of total prostate volume, TZ volume and TZ index and clinical as well as 
pressure-flow parameters. In the assessment of clinical and pressure-flow 
parameters, estimation of the total prostate volume by TRUS was a 
reasonable way to obtain the required information concerning the prostate 
size and measuring TZ volume and calculating TZ index was of limited 
additional value. Symptoms and bladder outlet obstruction were mainly 
determined by other factors than prostate and, specifically, TZ volume. 
Since earlier studies have indicated that inclusion of pressure-flow data in 
the preoperative evaluation and patient selection for interventional ther-
apies may improve the overall clinical results, it is our opinion that prostate 
volume, TZ volume or symptoms alone should not be used as the main 
indication for deciding on the appropriate invasive treatment options. 
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Introduction 
Estimation of the prostate volume is an important evaluative 
parameter in the assessment of patients with lower urinary tract symp-
toms (LUTS). Transrectal ultrasound (TRUS) of the prostate is now widely 
used to support the diagnosis and choice of treatment.1 TRUS currently 
provides the most accurate means of measuring prostate volume and also 
demonstrates the true extent of transition zone (TZ) enlargement.2 Accord-
ing to McNeal's assumption of zonal anatomy of the prostate, the TZ is 
the major site for development of benign prostatic hyperplasia.3 With the 
enlargement of the adenoma it compresses the outer part of the gland, the 
peripheral zone which is traditionally known as the surgical capsule. 
The value of volumetric determination of the TZ was recently 
reported in several studies. Hammerer et al assessed the unique relation-
ship of TZ tissue to prostate specific antigen (PSA) elevation and under-
scored the importance of considering the TZ as a source of false-positive 
diagnosis of prostate cancer.4 Hence, determination of the whole prostate 
volume and TZ volume by TRUS may increase the sensitivity of PSA in 
detecting prostate cancer. Tempany et al analyzed differential zonal 
volumes and their changes after treatment with finasteride and concluded 
that the TZ was more affected by medical treatment than the peripheral 
zone.5 Tewari et al analyzed the differences in TZ and total volume reduc-
tion among patients who improve peak urinary flow rates following 
finasteride therapy.8 Patients who had an improvement of peak urinary 
flow rate of more than 3 ml/s had a significantly greater reduction of TZ 
volume and TZ index, that is the ratio between the TZ volume and total 
gland volume, when compared with those who had not. They concluded 
that pretreatment TZ index may help in predicting peak flow improvement 
following finasteride therapy.6 
Using these ideas, some studies investigated whether separation of 
the peripheral zone volume from the adenoma would improve the correla-
tion with other clinical and urodynamic parameters. Furthermore, the 
relation between the TZ and total gland volume, expressed as TZ index 
was reported to correlate better than total volume alone with other clinical 
and urodynamic parameters.7 
We conducted a study to delineate the relation between the three 
methods of adenoma assessment (total prostate volume, TZ volume and 
TZ index) and their correlations with age, symptoms and the results of 
urodynamic investigations. 
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Patients and methods 
A total of 150 consecutive patients with LUTS was analyzed. All 
patients included in the present study were subjected to a standardized 
screening program including history (including international prostate 
symptom scores [l-PSS]), physical examination (including digital rectal 
examination), biochemistry (including PSA), urinalysis and culture, urine 
cytology, TRUS of the prostate, and urodynamic investigations with 
pressure-flow studies. 
The prostate size was determined using the Kretz combison 330 
ultrasound scanner with a 7.5 MHz transrectal probe (multi 3-D VRW 177 
AK). The prostate was imaged from base to apex, documenting the 
presence of prostate abnormalities and measuring the prostate volume 
using the ellipsoid formula height χ width χ length χ я/6.8 The TZ volume 
was calculated by using the same formula. Maximum diameters were used 
for each measurement. TZ index was defined as the ratio between TZ 
volume and total gland volume. 
Urodynamic investigations were performed using an 8F 
transurethral lumen catheter and an 8F transrectal catheter both equipped 
with a microtip pressure sensor (MTC, Drager, The Netherlands). Before 
cystometry, the bladder was emptied through the lumen of a transurethral 
catheter to quantify residual urine after free uroflowmetry. The pressure 
sensors were zeroed to atmospheric pressure before introduction. The 
bladder was filled with water of 20* С with a filling speed of 50 ml/min 
with the patient supine. Filling was stopped when the patient expressed a 
strong urge to void and micturition in standing position was allowed in 
private. Digitally stored data were analyzed with equipment developed at 
our department (UIC/BME Research center. Department of Urology, 
Nijmegen, The Netherlands). In order to get useful information from 
pressure-flow curves, it was necessary to relate detrusor pressure to 
corresponding flow. To quantify the grade of outlet obstruction, we used 
the concept of the Linear-Passive Urethral Resistance Relation (L-PURR), 
relating minimal urethral opening pressure observed at the end of voiding 
(Pvo¡dmin) with detrusor pressure at maximum flow (p^Qmax).9 Patients in 
L-PURR classes 0 and 1 had no bladder outlet obstruction, patients in 
classes 2 and 3 had mild and moderate bladder outlet obstruction and 
patients in higher classes had increasingly severe obstruction. We also 
used the urethral resistance factor (URA) for grading bladder outlet 
obstruction. Calculation of URA was based on the point of maximum flow 
and corresponding detrusor pressure.10 A URA value > 29 cm water 
indicated obstruction. 
Descriptive statistics were used to illustrate the studied population. 
56 
Chapter 4 
Spearman's rank correlation coefficients were calculated between different 
measurements of prostate volume and age, each separate symptom 
question, symptom scores and the following urodynamic measures: 
maximum free f low rate (Qmax), free voided volume, residual urinary 
volume after free flowmetry, minimal urethral opening pressure (Pvo¡dmin), 
detrusor pressure at maximum flow (p^Qmax), urethral resistance factor 
(URA) and linear passive urethral resistance relation classification (L-
PURR). The total score of l-PSS questions 2; repeated urination, 4 ; urge 
and 7; nocturia represented the filling component of the l-PSS symptom 
score, while the total score of question 1 ; incomplete emptying, 3; 
intermittency, 5; reduced stream and 6; strain to start represented the 
voiding component. The statistical significance of these correlations was 
ascertained with a two-sided ρ value. Applying the Bonferroni correction 
for multiple testing would imply a cutoff point of about 0.0025 for each 
individual ρ value to retain an overall 0.05 significance level. Since the 
symptoms and urodynamic variables are associated with each other, such 
a correction would be conservative, hence for the present analyses, a 
cutoff point of 0.01 was used, with significance between 0.01 and 0.05 
being regarded as marginal. On the basis of a cutoff point equal to the 
median value of total prostate volume, TZ volume and TZ index, the group 
of patients was divided in 2 and mean symptom scores, free Qmax, 
p^Qmax and L-PURR between groups were compared using the Wilcoxon 
rank sum W test. 
Results 
Descriptive statistics with respect to the patients, ages, prostate 
volumes measurements, and urodynamic parameters are summarized in 
table 1. The correlation between the prostate volume, TZ volume and TZ 
index and age and symptomatic parameters are presented in table 2. When 
evaluating the relationship between age, total prostate volume and TZ 
volume we noted a statistically significant positive correlation (r = 0.48 
and r = 0.47, respectively). The TZ index was also statistically significant­
ly correlated with age (r = 0.35). 
The relationships between specific l-PSS symptoms, symptom 
scores and the investigated volume measurements were not statistically 
significant except for one question, nocturia that appeared to marginally 
significantly correlate with TZ volume and statistically significantly corre­
late with TZ index. However, the magnitude of the correlation was only 
weak as demonstrated by a Spearman correlation coefficient of 0.19 and 
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Table 1. Descriptive statistics of the parameters of the study patients 
(n=150). 
Mean ± SD Median Range 
Age (years) 
l-PSS 
Prostate Volume (ml) 
TZ Volume (ml) 
TZ Index 
Qmax (ml/s) 
p^Qmax (cm water) 
L-PURR 
63 ± 10 
17.3 ± 6.9 
41.6 ± 20.8 
22.5 ± 15.9 
0.50 ± 0.17 
12.5 ± Θ.9 
49.4 ± 25.Θ 
2.1 ± 1.5 
63 
16.0 
36.8 
19.2 
0.50 
11.3 
44.0 
2.0 
3 4 - 8 5 
1 - 3 3 
15.7 - 123.0 
1.8-81.1 
0 . 1 0 - 0 . 8 8 
2.6 - 50.1 
4 . 0 - 145.0 
0 - 6 
0.25, respectively. As a result of this significant correlation with nocturia, 
the cumulative filling component of the l-PSS score was also marginally 
significantly correlated with TZ volume and TZ index. When the nocturia 
question was removed from the filling component of the l-PSS score the 
correlation was not significant anymore. 
Table 3 indicates the correlation between prostate volume measure­
ments and specific urodynamic values. Statistical significant but moderate 
correlations were found between prostate volume, TZ volume and TZ 
index and free flowmetry parameters Qmax and voided volume. The 
correlations between TZ volume and TZ index and Qmax were both 0.26 
and the correlations with voided volume were 0.34 and 0 . 3 1 , respectively, 
indicating slightly higher correlations than with prostate volume (r = 0.22 
for Qmax and 0.28 for voided volume, respectively). The correlations of 
prostate volume measurements and residual volume were not statistically 
significant for prostate volume and marginally significant but weak for TZ 
volume (r = 0.18) and TZ index (r = 0.20), respectively. The correlations 
for the pressure-flow parameters and prostate volume measurements were 
stronger than those of free flowmetry parameters. The highest correlations 
were between TZ volume and L-PURR (figure 1), URA and p^Qmax (r = 
0.43, 0.44 and 0.40, respectively). The differences between the correla­
tions of prostate volume and TZ index and these parameters were not 
great (r = 0.39, 0.38 and 0.37, respectively for prostate volume and r = 
0.38, 0.40 and 0.33, respectively for TZ indexHfigure 1). The correlations 
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between specific measurements of the TZ zone (height, width and length) 
and the specific urodynamic and symptomatic parameters were within the 
same range as those of TZ volume and TZ index. Table 4 lists the mean I-
PSS, free Qmax, p„.tQmax and L-PURR category for those below and 
above the median value of the prostate volume (36.8 ml), TZ volume (19.2 
ml) and TZ index (0.50), respectively. There were no significant differ-
ences in l-PSS scores while the differences in Qmax, p^Qmax and L-PURR 
were significant for the cutoff points of all volume measurements. 
Table 2. Spearman's rank correlation coefficients and their significance levels 
in italics for each prostate value with age, symptoms and symptom 
scores. 
Age 
l-PSS 1 ; incomplete emptying 
l-PSS 2; repeated urination 
l-PSS 3; intermittency 
l-PSS 4; urge 
l-PSS 5; reduced stream 
l-PSS 6; strain to start 
l-PSS 7; nocturia 
l-PSS fill (l-PSS 2 + 4 + 7) 
l-PSS void (l-PSS 1+3 + 5 + 6) 
total l-PSS 
Prostate Volume 
.48 
.02 
.06 
.04 
.10 
.04 
.17 
.11 
.12 
.09 
.03 
<.001 
.79 
.62 
.66 
.27 
.66 
.06 
.22 
.17 
.31 
.76 
TZ Volume 
.47 
.02 
.11 
.07 
.11 
.02 
.16 
.19 
.19 
.10 
.04 
K.001 
.ao 
.20 
.44 
.20 
.81 
.06 
.03 
.03 
.26 
.62 
TZ index 
.35 
.02 
.15 
.04 
.08 
.03 
.08 
.25 
.21 
.04 
.08 
<.001 
.86 
.08 
.68 
.37 
.74 
.34 
.004 
.02 
.64 
.36 
Discussion 
Estimation of prostate volume may be useful in a variety of ways. 
A precise estimate of the amount of BPH would help to decide upon the 
appropriate therapy and assist in the interpretation of serum PSA level for 
the presence of cancer.11 Also, the decrease in prostate mass after 
hormonal manipulation or radiation can be used as an indication of thera-
peutic efficacy.12 As the goal of many researchers has been an accurate 
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Table 3. Spearman's rank correlation coefficients and their significance levels 
in italics for each prostate value with specific urodynamic values. 
Qmax 
Voided Volume 
Residual Volume 
PvoWmin 
p„. tQmax 
URA 
L-PURR 
Prostate Volume 
.22 
.28 
.14 
.26 
.37 
.38 
.39 
.009 
.001 
.11 
.002 
<.0O1 
<.001 
<.001 
TZ Volume 
.26 
.34 
.18 
.32 
.40 
.44 
.43 
.002 
<.ooi 
.03 
<.ooi 
K.001 
<.001 
<.001 
TZ index 
.26 
.31 
.20 
.31 
.33 
.40 
.38 
.002 
K.OOt 
.02 
K.001 
<.001 
<.001 
<.001 
Table 4 . Mean micturition variables for those below and above the median 
value of prostate volume (36.8 ml), TZ volume (19.2 mil and TZ 
index (0.501 respectively. Ρ value (bold) indicates the comparison 
between the groups below and above the median value using the 
WHcoxon rank sum W test. 
Prostate Volume 
¿ 36.8 ml 
< 36.8 ml 
TZ Volume 
a: 19.2 ml 
< 19.2 ml 
TZ Index 
;» 0.50 
< 0.50 
l-PSS 
ρ = 0.95 
17.1 
17.6 
ρ = 0.53 
17.7 
17.0 
ρ = 0.28 
18.0 
16.7 
Qmax 
(ml/s) 
ρ = 0.04 
11.3 
13.7 
ρ = 0.02 
11.2 
13.8 
ρ = 0.01 
10.7 
14.4 
p^Qmax 
(cm water) 
ρ < 0.001 
57.9 
41.1 
ρ = 0.002 
55.4 
43.6 
ρ = 0.006 
54.5 
44.0 
L-PURR 
ρ < 0.001 
2.6 
1.5 
ρ < 0.001 
2.5 
1.6 
ρ = 0.001 
2.4 
1.7 
estimation of prostate volume, there have been several studies performed 
to this end.13,14 Earlier studies applied suprapubic ultrasound to measure 
prostate size. Although some studies reported accurate results with this 
technique, others felt this method had an inherent problem.14 An accurate 
estimation of the prostate volume only seems possible when the investiga­
tion is performed transrectally. The most commonly used methods for 
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estimation of the size of the prostate are the planimetrie method and the 
ellipsoid method using the three dimensions of the prostate. It is generally 
accepted that the step section planimetrie method of volume determination 
is most accurate but it is tedious and time consuming.14·16 In addition, this 
method requires sophisticated software to execute the program. In the 
present study we used the ellipsoid formula to obtain an accurate assess-
ment of prostate volume and TZ volume. 
In the present study, total prostate volume and TZ volume corre-
lated statistically significantly with age of the patients which is in agree-
ment with the assumption that the prostate gland increases in size as men 
age. The increase in prostate size seems to be mainly attributed to the TZ 
since the correlation between the TZ index and age was also highly 
significant (r = 0.35). 
The relationships between symptoms and total prostate volume 
have also been described by Ezz El Din et al who in 803 patients found no 
correlation.17 We confirmed the results of this study finding no correlations 
between total prostate volume, TZ volume or TZ index and each separate 
symptom and cumulative symptom score. There was only one exception, 
nocturia, that had a marginally significant but weak correlation with TZ 
volume (r = 0.19) and a statistically significant correlation with TZ index 
(r = 0.25). The clinical relevance of this finding is questionable. 
The correlation between urodynamic parameters of obstruction and 
total prostate volume have been shown to be statistically significant but 
S. s 
¿ 2 a. 
£ 1 
o o o ** o 
O O <* 
OO СВООФ « « M D +0+-O + ^ * O 
• л « в « «оме o> •+.- tì»o 
> «в>*о> *d» • « 
во о·* • · · * о « 
10 20 30 40 50 70 ВО 90 100 110 120 13 
TZ volume and Total Prosiate Volume (ml) 
Figure 1 . Scatterplot with the L-PURR obstruction category on the Y-axis and 
the total prostate volume ( + ) and transition zone volume (0) in ml on 
the X-axis with the regression lines (correlation coefficients rTol<, *„«*» 
ν*»» = 0.39; ρ < 0.001 [solid line] and г
І 2 ¥ 0 к и п . = 0.43; ρ < 0.001 
[striped line], respectively). 
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weak. This has been reported by Rosier et al and by Bosch et al. 1 8 1 8 Rosier 
et al, retrospectively evaluated 521 men with micturition complaints and 
determined the relationship between total prostate volume and bladder 
outlet obstruction. Their study showed a statistically significant weak 
correlation between bladder outlet obstruction and prostate size. 
Urodynamic outlet obstruction was confirmed in 9 0 % of the patients with 
a prostate size of more than 80 ml.18 Bosch et al distinguished between 
urodynamic parameters that selectively quantify compression, those 
correlated weakly to moderately with total prostate volume, and 
urodynamic parameters that quantify constriction that do not correlate 
with prostate volume et al.18 The compressive type is characterized by a 
high urethral opening pressure and a prolonged isovolumetric contraction 
phase before flow starts, and the constrictive type by a normal opening 
pressure and an increased slope of the passive urethral resistance relation 
reflecting a narrow urethral lumen during voiding. This stratification can 
only be done when the results of pressure-flow studies are available and 
this stratification may be of prognostic importance. Tubaro et al showed 
that patients with a constrictive obstruction had a higher likelihood to 
benefit from transurethral microwave thermotherapy using the low energy 
(2.0) software when compared to patients with a compressive obstruc­
tion.20 On the other hand, in patients who were treated with high energy 
(2.5 software) transurethral microwave thermotherapy, patients with large 
prostates benefitted most from therapy.21 In the current study we con­
firmed the statistically significant but moderate correlation between 
prostate volume and the results of pressure-flow studies. Also TZ volume 
and TZ index were significantly correlated with urodynamic parameters but 
the correlation was only moderate at best (table 3). There were very small 
differences among total prostate volume, TZ volume and TZ index con­
cerning their correlations with the clinical parameters as well as the results 
of urodynamic investigations with pressure-flow analysis (tables 2, 3 and 
4). Moreover, precise determination of the TZ volume is not an easy task 
and requires an expert TRUS investigator. Therefore, we conclude that in 
the assessment of clinical and pressure-flow parameters, estimation of the 
total prostate volume by TRUS is a reasonable way to obtain the required 
information concerning the prostate size and measuring TZ volume and 
calculating TZ index is of limited additional value. These results are at 
variance with the results of a similar study reported by Kaplan et al.7 The 
correlation between AUA symptom score, Qmax and TZ index in their 
study appeared to be strong and highly significant (r = 0.75; ρ = 0.001 
and r = 0 . 7 1 ; ρ = 0.001, respectively). The correlation between TZ index 
and р в о т а х was moderate (r = 0.43; ρ = 0.001) and higher than in the 
present study. They concluded that TZ index may serve as a useful proxy 
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for the evaluation of worsening obstruction. We agree with their con-
clusion but have to add that TZ volume and total prostate volume alone 
are in this context equally useful (table 4). 
From our study we conclude that symptoms and bladder outlet 
obstruction are mainly determined by other factors than prostate and, 
specifically, TZ volume alone. Since the correlation between clinical and 
urodynamic investigations and prostate volume and TZ volume is weak or 
moderate at best, the size of the prostate should not be an important 
consideration when determining the necessity of therapy. However, the 
choice of therapy could depend on the distinction between the 
compressive and constrictive types of obstruction. If there is an obstruc-
tive condition and a large prostate gland, it is likely that the prostate is the 
major cause of obstruction and the therapy should be designed to reduce 
the prostate volume medically or surgically. 
A correlation between symptoms and urodynamically proven 
obstruction has been shown in 1 study only, and only for the symptoms of 
weak stream and hesitancy.16 Other studies were, to our knowledge, not 
able to confirm these findings.23 The correlation of isolated objective non-
urodynamic parameters is generally believed to be too inaccurate for 
clinical decision making. However, a combination of the objective 
noninvasive measurements prostate size, post-void residual volume, voided 
volume and maximum flow, named the clinical prostate score (CLIPS), 
correlated well with the results of urodynamics in a retrospective investiga-
tion in a large group of patients.24 Using this scoring system, we may be 
able to distinguish groups of patients with and without bladder outlet 
obstruction without the need for an invasive and costly urodynamic 
pressure-flow analysis. However, for the individual patient, CLIPS has 
predictive value but without a urodynamic investigation with pressure-flow 
analysis a quantitative assessment of bladder outlet obstruction is not 
possible. From the four investigations used in CLIPS, maximum flow is 
considered to be the most relevant and consequently has the highest 
weight. Prostate volume is the investigation which after maximum flow 
has the highest weight and is therefore less important.24 
Since earlier studies have indicated that inclusion of pressure-flow 
data in the preoperative evaluation and patient selection for interventional 
therapies such as transurethral resection of the prostate22 and transurethral 
microwave thermotherapy20 may improve the overall clinical results, it is 
our opinion that prostate volume, TZ volume or symptoms alone should 
not be used as the main indication for deciding on the appropriate (mini-
mal) invasive treatment options. 
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Variability in uroflow measurements 
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Computerized artifact correction 
Abstract 
Objectives: To evaluate a computerized method of artifact detection and 
correction of uroflow and compare the quantitative assessment of maxi-
mum flow obtained by the computer with visual correction by experts. 
Methods: A total of 90 randomly chosen flows was scanned into the 
computer whereafter automated artifact detection and correction was 
performed according to pre-established rules implemented in the software. 
Three experts visually corrected the flows using the same artifact detec-
tion and correction specifications as the computer. Measuring agreement 
between different methods of assessment of maximum flow was evalu-
ated by calculating the difference and the standard deviation (SD) of the 
differences. The repeatability of assessing the maximum flow value by the 
computer and by expert 1 was assessed by calculating the difference 
between 2 readings and the coefficient of repeatability. 
Results: The coefficient of repeatability of maximum flow after detection 
and correction of artifacts by the computer (0.38 ml/s) was slightly better 
when compared with the coefficient of repeatability between 2 observa-
tions by one expert (1.12 ml/s). The interobserver variation for the quanti-
tative assessment of maximum flow appeared to be great. A total of 51 % 
of the maximum flow values assessed by expert 2 was 1 ml/s or more 
greater than those assessed by expert 1. When comparing the results of 
the computer with those of the experts the mean value of maximum flow 
from expert 1 was 0.71 ml/s smaller than the computer value (p < 0.01), 
the mean value from expert 2 was 0.53 ml/s greater (p < 0.01) and the 
mean value from expert 3 was not significantly different (0.25 ml/s 
greater). The SD of maximum flow after correction by the computer was 
0.3 ml/s smaller than the SD of the raw data from the flowmeter and the 
corrected values by 2 experts. 
Conclusions: Computerized artifact detection and correction eliminates an 
important fraction of the variability of manually corrected maximum flow 
values. This may lead to smaller sample size requirements, especially in 
studies where the primary objective is to assess a small ( ± 1 ml/s) differ-
ence in mean maximum flow between groups. 
Introduction 
For decades uroflowmetry has played a major role in the evaluation 
of lower urinary tract symptoms (LUTS). Urologists use measurements of 
uroflowmetry along with patient symptoms and other clinical findings to 
make decisions regarding the need for therapeutic intervention. Besides its 
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diagnostic role, uroflowmetry has evolved as one of the most important 
investigations in the assessment of the efficacy of drug treatments and 
other therapies in patients with LUTS. It is a noninvasive measurement 
technique that is simple to perform, the results are readily available, and 
sophisticated flowmeters are easy to use.1 The most modern flowmeters 
allow the measurement of voided volume, maximum flow, mean f low, time 
to maximum flow, voiding time and flow time. Moreover, the flow pattern 
can be described. Among the many parameters maximum flow is regarded 
as the most useful to assess the degree of obstruction and to monitor 
treatment effects. Despite its popularity, uroflowmetry is hampered by 
several draw-backs including its inability to differentiate between bladder 
outlet obstruction and impaired detrusor activity,2 artifacts,3 reproducibil-
ity,4 and intra and interobserver variation.6 
In clinical trials, these draw-backs may have a negative impact on 
sample size requirements to achieve statistical power.3 Therefore, artifacts 
such as wag-artifacts (caused by moving the stream)6 or artifacts due to 
defective damping of the device7 are usually corrected visually by experts 
who apply pre-established rules. However, visual validation is time-con-
suming and subjected to intra an interexpert variations. 
We present a computerized method of validation of uroflowcurves 
that was developed with the aim to part with the interexpert variation and 
to minimize the intraobserver variation and the variability of maximum flow 
rate by automatic artifact detection and correction and compared the 
results with those obtained after visual correction by the experts. 
Patients and methods 
We evaluated a set of 90 randomly chosen flows with different 
types of artifacts from 35 patients out of 9 centres participating in the 
ALFSTOP trial, a multicentric trial in which patients with LUTS and benign 
prostatic enlargement were treated with alfuzosin. The flows were gener-
ated at different times during the study period by using a Dantec Urodyn 
1000 flowmeter that recorded the uroflow parameters automatically. 
The automatically recorded uroflowparameters were blinded and 
maximum flow and flow time, that is the total duration of micturition 
minus interruptions, were assessed by one of the experts (JdIR). At this 
first stage no specifications were given to the expert how artifacts should 
be corrected. When comparing the results with the automatically recorded 
parameters by the flowmeter, there appeared to be a large number of 
differences that were likely to be a result of inconsistencies of the interpre-
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tation of the definition of an artifact and how it should be corrected. 
Therefore, we developed the following artifact definition and 
correction specifications: 1) Incomplete curves and curves with faulty 
position of the baseline (e.g. maximum flow is not zero at time zero or at 
the end of the curve) should be detected and not validated. 2) Defective 
damping of the flowmeter with oscillations of the peak flow during less 
than 1 second should be detected and corrected whatever the amplitude. 
3) Wag-artifacts defined as an increase of the flow up to 2 ml per second 
up and down (or down and up) within 4 seconds should be detected and 
corrected. 4) The last drops less than 2 ml of voided volume should not be 
used in the calculation of flow time. 5) Very acute initial peaks (related to 
ejection of the rinsing fluid in the rotating disk when it begins to turn) 
should be disregarded. 6) The maximum flow is the highest flow value 
after artifact correction. 
Hereafter, the curves were scanned (HP Deskjet scanner) into an 
MS-DOS computer (Pentium 90 Mhz). After scanning, a specific software 
program analyzed the scans and reconstructed the flowcurves. Then, the 
parameters were calculated before and after correcting for artifacts 
automatically using the above mentioned specifications implemented in the 
software. The raw data as well as the corrected data generated by the 
computer were compared with the automatically reported results of the 
flowmeter. 
Test-retest repeatability of the computer was evaluated by re-
scanning 44 curves into the computer and recalculating the parameters. 
Furthermore, using the above mentioned artifact definition and correction 
specifications implemented in the software the maximum flow and flow 
time was assessed by three experts (JdIR, GV, MZ) who were blinded for 
the automatically recorded results. The experts quantified maximum flow 
values manually by using the following scale: ... 4.0 - 4.5 - 5.0 - 5.5 ... 
ml/s. Flow time values were assessed manually without using decimals. 
One expert also re-assessed the maximum flow and flow time values after 
a period of 2 weeks. 
We analyzed the differences between the results of the computer 
and the results of the three experts and calculated the impact on sample 
size requirements of the applied method for a hypothetical trial. To assess 
the measuring agreement of two methods of measurement, we used the 
statistical approach recommended by Bland and Altman:8 the paired differ-
ences between two measurements were plotted against the mean of the 
two readings and the mean difference and the standard deviation (SD) of 
the differences were calculated. Values obtained by two methods of 
measurement were compared by using the paired Student's t test or 
signed rank test. To assess the repeatability of the method of measure-
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ment, the absolute differences between the measurements were plotted 
against the average of the two readings. Furthermore, test-retest 
repeatability for expert 1 and the computer was determined by calculating 
the SD of the differences between two readings and the repeatability 
coefficient (2SD) as defined by the British Standards Institution.9 
Results 
In table 1 the mean values of maximum flow, flow time and voided 
volume and their standard deviations obtained from the Dantec machine, 
the computer and the experts are presented. The SD of maximum flow 
after correction by the computer was 0.3 ml/s smaller than the SD of 
maximum flow from the Dantec machine. Flow time and voided volume 
values were not different between the Dantec machine and the computer 
either before or after correction. 
The mean difference ± SD between maximum flow calculated after 
scanning by the computer (raw data) and the maximum flow value from 
Table 1 . Mean maximum flow, flow time and voided volume values as 
measured by the applied methods ± SD. na: not available; The 
experts assessed the values without using specified correction rules 
flat and using specified correction rules (lb, 1c, 2 and 3, respect-
ively). 
Dantec value 
Raw computer value 
Calculated computer 
value 
Expert 1a 
Expert 1b 
Expert 1c 
Expert 2 
Expert 3 
Mean 
max. flow 
(ml/s) 
11.4 ±3 .3 
11.3 ± 3.3 
10.7 ± 3.0 
9.9 ± 2.7 
10.1 ± 2.8 
10.0 ± 2.6 
11.3 ±3 .4 
11.0 ± 3.3 
Maximum 
flow 
range (ml/s) 
5.8 - 26 .0 
5.7 - 2 5 . 6 
5.2 - 2 5 . 2 
4 . 0 - 2 1 . 0 
5.0 - 22 .0 
5 . 0 - 2 1 . 0 
6.0 - 26 .0 
7 . 0 - 2 5 . 0 
Mean 
flowtime 
(s) 
47 ± 19 
47 ± 19 
47 ± 19 
48 ± 20 
50 ± 20 
50 ± 20 
49 ± 19 
46 ± 18 
Mean 
voided volume 
(ml) 
236 ± 75 
236 ± 75 
236 ± 74 
na 
na 
na 
na 
na 
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the Dantec machine was 0.10 ± 0.22 ml/s (paired Student's t test; ρ < 
0.01). In figure 1, a plot of the differences between the maximum flow 
value from the Dantec machine and the raw data from the computer 
against their mean is indicated. This figure suggests that more than 95 % 
of the differences between the maximum flow values as calculated by the 
computer (raw data) and those from the Dantec machine were less than 
0.44 ml/s and that the differences were normally distributed. After artifact 
detection and correction by the computer the mean difference ± SD of 
maximum flow with the Dantec machine was 0.66 ± 0.95 ml/s (paired 
Student's t test; ρ < 0.01) and the median value was 0.40 ml/s (signed 
rank test; ρ < 0.01). As indicated in figure 2, the differences between the 
maximum flow values calculated by the computer and those from the 
Dantec machine were not normally distributed and the maximum flow 
values calculated by the computer were, except for 1 flow, smaller than 
the Dantec value. 
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Average max. flow by Danlec and raw computer value (ml/s) 
Figure 1 . Scatterplot of the differences between the Dantec maximum flow 
values and the raw maximum flow values as assessed by the com­
puter against their mean. Reference lines that are indicated are the 
mean difference Y = 0.10 ml/s [solid line] and the mean ± 2 SD (SD 
= 0.22 ml/s) [dotted line]. 
The mean difference ± SD between the 2 observations by one 
expert was 0.10 ± 0.56 ml/s (not significantly different; ρ = 0.09). 
Figure 3 suggests that the within flow SD for expert 1 was not associated 
with the magnitude of the flow value. The calculated coefficient of 
repeatability was 1.12 ml/s, agreeing with figure 3 where 95 % of the 
differences between the 2 observations by expert 1 were :£ 1 ml/s. In 69 
% of the flows the interpretation of the value of maximum flow by expert 
1 was similar after reassessing the maximum flow values and in 1 θ % the 
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difference was 0.5 ml/s. 
The test-retest repeatability of the computer was tested by scan­
ning and calculating and rescanning and recalculating the maximum flow 
values of 44 randomly chosen flows. The mean difference between scan-
rescan values of the raw maximum flow was 0.00 ± 0.14 ml/s with a 
coefficient of repeatability of 0.28 ml/s, indicating that 95 % of the 
differences between raw maximum flow values was less than 0.28 ml/s. 
Figure 2. 
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Average Danlec value and computer corrected value (ml/s) 
Scatterplot of the differences between the Dantec maximum flow 
values and the corrected values as assessed by the computer against 
their mean. Reference lines that are indicated are the mean difference 
Y = 0.66 ml/s [solid line] and the mean ± 2 SD (SD = 0.95 ml/s) 
[dotted line]. 
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Figure 3. 
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Average max. flow value by expert 1 (ml/s) 
Scatterplot of the absolute differences of maximum flow values 
between 2 observations of expert 1 against their mean. 
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The difference between scan-rescan values of the raw data was 0.40 ml/s 
or less in all flows. The mean difference between scan-rescan values of 
maximum flow values after detection and correction for artifacts was 0.00 
± 0.19 ml/s with a coefficient of repeatability of 0.38 ml/s. The difference 
between scan-rescan values of the corrected data was 0.50 ml/s or less in 
all flows. 
When comparing the mean corrected maximum flow values from 
the computer, with those of the experts, expert 1 had a significantly 
smaller mean maximum flow value, expert 2 had a significantly greater 
mean maximum flow value and expert 3 had a greater mean maximum 
flow value but the difference was not statistically significant (table 1,2). 
The interobserver difference between expert 1 and 2 is depicted in figure 
4. It is remarkable that, using the same correction specifications, 70 % of 
the maximum flow values assessed by expert 2 were greater (mean 
difference ± SD = 1.24 ± 1.66, range 0 - 1 0 ml/s) when compared to 
those assessed by expert 1. Moreover, 51 % of the maximum flow values 
assessed by expert 1 were 1 ml/s or more smaller than those assessed by 
expert 2. Some of the discrepancies could easily be explained by simply 
Overlooking' the scale of the flowcurve (Dantec machine gives 25 and 50 
ml/s full scale). Two flows with large discrepancies between expert 1 and 
2 are shown in figure 5. 
In figure 6, the sample size requirements of a hypothetical study to 
detect a difference in maximum flow change between treatment groups 
with a type 1 error of 0.05 and a type 2 error of 0.10 are plotted when 
the computer is used (SD = 3.0 ml/s) and when the uncorrected results of 
the Dantec flowmeter or the corrected results of expert 2 or 3 are used 
(SD = 3.3 ml/s). As shown by figure 6, the smaller the detectable differ-
ence, the larger the gain when using the calculated values by the com-
puter. When the aim is to detect a difference of 1.5, 1.0 or 0.75 ml/s -
Table 2 . Mean differences ± SD and range of maximum flow between 
experts and computer using the same artifact detection and correc-
tion specifications. Also indicated is the p-value when comparing the 
computer calculated value with the expert. 
Mean ± SD range p-value 
(ml/s) (ml/s) 
Expert 1 - computer corrected value -0.71 ± 1.13 -6.05/2.76 < 0.01 
Expert 2 - computer corrected value +0.53 ± 1.62 -6.05/8.92 < 0.01 
Expert 3 - computer corrected value +0.25 ± 1.22 -1.55/6.92 0.05 
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Average max flow between expert 1 and 2 
Figure 4. Scatterplot of the differences of maximum flow values between 
experts 1 and 2 against their mean. Reference line that is indicated is 
the mean difference Y = -1.24 ml/s [solid line]. Note that 70 % of 
the maximum flow values assessed by expert 1 are smaller than those 
assessed by expert 2 
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Figure 5. Two flowcurves with the raw flowdata (thin line) and the calculated 
flowdata (bold line) (X-axis: timescale = 70 sec, Y-axis: flowscale = 
25 ml/s). The values of maximum flow of the dantec machine, expert 
7, expert 2, expert 3, raw maximum flow and calculated maximum 
flow by the computer were for flow V 23 2, 75.0, 25.0, 23.0, 23.3 
and 16.4 ml/s and for flow 2: 15 0, 70.0, 15 0, 75.0, 15.1 and 74.0 
ml/s, respectively. 
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Maximum flew change between groups (ml/s) 
Figure 6. Sample size requirements (Y-axis) in hypothetical studies with a type 
1 error of 0.05 and a type 2 error of 0.10 to detect a difference in 
maximum flow change between treatment groups (X-axis). The solid 
and dotted line indicate the sample size requirements when the SD of 
maximum flow is 3.0 (computer) and 3.3 ml/s (Dantec machine and 
expert 2 and 3), respectively. 
between t w o treatments, 1 8 , 4 0 and 71 patients less, respectively, are 
needed in each treatment arm. 
Discussion 
Since considerable variability between consecutive flow measure­
ments may be found in various voiding parameters, and specifically 
maximum flow, any decision based on a single flow measurement seems 
to be questionable. The problem of reproducibility has been illustrated 
recently. Reynard et al. showed that there is a significant increase in 
maximum flow with each successive voiding when men with LUTS 
performed multiple free-flow measurements.1 0 The specificity and positive 
predictive value of maximum flow for bladder outlet obstruction was sig­
nificantly improved by multiple free-flow measurements. If the highest 
maximum flow after 3 voidings was less than 10 ml/s, the specificity and 
positive predictive values for bladder outlet obstruction were 9 0 and 9 4 %, 
respectively. As specificity and positive predictive value for bladder outlet 
obstruction improve when multiple free-flow measurements are used, the 
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specificity and positive predictive value of a genuine improvement of free 
flow as a result of treatment may also be improved when the results of 
multiple free-flow measurements are evaluated. We agree with Reynard 
that multiple free-flow measurements are most efficient for an accurate 
assessment.10 For this reason, many units have developed urine flow 
clinics to obtain multiple uroflowmetry results. Although this approach 
increases the number of reliable measurements, this still is not an ideal 
situation. It is time consuming both for the patient and doctor while the 
patient is still not voiding under 'normal conditions'. Therefore, another 
method was recently suggested to get multiple reliable measurements: 
home-based uroflowmetry.11 Home-based uroflowmetry is now used as an 
accurate tool to quantify and document changes in flow as a result of 
therapy. Besides obtaining reliable measurements, the interpretation of the 
flow should show minimal intra and inter observer variability. 
J0rgensen et al reported the interobserver variation between 
experienced and inexperienced physicians in a study where 176 flow 
curves were classified according to their flow-curve pattern into 1 of 5 
categories.6 The experienced physicians disagreed on 20 % of the 
flowcurves whereas the inexperienced physicians disagreed on 45 % of 
the flowcurves. When experienced urodynamicists were asked to reevalu-
ate the flows, the percentage of disagreement was as high as 16 %. 
In the present study, the interobserver variation in the quantitative 
assessment of maximum flow also appeared to be great. Using the same 
artifact definition and correction specifications, in 70 % of the flows 
expert 2 assessed the values of maximum flow greater than expert 1 . A 
total of 51 % of the maximum flow values assessed by expert 2 was 1 
ml/s or more greater than those assessed by expert 1. The coefficient of 
repeatability for expert 1 was 1.12 ml/s and this indicates that 95 % of 
the differences between the 2 observations by one expert was equal to or 
less than 1 ml/s. Hence, in the present study, the intraobserver variation 
for expert 1 was smaller than the interobserver variation. 
Can the quantitative assessment of maximum flow be improved by 
using sophisticated flowmeters or computers with special developed 
software ? A variant of observer variation has arisen due to the automatic 
quantitative assessment of flow-rate of some new uroflowmeters. Due to 
the high sensitivity of the flowmeter that registers any change in flow rate 
lasting 0.25 seconds or more, small oscillations that have no physiological 
meaning frequently occur. Another artifact that is frequently seen is 
caused by changing the direction of the urinary stream abruptly. Rollema 
described these artifacts as wag-artifacts.6 It is clear that the commonly 
used flowmeters do not exclude these artifacts. The error as a result of 
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these artifacts has been shown to be more than 3 ml/s in 9 % of the 
flows, more than 2 ml/s in 20 % of the flows and more than 1 ml/s in 62 
% of the flows.3 Grino et al manually corrected the maximum flow rate 
values as given by the flowmeter in a study with 23.857 flows.3 They 
concluded that manual reading of the maximum urinary flow rate elimin-
ates an important fraction of the high variability of machine read maximum 
flow rate values. 
The coefficient of repeatability of maximum flow after detection 
and correction of artifacts by the computer (0.38 ml/s) was slightly better 
when compared with the coefficient of repeatability between 2 observa-
tions by one expert (1.12 ml/s). This implies that the computer assesses 
maximum flow more consistent than expert 1. When comparing the 
coefficients of repeatability between the by the computer corrected maxi-
mum flow values (0.38 ml/s) and the raw maximum flow data generated 
by the computer (0.28 ml/s), the coefficient of the corrected flow values 
was slightly but not relevantly greater. This could be explained by the fact 
that the raw values depend on the scanning process only, but the cor-
rected values also depend on the variation in the correction algorhythm as 
a result of the variation in the scanning. 
However, when the test-retest results of the computer or the 
intraobserver results of expert 1 are reproducible, this does not persé mean 
that the measurement is correct. The absence of a reference value in the 
individual patient and the absence of a commonly agreed upon 'golden 
standard' for the correction algorhythm complicates the quantitative 
assessment of maximum flow. Furthermore, there is a great variation of 
maximum flow values within one patient and from the majority of the 
flows performed in the hospital we do not know whether a particular flow 
is entirely representative for the patient. In common clinical practice 
representability of the flow can easily be assessed by asking the patient 
and artifacts can easily be identified and manually corrected by the urolo-
gist. This is not easily done in large multicenter clinical trials where 
thousands of flows have to be assessed manually. A great interobserver 
variation can decrease the power of the study considerably.3 Using a 
computerized artifact detection and correction program the interobserver 
variation problem is not of any relevance anymore and the intraobserver 
variation may be decreased further because the artifact detection and 
correction is always performed on the same way by the computer whereas 
the interpretation of the artifact detection and correction rules may differ 
among experts and may not be consistent when one expert evaluates the 
same flows at different time points of the day. When comparing the 
results of the computer with those of the experts the mean value of 
maximum flow of expert 1 was statistically significantly smaller than the 
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computer value whereas the mean value of maximum flow of expert 2 was 
statistically significantly greater than the computer value (table 2). The 
mean value of maximum flow assessed by expert 3 was not significantly 
different when compared to the by the computer corrected value. This 
again shows that the computer may correct artifacts on a more consistent 
way when compared to experts. 
Furthermore, computerized handling of flowdata offers the possibil­
ity to create and evaluate new uroflowparameters that may be of rel­
evance in the evaluation of patients with LUTS such as voiding time for 
the central 9 0 % of the voided volume, time of the descending leg of the 
flow rate pattern, maximum flow during 2 seconds, maximum flow 2 
seconds after start of the micturition etc. The creation of new or 
recalculated parameters is very difficult or, for some of the above men­
tioned new parameters, impossible when using manual artifact correction. 
Also maximum flow can easily be corrected for age as has been suggested 
by Drach12 and for voided volume as has been suggested by Siroky13 and 
Haylen.14 Is this of clinical value ? One of the key-issues in deciding on the 
most appropriate treatment is whether the physician should focus on 
relieving symptoms and related bother or relieving urodynamically proved 
obstruction. Earlier studies have indicated that inclusion of pressure flow 
data in the preoperative evaluation and patient selection for interventional 
therapies such as transurethral resection of the prostate and transurethral 
microwave thermotherapy may improve the overall clinical results.1 5 , 1 β The 
correlation between symptoms and the results of urodynamic pressure-
flow studies and maximum free flow have been reported to be poor, 
indicating that these methods measure different aspects of the clinical 
condition.1 7·1 8 The correlation of isolated objective parameters is generally 
believed to be too inaccurate for clinical decision making. However, a 
combination of prostate size, post-void residual volume, voided volume and 
maximum flow correlated well with the results of urodynamics.19 This 
combination of objective noninvasive measurement is named the clinical 
prostate score (CLIPS). Using this scoring system, we may be able to 
distinguish patients with and without bladder outlet obstruction without 
the need for an invasive and costly urodynamic pressure-flow analysis. 
From the four investigations used in this clinical prostate score, maximum 
flow is considered to be the most relevant and consequently has the 
highest weight. This confirms that maximum flow is regarded as the most 
useful investigation to assess the degree of obstruction and to monitor 
treatment effects. 
Due to a more consistent detection and correction of artifacts, the 
coefficient of repeatability of maximum flow after computerized artifact 
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detection and correction is smaller when compared to the expert. Maxi­
mum flow is a quantitative variable on which the sample size of the study 
is frequently based. Clearly, a small coefficient of repeatability is of benefit 
because, with less variability due to the consistent detection and correc­
tion of artifacts, less patients are needed to assess a difference between 
treatment arms. Obviously, the large variability of maximum flow due to 
circadian changes, psychogenic inhibition, different urinary volumes or 
abdominal pressing is not influenced by this correction algorhythm. 
In the present study, we have illustrated the potential advantages 
of a computerized method for artifact detection and correction of uroflows 
including its possible repercussions on sample size requirements. It is now 
time to assess the value of the presented method in a multicenter (drug 
treatment) trial. 
Conclusions 
Computerized artifact detection and correction eliminates an 
important fraction of the variability of manually corrected maximum flow 
values. This may lead to smaller sample size requirements especially in 
studies where the primary objective is to assess a small ( ± 1 ml/s) differ­
ence in mean maximum flow between groups. 
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Portable home-based uroflowmetry 
Abstract 
Purpose: To compare the results obtained using a portable home-based 
uroflowmeter with the results of traditional flowmetry in the out-patient 
department. 
Patients and methods: Sixty-seven patients (mean age 61 years, range 
38-79) with lower urinary tract symptoms and/or benign prostatic enlarge-
ment used a home-based uroflowmeter comprising a datalogger and 
specially designed fluid sensors incorporated into disposable beakers. The 
results of these measurements were compared with those from 
uroflowmetry in the out-patient department and with other clinical vari-
ables. 
Results: There was a good correlation between the uroflow results 
obtained when voiding at home and at the out-patient department. The 
highest measured maximum flow and voided volume were obtained with 
the home-based uroflowmeter system. However, the mean of all consecu-
tive home-based maximum flow and voided volume measurements were 
lower than those obtained by single-void uroflowmetry in the out-patient 
department. 
Conclusions: Home-based uroflowmetry provides reliable voiding results 
which are comparable with those obtained in the out-patient department. 
Introduction 
About one-third of men older than 50 years present with lower 
urinary tract symptoms;1 such symptoms eventually develop in most men 
and the predominant mechanism for this disorder is bladder outlet obstruc-
tion, caused by the prostatic adenoma.2 However, clinical experience sug-
gests that the degree of obstruction is not always related to the volume of 
the prostate. Small prostates in younger men can cause severe obstruction 
and voiding disorders, but large adenomas can be present without causing 
obstruction.3 In the treatment of patients with lower urinary tract symp-
toms and benign prostatic enlargement, the success of (surgical) treatment 
seems to be closely related to the presence of bladder outlet obstruction.4,6 
Therefore, if patients with lower urinary tract symptoms and benign 
prostatic enlargement are to be treated appropriately, information about 
the grade of obstruction should be obtained. 
A urodynamic investigation with pressure-flow study analysis is 
considered to be the 'gold standard' to determine bladder outlet obstruc-
tion.9 However, rather than performing this invasive investigation, 
uroflowmetry is most often used to document voiding disorders because it 
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is simple, readily available, and easy to use.7 The most recent 
uroflowmeters measure voided volume, the maximum flow rate (Qmax), 
the mean flow rate, time to maximum flow, and the duration of f low. 
Moreover, the pattern of flow can be described and characterized. In 
general, urologists use measurements of Qmax, with patient's symptoms 
and other clinical findings, to make decisions about the need for thera-
peutic intervention to relieve lower urinary tract symptoms and/or bladder 
outlet obstruction. These clinical investigations can also be used in the 
followup of patients and to document the outcome of therapy. 
The uroflow can be measured using several methods, e.g. a 
rotating disc, an electronic dipstick or gravimetric measurement. These 
systems are used mainly in the clinical environment and consequently the 
results are seldom obtained under conditions equivalent to 'voiding at 
home'; indeed, the patient has to void in an environment that can be very 
embarrassing. He must also void with a bladder full enough to obtain a 
representative voided volume. Moreover, the results of uroflowmetry may 
vary during the day.8 To overcome these problems, a home-based system 
of uroflowmetry has been introduced. A system was designed and devel-
oped that would provide reliable results, was easy to use by the patient, 
had quality-control of flow-measurement, was hand-held for practical use, 
used hygienic disposable beakers and from which the results were quickly 
and easily available. In the present pilot study, the results from a portable 
home-based uroflowmeter were compared with other clinical variables and 
the results from uroflowmetry performed in the out-patient department. 
Patients and methods 
Sixty-seven consecutive patients (mean age 61 years, range 38-79) 
with voiding complaints were seen in the out-patient department; all were 
evaluated initially by a medical history, an International Prostate Symptom 
Score (l-PSS), a physical examination including digital rectal examination 
and transurethral ultrasonographic examination of the prostate, free urinary 
flowmetry in the hospital, a urodynamic evaluation (including pressure-flow 
studies), and a series of measurements from the home-based 
uroflowmeter. Prostate volume was calculated using the planimetrie 
method with a Kretz Combison 330 ultrasound scanner with a multiplane 
3-D rectal transducer (VRW 177AK). For free urinary flowmetry in the 
hospital, the Dantec Urodyn 1000 flowmeter was used. Home-based 
uroflowmetry was performed with a portable flowmeter using disposable 
beakers. The patients were asked to produce consecutive flows starting in 
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the morning and asked to void 'as they would normally do'. The results of 
these uroflowmetry readings were stored in the portable flowmeter and 
transferred to a computer for analysis during the second visit to the out-
patient department. 
The portable flowmeter 
To meet with the requirements of a home-based uroflowmeter, a 
new method of measuring urine volume and flow was developed consist-
ing of four self-calibrating cup-shaped volume sensors, printed on paper-
like material that was disposable and not re-useable (figure 1), with each 
sensor comprising a measuring and calibration section. The flowmeter 
measures the changes in the electrical properties of the sensors caused by 
the fluid and the results are independent of the chemical properties of the 
fluid. The sensors can be shaped into a collecting beaker and disposed of 
after use. The goal was to develop a measuring system which could be 
held in the hand during the flow measurement. The system was designed 
so that the height of the fluid column could be determined accurately even 
when the system was tilted. The upper surface of the fluid column is 
measured by four sensors, although three sensors would be sufficient for 
determining a surface in three dimensions. However, a fourth sensor was 
added to allow quality control; using four sensors allows possible artifacts 
(e.g. caused by strong shaking) to be detected. Each sensor has a section 
which calibrates the measuring section during the measurement. After 
each voiding session, a new disposable beaker is mounted on the registra-
Figure 1 . Disposable beaker (left) with its contents: the sensors are printed on 
paper-like material (right). 
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tion device (figure 2). Voiding is performed into this beaker after 
activatingthe system by pressing a red button (figure 2). The voiding 
record is terminated by pressing the same button again and each flow 
measurement is stored in the device. The system is easy to use; it is 
activated and deactivated with a single button, and two coloured lights 
and a 'beeper' present the status of the system. After activation, all 
sensors are tested, the measuring electronics calibrated and, when the test 
is successful, a green indicator is lit, the 'beeper' sounds and voiding can 
start. When the test is unsuccessful, a red indicator is lit and several beeps 
are generated, indicating a fault in the sensor. The tests are completed 
successfully 99.9% of the time because all sensors are tested during 
production. The power supply to the system consists of three small 
batteries which can be used for several flow sessions. When the battery 
voltage becomes too low, a flashing green and red light indicate that the 
user should replace the batteries. 
Figure 2. Demonstration of the use of the home-based uroflowmeter. 
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The device includes a micro-processor board, memory, a real-time 
clock and the measurement electronics. Each measurement is stored in the 
memory, together with the exact time and date. After completion of the 
required flow measurements, the system is returned to the physician. At 
the out-patient department, the device is connected to a desktop computer 
and the contents of the memory (the flow records and times) read from 
the flowmeter. Flow curves can be presented on the computer screen and 
printed as hardcopy. Flow variables, e.g. peak flow and mean flow rates, 
are calculated, stored in a database and can be presented on the screen or 
printer. These variables are also presented as a flow diary with all vari­
ables, including date and time, displayed; the mean, minimum and maxi­
mum values are also calculated. A program to automatically detect arti­
facts was also implemented and was able to identify those flows that 
were probably measured incorrectly. 
The variables are stored in a database on the computer (in a 
standard Dbase format), together with data identifying the patient; the 
data can thus be exported to other programs like spreadsheets or statisti­
cal packages. 
Almost 7 hours of continuous use can be stored and processed by 
the home-based uroflowmeter, equivalent to about 400 flow measure­
ments. The accuracy of the volume measurement was determined by filling 
the beakers with known quantities of fluid and was also tested with the 
beakers in two angles (0° and 15°); the error of the measured volume was 
< 1 % of full scale (800 ml.) at any angle. The flow error was measured 
similarly using a constant flow source and was < 5% of full scale (50 
ml./s.). 
Urodynamic evaluation 
Urodynamic investigations were performed with an 8F transurethral 
lumen catheter equipped with an intravesical microtip pressure sensor for 
recording bladder pressure. Abdominal pressure was recorded intrarectally 
with an 8F microtip-sensor catheter (MTC, Drager, Germany). Before 
cystometry, the bladder was emptied through the lumen of the 
transurethral catheter. The bladder was filled with water of 20° С and at a 
filling speed of 50 ml./min. Equipment developed at our department 
(UIC/BME Research Centre, Department of Urology, Nijmegen, The Nether­
lands) was used to record the pressure and flow data. The linear passive 
urethral resistance (L-PURR) concept was used to provide an objective and 
accurate grading of obstruction;9 in this system, patients graded 0-2 are 
minimally obstructed and those graded 3-6 definitely obstructed. 
Descriptive statistics were used to assess the results of the home-
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based uroflowmeter and the other clinical findings. Student's t-test was 
used to compare the mean Qmax and mean voided volume obtained at 
home and at the out-patient department. 
Results 
All the patients confirmed that the system was easy to use. All 67 
patients received 12 beakers each and completed several micturitions free 
of artifacts. During a 3 day period, 6-12 (mean 10) measurements were 
obtained from each patient. A total of 673 flow-measurements were 
recorded and the quality-control system indicated that there were possible 
artifacts in 142 flows (21%). After visual evaluation of these records, 
there were 572 (85 %) correctly measured flows in total. 
The mean prostate volume was 43 ml. (range 16-115) and the 
mean l-PSS score was 15.4 (range 1-33). The mean values of voided 
volume and Qmax for the consecutive measurements made at home are 
shown in table 1, which shows that the means were stable but with a 
large dispersion, indicated by the 95% CI. Evaluation of the uroflowmetry 
studies showed that the Qmax at the out-patient department ranged from 
3.0 to 35.0 ml./s. and the comparison between the mean Qmax using the 
home-based uroflowmeter and at the out-patient department is shown in 
figure 3. The mean Qmax at the out-patient department (13.7 ml./s.) was 
slightly higher, but not significantly, than the mean Qmax from the home-
based uroflowmeter (12.9 ml./s.; ρ = 0.11), possibly because the mean 
voided volume was significantly higher at the out-patient department (277 
ml.) compared to that from the home-based uroflowmeter (215 ml.; ρ < 
0.01). There was a difference in the highest Qmax achieved with the 
home-based uroflowmeter and at the out-patient department (figure 4); in 
most cases, the highest Qmax of the individual home-based uroflowmeter 
sessions was considerably higher than that obtained in the out-patient 
department. There was a similar pattern for the measurements of voided 
volume. 
The Qmax at home was larger than that obtained in the out-patient 
department on 234 occasions (41 % ) , was similar on 7 occasions and 
smaller on 331 (58 % ) . The differences between the Qmax obtained at 
home and in the out-patient department were very variable; figure 5 shows 
that these differences appeared to have a Gaussian distribution, either 
negative or positive. On 373 occasions (65%), the absolute difference 
between the Qmax obtained at the out-patient department and at home 
was < 4 ml./s. and on the other 199 occasions, the absolute difference 
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Table 1 . Mean values and their 95 % confidence intervals ¡CI] of voided 
volume and maximum flow for consecutive measurements at home. 
Number of Number of Mean voided Mean maximum 
home-based patients volume flow 
uroflowmeter (ml. (96% CH) (ml./s. [96% cu) 
estimates 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
67 
67 
67 
65 
64 
62 
57 
50 
34 
24 
15 
194 
211 
211 
226 
224 
209 
212 
202 
211 
196 
240 
[57-381] 
(71-427) 
[74-656) 
[73-645] 
(95-5511 
[67-493] 
[89-434] 
[45-488] 
[47-440] 
[94-430] 
(96-4201 
13.1 
13.0 
12.9 
12.6 
13.4 
12.5 
12.6 
11.6 
12.3 
10.7 
12.6 
[3.0-28.41 
(3.5-22.6) 
(3.3-25.4) 
[2.9-25.61 
(2.8-25.51 
[2.1-22.11 
[2.2-21.6] 
[1.9-22.11 
[2.1-25.0] 
[1.6-20.5] 
[1.8-26.0] 
was > 4 ml./s. (figure 5). There was a similar distribution of differences 
between the measurements of voided volume at the out-patient depart-
ment and at home; on 396 occasions (69%) the voided volume at home 
was smaller than the flow at the out-patient department. On urodynamic 
study using pressure-flow analysis, the L-PURR ranged from 0-6 (mean 
1.8). There were no significant differences in the variability of values from 
the home-based uroflowmeter between the groups with minimal (n = 49) 
and definite bladder outlet obstruction (n = 18) (figure 5). 
Discussion 
For decades, uroflowmetry has played a major role in the evaluation 
of voiding complaints. Urologists use the results of uroflowmetry with the 
patient's symptoms and other clinical findings to make decisions about the 
need for therapeutic intervention to relieve bladder outlet obstruction. 
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Figure 3. Comparison between the mean maximum flow using the home-based 
uroflowmeter and at the outpatient department. The regression line 
with individual 95 % confidence intervals is indicated. 
j j 
E 
CU 
υ 
ε 
о 
φ 
.с 
со 
χ 
со 
Ε 
Ο 
ι 
Ο 
Ε 
ο 
с 
со 
χ 
η 
b 
σ 
Ε 
э 
Ε 
χ 
C0 
30 
?η 
10 
η 
-10 
Individual Patients 
Figure 4. The difference between the highest maximum flow measured with the 
home-based uroflowmeter and the maximum flow obtained at the 
outpatient department for each patient. 
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Figure 5. The number of flows from the home-based uroflowmeter with a Qmax 
greater (right) or smaller (left) than that obtained at the out-patient 
department (OPD). The absolute differences (ml./s.) between the flow 
at home and at the out-patient department for each group (striped 
definitely obstructed, L-PURR «> 3; and, black, minimally obstructed, 
L-PURR < 3) are indicated below the figure. 
Although uroflowmetry can provide useful information suggesting whether 
a patient has bladder outlet obstruction, and a particular flow pattern may 
suggest the possible underlying pathology, the interpretation of results 
may sometimes be difficult and misleading. For the appropriate use of the 
results of uroflowmetry, certain aspects should be considered, i.e. repro­
ducibility, artifacts, circadian changes, variation within and between 
observers, association with volume and outlet obstruction, reference 
values and the clinical relevance to benign prostatic enlargement.10"13 
Reliability is a prerequisite for any measuring technique; because 
consecutive flow measurements can produce variable results, particularly 
for Qmax, any decision based on a single-flow measurement is question­
able. We agree with Blaivas that multiple samples are the most reliable for 
an accurate assessment.14 For this reason, many units have developed 
urine-flow clinics to obtain multiple uroflowmetry results. Although this 
approach increases the number of reliable measurements, it is still not an 
ideal situation, being time-consuming for both the patient and doctor, 
while the patient is still not voiding under 'normal conditions'. Therefore, 
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another method was suggested to obtain multiple and reliable measure-
ments, i.e. ambulatory home uroflowmetry. Golomb et al. were among the 
first to report about the results of a home uroflowmetry study,8 in which 
the Home Uro Data System (Biodan Medical Systems Ltd, Rehovot, Israel) 
was used, and they concluded that there was large variability between 
consecutive maximum flows. This was confirmed by Meier et al.16 who 
presented results from 140 men with micturition disorders using another 
home flowmeter. 
In view of the importance of obtaining reliable uroflowmetry 
results, a portable home-based uroflowmeter was developed in our depart-
ment. The present pilot study assessed the practical use of this flowmeter 
for both the patient and the urologist and whether it is possible to over-
come some of the disadvantages of the 'traditional' uroflowmetry. 
There was a close relationship between the mean Qmax and voided 
volume from the home-based uroflowmeter and those obtained in a single 
void at the out-patient department. However, during the voids at the out-
patient department, there was a slightly higher mean Qmax and a signifi-
cantly higher mean voided volume when compared with the results from 
the home-based uroflowmeter. The slightly higher maximum flow at the 
out-patient department could be explained by the higher voided volume, 
probably because the results in the out-patient department were obtained 
under 'forced' conditions. When the highest maximum flow achieved 
during voids at home was compared with the maximum flow at the out-
patient department, a considerable number of patients showed a signifi-
cant difference in voiding performance, as expected, because more voids 
were performed using the home-based uroflowmeter. However, almost 
one-third of the patients produced their highest maximum flow at the out-
patient department, which is not surprising because the sole aim at the 
out-patient department is to have the bladder as full as possible, while at 
home the timing of micturition is related to other normal daily activities. 
The value of the 'supranormal' values obtained in the conditions of the 
out-patient department may be questioned when they are used as inclusion 
criteria in treatment protocols. 
How many voiding sessions are needed to obtain reliable 
uroflowmetry results and should these be obtained by using the home-
based uroflowmeter ? By establishing a 'flow clinic', several recordings of 
voids can be obtained and the results of such repeated uroflowmetry can 
then be assessed.16 It is generally accepted that at least two or three 
voiding sessions, with an adequate voided volume, are required; indeed the 
maximum flow and voided volumes of the first 3 consecutive home-based 
uroflowmeter measurements show 'stable' results (table 1). Whether this 
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is enough to judge the voiding performance accurately needs to be 
assessed further. However, few would question that the 'voiding under 
normal conditions' is better achieved when using the home-based 
uroflowmeter than in the out-patient department. 
One of the key questions in the treatment of patients with lower 
urinary tract symptoms and benign prostatic enlargement is whether or not 
they have bladder outlet obstruction. However, when using the home-
based uroflowmeter, the relationship between the grade of obstruction and 
the results of uroflowmetry were no better than those from the out-patient 
department. There was a large variation in maximum flow in minimally 
obstructed patients and in those with definite obstruction (figure 5). 
Although a low maximum flow ( < 10 ml./s. at an appropriate volume) has 
a higher probability of originating from a patient with bladder outlet 
obstruction, only a full urodynamic study with pressure-flow analysis can 
determine the exact grade of obstruction. 
Another important factor in improving the reliability of 
uroflowmetry is quality control; all voiding studies are subject to numerous 
artifacts and many stem from the lack of privacy. Because environmental 
factors can significantly influence the results of voiding, a considerable 
effort should be made to make patients comfortable with their surround-
ings during any flow studies. The home-based uroflowmeter used in the 
present study complies with these requirements. Artifacts may also occur 
during flow recording; all modern flowmeters are sufficiently accurate, but 
need to be used with care; modern technology creates other problems, 
often explicable as incorrect instructions to the patient and/or incorrect use 
by the patient. For example, a patient may vary his urine stream across the 
collecting beaker or squeeze his penis or prepuce, leading to changes in 
the flow recording. He may also simply shake the home-based 
uroflowmeter or handle the device incorrectly. In the present study, the 
program to automatically detect artifacts indicated problems in 21 % of 
the voiding registrations. However, after visual inspection, the number of 
artifacts detected correctly was decreased to 15%. In conjunction with the 
technical specifications, this guarantees reliable uroflowmetry results if the 
home-based uroflowmeter reports no abnormalities. Many artifacts were 
detected in the present study; because the threshold values were deter-
mined by the software; based on the present results, the software has 
been adapted and the thresholds modified so that fewer flows are 
inspected unnecessarily. 
Irrespective of age and education, patients confirmed that the 
home-based uroflowmeter was easy to use; it is relatively small and the 
functions are easily available. Thus, the home-based uroflowmeter can be 
installed easily for practical use at home and during outdoor activities. The 
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device is readily available and hygienic because of the disposable beakers 
used with the device. Thus, specific voiding difficulties that cannot be 
assessed by uroflowmetry in a daily clinical practice can be documented. 
We are aware that there is a significant circadian change in voiding values; 
a multicentre study has been initiated to examine these changes and to 
investigate the precise role of the home-based uroflowmeter. 
In conclusion, home-based uroflowmetry studies are an interesting 
diagnostic investigation which provide more detailed information than does 
single-void traditional uroflowmetry. However, the exact utility of home-
based uroflowmetry still needs to be determined. 
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Circadian rhythm of uroflow 
Abstract 
Objectives: To investigate if the circadian rhythm of urinary flow values 
varies within groups of patients with various degrees of bladder outlet 
obstruction. 
Methods: A total of 170 patients with lower urinary tract symptoms 
suggestive of bladder outlet obstruction used a home-based uroflowmeter 
and produced a total of 1670 correctly measured flows at home. These 
patients also underwent a screening program with free urinary flowmetry 
in the hospital and a urodynamic pressure and f low study. 
Results: There is a circadian variability in that men with higher grades of 
obstruction having a higher peak urinary flow with a smaller voided volume 
and a shorter flow time as a result of the above two in the early afternoon 
when compared to late evening, early morning, and the mid-night to 
morning periods. 
Conclusions: This significantly greater maximum flow in the afternoon in 
men with higher grades of obstruction, can be an important bias in studies 
where the primary endpoint is to assess a small improvement of maximum 
flow. Therefore, the circadian rhythm of uroflow has to be taken into 
account in the evaluation of the efficacy of treatment. Patients participat-
ing in clinical research studies should produce their urinary flow in the 
clinic always in the same time period, either in the morning or in the 
afternoon, and should not switch their appointment time. 
Introduction 
Single uroflowmetry may not be sufficiently reliable for the determi-
nation of bladder outlet obstruction because many patients are unable to 
relax and void in the normal fashion while at the clinic. Therefore, Blaivas 
suggested that multiple samples are most efficient for enhancing an 
accurate assessment.1 For this reason, many units have developed urine-
flow clinics to obtain multiple uroflowmetry results. Although this 
approach increases the number of reliable measurements, it is still not an 
ideal situation, being time-consuming for both the patient and doctor, 
while the patient is still not voiding under 'normal conditions'. To over-
come these problems, several home-based systems of uroflowmetry have 
been introduced.2'5 We recently reported on a system designed and devel-
oped to provide reliable results, is easy to use by the patient at home, has 
quality-control of flow-measurement, is hand-held for practical use, uses 
hygienic disposable beakers and from which the results are quickly and 
easily available.4 However, it was concluded that when multiple samples 
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are available the problem arises which sample(s) should be used for the 
evaluation particularly if the reported circadian changes are of clinical 
relevance.2,Б"7 
In the present study, the results from the aforesaid portable home-
based uroflowmeter were used to evaluate circadian changes in 
uroflowmetry parameters in patients with lower urinary tract symptoms. 
Furthermore, we investigated if circadian changes vary within various 
obstruction groups according to the Schäfer linear passive urethral resis-
tance relation (L-PURR) nomogram.8 
Patients and methods 
A total of 170 consecutive patients (mean age 62 years, range 38-
80) with voiding complaints was seen in the out-patient department; all 
were evaluated initially by a medical history, an International Prostate 
Symptom Score (l-PSS), a physical examination including digital rectal 
examination and transurethral ultrasonographic examination of the pros-
tate, one free urinary flowmetry in the hospital, a urodynamic evaluation 
(including pressure-flow studies), and a series of measurements from the 
home-based uroflowmeter. Prostate volume was calculated using the 
planimetrie method with a Kretz Combison 330 ultrasound scanner with a 
multiplane 3-D rectal transducer (VRW 177AK). For free urinary flowmetry 
in the hospital, the Dantec Urodyn 1000 flowmeter was used. Home-based 
uroflowmetry was performed with the home-based uroflowmeter, P-flow®. 
Patients were supplied with the home-based uroflowmeter and 12 dispos-
able beakers and were instructed to use the home-based flowmeter at 12 
consecutive flows during 2 or 3 days. The patients were asked to start 
producing flows in the morning and to void 'as they would normally do'. 
The results of the uroflowmetry readings were stored in the home-based 
uroflowmeter and transferred to a computer for analysis during the second 
visit to the out-patient department (figure 1). When the patient used the 
home-based uroflow system incorrectly, an automatic artifact detection 
program indicated whether an artifact could be expected. The home-based 
uroflowmeter has been described in detail previously.4 Excluded were 
patients previously treated with transurethral (laser) resection of the 
prostate, transurethral microwave thermotherapy or 5a-reductase 
inhibitors. Patients using σ1 receptor antagonists were also excluded. 
Urodynamic investigations were performed using an 8F 
transurethral lumen catheter and an 8F transrectal catheter both equipped 
with a microtip pressure sensor (MTC, Dräger, The Netherlands). Before 
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Figure 1. Demonstration of the P-flow®. 
cystometry, the bladder was emptied through the lumen of a transurethral 
catheter to quantify residual urine after free uroflowmetry. The pressure 
sensors were zeroed to atmospheric pressure before introduction. The 
bladder was filled with water of 20* С with a filling speed of 50 ml/min 
with the patient in supine position. Filling was stopped when the patient 
expressed a strong urge to void and micturition in standing position was 
allowed in private. Digitally stored data were analyzed with equipment 
developed at our department (UIC/BME Research center. Department of 
Urology, Nijmegen, The Netherlands). In order to get useful information 
from pressure-flow study curves, it was necessary to relate detrusor 
pressure to corresponding flow. To quantify the grade of outlet obstruc­
tion, we used the concept of the linear-passive urethral resistance relation 
(L-PURR), relating minimal urethral opening pressure observed at the end of 
voiding with detrusor pressure at maximum flow.8 Patients in L-PURR 
classes 0 and 1 had no bladder outlet obstruction, patients in classes 2 
and 3 had moderate bladder outlet obstruction and patients in higher 
classes had severe obstruction. We also used the urethral resistance factor 
(URA) for grading bladder outlet obstruction. Calculation of URA was 
based on the point of maximum flow and corresponding detrusor pres-
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sure.8 A URA value > 29 cm water indicated obstruction. 
Circadian changes were examined by dividing the 24 hour recording 
period into 4 periods with daytime periods 1 to 4 corresponding to mid-
night to 6 a.m. (night), 6 a.m. to noon (morning), noon to 6 p.m. (after-
noon) and 6 p.m. to midnight (evening). The following parameters were 
evaluated for each of the obstruction categories: voided volume, maximum 
flow, mean flow and flow time. Mean values of these parameters were 
calculated for each daytime period per patient. These mean values were 
used to calculate the mean of the studied population. Descriptive statistics 
were used to illustrate the studied population. The Kruskal-Wallis one Way 
ANOVA test, the Wilcoxon matched pairs signed rank test and the 
Wilcoxon rank sum W test were used for the statistical analysis. 
Results 
A total of 170 patients with a median prostate volume of 34 ml. 
(range 16-120) and a median l-PSS score of 15 (range 1-33) received 12 
beakers each and completed several micturitions free of artifacts. During a 
2 or 3 days period, 3-12 (median 10) measurements were obtained from 
each patient. A total of 1850 flowmeasurements were recorded at home 
and the quality control system indicated that there were possible artifacts 
in 223 flows (12%). After visual evaluation of all f lows by one of the 
authors (WW), there appeared to be 1670 (90 %) correctly measured 
flows in total. The median number of registered flows per patient for each 
daytime period as well as the total number of flows within each obstruc-
tion category is indicated in table 1. This table shows that the number of 
f lows produced at specific daytime periods was not significantly different 
between obstruction groups. 
Table 2 and figures 2a-c indicate the mean flow values for the f low 
produced in the hospital and the flows produced at home for each daytime 
period within obstruction categories. Except for voided volumes produced 
between midnight and 6 h a.m., the differences in voided volume and 
maximum flow between obstruction groups were all statistically significant 
(table 2). Severely obstructed patients (L-PURR 2: 4) had a significantly 
smaller mean voided volume and mean maximum flow. 
Table 2 and figure 2a show that in all obstruction categories the 
mean voided volume produced between midnight and 6 h a.m. was 
significantly greater compared with the flows produced in the afternoon 
and evening while the smallest mean voided volume at home is produced 
in the afternoon (figure 2a). For the groups without obstruction (L-PURR = 
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Table 1. The median number (range) of flows per patient for each daytime 
period as well as, in italics, the total number of flows within each 
obstruction category. 
L-PURR = 0,1 
(n = 64) 
L-PURR = 2,3 
(n = 70) 
L-PURR = 4,5,6 
(n = 36) 
midnight-
6 h a.m. 
1.0 ю-*) 
89 
1.0 (0-51 
98 
1.0 (0-41 
49 
6-12 h 
a.m. 
2.0 (0-5) 
154 
3.0 (OS) 
206 
3.0 (1-е» 
108 
12-6 h 
p.m. 
3.0 (0-Θ) 
181 
3.0 (Ο-β) 
208 
3.0 (о- і 
105 
6 p.m.-
midnight 
3.0 (ο-β) 
181 
3.0 (0-5) 
194 
3.0 (0-Θ) 
97 
Total 
10.0 (3-12) 
605 
11.0 (3-12) 
706 
10.5 (4-12) 
359 
0,1) and with moderate obstruction (L-PURR = 2,3), mean voided volume 
produced at the hospital was significantly greater compared to that 
produced at home in the afternoon (figure 2a). 
The mean maximum flow in patients without obstruction was not 
significantly different between specific daytime periods (table 2, figure 2b). 
In the patients with moderate and severe obstruction, the maximum flow 
produced at home in the afternoon was significantly greater than that 
produced in the morning. Moreover, in severely obstructed patients the 
maximum flow in the evening was again significantly smaller (figure 2b). 
In the moderate and severely obstructed patients, the significant 
greater mean voided volumes and smaller mean maximum flow values 
between midnight and 6 a.m. resulted in statistically significant differences 
in mean flow time in that period but not in other periods of the day. 
Severely obstructed patients had approximately a doubling of their flow 
time between midnight and 6 a.m. when compared to the afternoon and 
evening. This difference was less pronounced in not obstructed patients. 
Mean flow time at the hospital was comparable with that produced at 
home between midnight and 6 h a.m. (figure 2c). 
We further investigated the group with extreme differences in 
voided volume and maximum flow between the flows produced in the 
morning and those produced in the afternoon. The median absolute differ­
ence for voided volume was 50 ml and for maximum flow 2 ml/s. As 
indicated by statistically significant differences in the urodynamic values 
detrusor pressure at maximum flow, URA and L-PURR obstruction cat­
egory, the group with absolute differences in voided volume exceeding 50 
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ml and in maximum flow exceeding 2 ml/s, was significantly less 
obstructed compared to those without extreme differences whereas the 
other clinical parameters age, total l-PSS and prostate volume were not 
significantly different (table 3). 
We also investigated differences between patients who had a 
voided volume of over 150 ml in less than 50 % of de flows produced at 
home versus those with voided volumes over 150 ml in 50 % or more of 
the flows produced at home. A total Of 125 patients (74%) had voided 
volumes over 150 ml in ^ 50 % of the flows produced at home. Patients 
who had voided volumes over 150 ml in < 50 % of the flows had signifi­
cant differences in the urodynamic values bladder capacity, detrusor 
Table 4. Patient characteristics of the groups of patients with < 50 % of the 
voided volumes produced at home > 150 ml (n = 45) and those 
with г 50 % of the voided volumes produced at home > 150 ml (n 
= 125). 
< 50 % of the voided 
volumes produced at 
home > 150 ml 
г 50 % of the voided 
volumes produced at 
home > 150 ml 
Age (years) 
Total l-PSS score 
l-PSS 1 ; incomplete emptying 
l-PSS 2; repeated urination 
l-PSS 3; intermittency 
l-PSS 4; urge 
l-PSS 5; reduced stream 
l-PSS 6; strain to start 
l-PSS 7; nocturia 
Prostate Volume (ml) 
Bladder capacity (ml) 
Detrusor pressure at maximum flow 
(cm water) 
URA (cm water) 
L-PURR category 
61 ± 9 
19.0 ± 7.7 
2.4 ± 1.8 
3.4 ± 1.5 
2.7 ± 2.0 
3.1 ± 2.0 
3.7 ± 1.6 
1.5 ± 1.6 
2.4 ± 1.3 
44 ± 25 
307 ± 91 
63.9 ± 34.9 
43.1 ± 26.3 
2.8 ± 1.9 
62 ± 8 
14.6 ± 5.9 * 
1.8 ± 1.6 
2.5 ± 1.5 * 
2.2 ± 1.6 
1.9 ± 1.7 · 
3.2 ± 1.5 
1.2 ± 1.3 
1.9 ± 1.1 * 
39 ± 17 
428 ± 123 * 
46.3 ± 19.5 * 
29.1 ± 13.2 * 
1.9 ± 1.3 * 
indicates significant difference (p < 0.05) between groups 
(Wilcoxon rank sum W test) 
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pressure at maximum flow, URA and L-PURR obstruction category, indicat-
ing that they were more obstructed compared to those who had voided 
volumes over 150 ml in ^ 50 % of the flows. The other clinical parame-
ters age and prostate volume were not significantly different among both 
groups (table 4). Total l-PSS symptom score was significantly greater in 
those who had voided volumes over 150 ml in < 50 % of the f lows. 
When evaluating the specific symptoms, it appeared that this significant 
greater total symptom score originated mainly from symptoms related to 
frequency: repeated urination, urge and nocturia. All these symptoms were 
significantly more frequently reported than in those who had voided 
volumes over 150 ml in < 50 % of the flows. 
The effect of excluding flows with voided volumes of less than 100 
ml and 150 ml on the mean voided volume and maximum flow produced in 
the morning and afternoon is indicated in table 5. 
Discussion 
For decades uroflowmetry has played a major role in the evaluation 
of patients with lower urinary tract symptoms. Urologists use 
uroflowmetry measurements together with patient symptoms and other 
clinical findings to decide upon the need for therapeutic intervention. Most 
urologists nowadays agree that only patients with bladder outlet obstruc-
tion should undergo surgical intervention10 but nevertheless the decision 
for surgery is usually based primarily on the nature and severity of symp-
toms and the results of uroflowmetry. A urodynamic investigation with 
pressure-flow studyanalysis is considered to be the 'gold standard' to 
determine bladder outlet obstruction.11 However, rather than performing 
this invasive investigation, uroflowmetry is most often used to document 
voiding disorders because it is simple to perform, the results are quickly 
available and refined flowmeters are easy to use.12 Besides its diagnostic 
role, uroflowmetry has evolved as one of the most important evaluation 
methods in the assessment of the efficacy of drug treatments and other 
therapies in patients with lower urinary tract symptoms. The most modern 
flowmeters allow the measurement of voided volume, maximum flow, 
mean flow and flow time. Moreover, the f low pattern can be described. 
Among the many parameters maximum flow is regarded as the most 
useful to assess the degree of obstruction and to monitor treatment 
effects. Despite its popularity, uroflowmetry is hampered by several 
difficulties including its inability to differentiate between bladder outlet 
obstruction and impaired detrusor activity, artifacts, reproducibility, and 
circadian changes.2B'7,13" ie 
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Figure 2. Mean voided volume (2a), maximum flow (2b) and flow time (2c) 
values and their 95 % Confidence Intervals (CI) for each L-PURR 
obstruction category. 
The circle and dotted CI indicate the mean values for the flow pro­
duced at the hospital. The squares and the striped CI's indicate from 
the left to the right side respectively the mean values of the flows 
produced at night (between midnight to 6 a.m.), in the morning (6 
a.m. to noon), in the afternoon (noon to 6 p.m.) and in the evening (6 
p.m. to midnight). 
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Golomb et al studied circadian changes in a group of patients with 
benign prostatic hyperplasia (BPH) and a group of healthy men and report-
ed in patients with BPH an increase in voided volume, interval to maximum 
flow and flow time, from midnight to 6 a.m. and a decrease in volume 
adjusted peak flow from midnight to noon and in peak flow from 6 a.m. to 
noon.2 Nakamura et al reported typical circadian rhythms for the majority 
of patients investigated.6 Most patients showed a decreased frequency at 
night and an increased voided volume in the early morning, which was 
considered the typical rhythm of urination.6 Nakamura et al also showed 
that, from midnight to 6 a.m., the frequency in elderly men was signifi-
cantly greater than that in a middle-aged group. This increased frequency 
was primarily due to an increase in diuresis in the elderly men investi-
gated.6 Burgio et al reported a frequency of diurnal urination of 5.5 for this 
age category.8 Unfortunately, we were not able to report circadian 
changes in frequency or diuresis. In the present study, the total number of 
flows measurements obtained from each patient during a 2-3 days period 
was between 3-12 (median 10). This is less than what could be expected 
when the home-based uroflowmeter was used continuously for this period 
of time. Although the flowmeter was not used continuously by all patients 
and we cannot, therefore, report on circadian changes in frequency, some 
important findings can be gleaned from the present study. 
We reported an increase in voided volume and flow time, both 
interrelated parameters, from midnight to 6 a.m. which is in agreement 
with the results of Golomb et al and Nakamura et al. Despite a clearly 
greater voided volume at night, maximum flow was not significantly 
greater. 
There was a close relationship between voided volume produced 
between midnight and 6 a.m. and voided volume produced at the hospital. 
The greater voided volume produced at the hospital could be explained 
probably because the results were obtained under 'forced' conditions. This 
is not surprising because the sole aim at the out-patient department in the 
hospital is to have the bladder as full as possible, whereas at home the 
timing of micturition is related to other normal daily activities. The value of 
the 'supranormal' values obtained in the conditions of the out-patient 
department may be questioned when they are used as inclusion criteria in 
treatment protocols. 
In the present study, it was shown that there is a circadian variabil-
ity in that men with higher grades of obstruction having a higher peak 
urinary flow with a smaller voided volume and a shorter flow time as a 
result of the above two in the early afternoon when compared to late 
evening, early morning, and the mid-night to morning periods. This signifi-
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cantly greater maximum flow in the afternoon in men with higher grades of 
obstruction, can be an important bias in studies where the primary 
endpoint is to assess a small improvement of maximum flow. Therefore, 
the circadian rhythm of uroflow has to be taken into account in the 
evaluation of the efficacy of treatment. 
Circadian changes in voided volume and maximum flow result in 
marked differences in flow time. While the differences between obstruc-
tion categories in flow time for the voidings produced at the hospital were 
not statistically significant, the difference in flow time for the voidings 
produced at home between midnight and 6 a.m. was statistically signifi-
cant. Between midnight and 6 a.m., severely obstructed patients have 
approximately a doubling of flow time compared with the flows produced 
in the afternoon and evening. 
How can we explain this circadian variability ? Kaplan et al., based 
on the similarity of patterns of occurrence between hypertension and BPH, 
suggested a shared underlying mechanism.17 He stated that "There is 
substantial evidence that the sympathetic nervous system plays an 
important etiologic role in both hypertension and BPH. The level of sym-
pathetic drive may have a circadian rhythm reaching a peak in the early 
morning, the time of the day at which most cardiovascular events occur." 
If this level of sympathetic drive really influences the lower urinary tract, 
the maximum flow of flows produced during the morning would be lower 
and this appeared to be true in our paper. This circadian rhythm also exists 
in asthmatic patients who experience a circadian variation with increased 
airway responsiveness and decreased lung function at night and the early 
morning compared with the rest of the day.18 Future studies are needed to 
elucidate the pathophysiology of the circadian variation in patients with 
hypertension, asthma and BPH. 
Patients with extreme differences between the morning and 
afternoon flow were more likely to be without bladder outlet obstruction. 
Obviously, patients without obstruction have greater voided volumes and 
greater maximum flows and consequently a greater variability may be 
expected. 
In the group of patients with severe obstruction, the flow produced 
in the afternoon had a mean voided volume of 143 ml with a standard 
deviation of 50 ml. This indicates that a considerable percentage of 
patients has an initial voided volume of less than 150 ml, a cut-off point 
that is frequently used as selection criterion in clinical trials. Evidently, 
some patients with obvious bladder outlet obstruction do not enter these 
trials whereas the largest urodynamic treatment responses are reported in 
patients with low maximal flow rates.19 When the flows with voided 
volumes less than 150 ml are excluded from the analysis and the morning 
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and afternoon results of flow at home are compared, it is clear that the 
improvement in maximum flow seems to increase. This may be explained 
by the fact that the afternoon flow has a significant lower voided volume 
and relatively more flows are excluded in the afternoon because the 
volume is less than 150 ml which may overemphasize the increase in 
maximum flow in the afternoon. 
In the present study, patients who had voided volumes less than 
150 ml in the majority of their flows were more obstructed than those 
who had voided volumes over 150 ml in the majority of their flows. 
Moreover, the total l-PSS score was significantly smaller in the latter 
group. This smaller total l-PSS score in patients who had voided volumes 
over 150 ml in the majority of their flows was primarily due to symptoms 
that are related to frequency: repeated urination, urge and nocturia. All 
these symptoms were significantly less frequently reported in patients who 
had voided volumes over 150 ml in the majority of their flows. Obviously, 
there is a direct relationship between obstruction, these patients have 
lower voided volumes, and frequency. These results are in agreement with 
the results of Ezz el Din et al who investigated the correlation between the 
diagnosis of bladder outlet obstruction and individual symptoms of the 
International-Prostate Symptom Score (l-PSS). They concluded that there 
was a statistically significant correlation between the specific questions of 
the l-PSS and objective grade of obstruction. Also in the study of Ezz el 
Din et al, the questions related to frequency: repeated urination, urge and 
nocturia showed better correlations with obstruction than other questions. 
However, the clinical significance of this finding was considered to be 
doubtful because none of the Spearman rank correlation coefficients was 
above 0.23, indicating very weak correlations. Furthermore, there was 
considerable overlap of symptom scores between patients with different 
grades of bladder outlet obstruction.20 We agree with their conclusion that 
subjective and objective methods measure different aspects of the clinical 
condition that should be viewed separately in the evaluation and treatment 
decision of the symptomatic patient. 
Conclusions 
There is an important circadian variability in that men with higher 
grades of obstruction having a higher peak urinary flow with a smaller 
voided volume and a shorter flow time as a result of the above two in the 
early afternoon when compared to late evening, early morning, and the 
mid-night to morning periods. This significantly greater maximum flow in 
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the afternoon in men with higher grades of obstruction, can be an import­
ant bias in studies where the primary endpoint is to assess a small 
improvement of maximum flow. Therefore, the circadian rhythm of uroflow 
has to be taken into account in the evaluation of the efficacy of treatment. 
Patients participating in clinical research studies should produce their 
urinary flow in the clinic always in the same time period, either in the 
morning or in the afternoon, and should not switch their appointment time. 
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Watchful Waiting 
Abstract 
Purpose: We quantified the physiological variability of clinical and pres-
sure-flow study variables in patients with symptomatic benign prostatic 
enlargement. 
Material and Methods: Symptom scores were measured, and advanced 
urodynamic studies with pressure-flow analysis were performed in 121 
patients before and 6 months after a period of watchful waiting. 
Results: Patients without bladder outlet obstruction experienced statisti-
cally significant symptomatic improvement. Symptoms in patients with 
obvious bladder outlet obstruction did not improve significantly. The 
reproducibility of mean pressure-flow variables was evident. However, 
there was an important intra-individual variability. Patients with obvious 
bladder outlet obstruction showed a significant decrease in detrusor 
pressure at maximal flow of 14 cm. water, a significant decrease in the 
urethral resistance factor URA of 7 cm. water and a significant decrease of 
1 obstruction class on the linear passive urethral resistance relation 
nomogram, indicating less severe bladder outlet obstruction. 
Conclusions: Mean differences among therapy groups must be regarded 
critically, especially when the differences are slight and possibly within 
physiological variability. 
Introduction 
Lower urinary tract symptoms (LUTS) in elderly men are traditional-
ly labeled prostatism. The term implies cause and remedy, whereas in 
reality the condition results not only from infravesical bladder outlet 
obstruction caused by the enlarged prostate gland, but also from motor or 
sensory abnormalities of detrusor and urethral function,1 or even from 
changes in habits and lifestyle that commonly occur as men age. Patients 
and physicians are anxious to know whether the symptoms are likely to be 
progressive and whether there is a risk of complications, such as obstruc-
tive nephropathy, acute or recurrent urinary retention, infection, bleeding, 
bladder stones or other complications that directly affect patient well-
being. 
The gold standard for treatment of patients with intractable urinary 
retention or obstructive uropathy in the upper urinary tract is still 
transurethral prostatectomy. In the past, physicians performed 
prostatectomy for all patients who presented with symptoms. Patients and 
physicians now have a variety of treatment modalities from which to 
choose. Presently, in most situations other factors must be considered 
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when deciding on the appropriate treatment, particularly bothersomeness 
of the voiding disturbances and patient preferences for treatment. A key 
issue is whether the physician should focus on relieving symptoms or 
obstruction. Unfortunately, lower urinary tract symptoms, prostate size, 
free uroflowmetry parameters and post-void residual urine are associated 
with obstructive voiding but the correlation with the grade of obstruction 
is poor.20 Furthermore, subjective efficacy of treatment cannot always be 
extrapolated to objective efficacy.7 
A non-invasive treatment approach is watchful waiting. More than 
a third of men with lower urinary tract symptoms who remain untreated or 
are treated with a placebo experience spontaneous improvement based on 
subjective criteria, and more than 20 % improve based on objective 
criteria.7 This spontaneous improvement usually occurs within the first 6 
months if at all.7 Due to the variable natural history of patients with lower 
urinary tract symptoms, and because new treatment modalities do not 
always result in such dramatic subjective and objective effects compared 
to prostatectomy, inclusion of a control-arm that allows quantification of 
these spontaneous effects is becoming increasingly important in any trial 
to evaluate accurately the efficacy of a new treatment modality. 
Urodynamic investigation is considered to be the gold standard to 
quantify the grade of bladder outlet obstruction in elderly men with lower 
urinary tract symptoms.8 Precise grading of obstruction is becoming 
increasingly important in the evaluation and comparison of new treatment 
modalities in patients with lower urinary tract symptoms and bladder outlet 
obstruction. However, precise grading is relatively sensitive to the effect 
of normal intra-individual variability. Rosier et al. showed that there is a 
considerable intra-individual variability in urodynamic pressure-flow vari-
ables when the filling and voiding session during a single urodynamic 
investigation is repeated.9 The second voiding session resulted in better 
voiding in a significant number of patients (65 % ) , with a lower detrusor 
pressure at maximum flow rate and a larger theoretical urethral area.9 
To compare the efficacy of new instrumental and non-invasive 
treatment modalities, and to investigate the reported spontaneous subjec-
tive and objective improvement after 6 months without active treatment, 
we determined the physiological variability of clinical and urodynamic 
pressure-flow study variables in patients with lower urinary tract symp-
toms and benign prostatic enlargement who were followed with the 
watchful waiting approach for 6 months. 
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Patients and methods 
In 1992, we initiated a prospective study to evaluate clinical and 
urodynamic changes in patients with lower urinary tract symptoms and 
benign prostatic enlargement in whom a watchful waiting approach was 
chosen. All patients were evaluated at baseline by medical history, interna­
tional prostate symptom score (l-PSS), prostate specific antigen (PSA) -
analysis, physical examination, including digital rectal examination and 
ultrasonography of the prostate, and free uroflowmetry with subsequent 
ultrasonographic measurement of residual urinary volume. The l-PSS 
consists of seven questions (total range 0 to 35), one of which constitutes 
nocturia score (range 0 to 5). The nocturia score indicates the number of 
times the patient must awaken to urinate during the night. A separate 
question constitutes quality of life (range 0 to 6; a greater score indicates 
worse perception of urinary performance). PSA was determined with the 
Hybritech Tandem-Ε PSA assay. 
Prostatic volume was calculated via the planimetrie method with a 
Kretz Combison 330 ultrasound scanner with a multiplane 3-dimensional 
rectal transducer. For free uroflowmetry the Dantec Urodyn 1000 
flowmeter was used. For evaluation of the voiding efficiency the voided 
percentage, which is the relative amount of bladder contents expelled 
during micturition, was calculated. All patients were considered neurologi-
cally normal based on history, symptoms and physical examination (no 
motor, sensory or reflex deficits). Patients in whom prostatic carcinoma or 
other diseases beyond the prostate, influencing the lower urinary tract 
symptoms (for example urethral stricture or bladder neck contracture) 
could be expected, ass well as those who had received previous treatment 
for lower urinary tract symptoms were excluded from the study. After 
clinical diagnosis of lower urinary tract symptoms and benign prostatic 
enlargement, patients were informed about the treatment options. When a 
urodynamic investigation showed no existence of bladder outlet obstruc­
tion and the patient experienced relatively few symptoms, or he was not 
bothered by symptoms, watchful waiting was recommended besides 
pharmacological treatment or other minimal invasive therapies. On the 
other hand, patients sometimes preferred watchful waiting even when 
bladder outlet obstruction was confirmed. l-PSS and urodynamic pressure-
flow studies before and after 6 months of watchful waiting were per­
formed to evaluate symptomatic and urodynamic changes. Urinalysis and 
culture were negative at the pressure-flow studies. 
Urodynamic pressure-flow studies were performed with an 8F 
transurethral lumen catheter equipped with an intravesical microtip pres­
sure sensor for bladder pressure recording. Abdominal pressure was 
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recorded intrarectally with an 8F microtip sensor catheter. Before 
cystometry, the bladder was emptied through the lumen of the 
transurethral catheter. The bladder was filled with water of 20° С with a 
filling speed of 50 ml. per minute with the patient supine. Commercially 
available equipment was used to record pressure and flow data. 
The pressure-flow relation during voiding was analyzed by a graph 
of flow and pressure with pressure projected on the Y-axis and flow on the 
X-axis. A pressure-flow graph near the Y-axis indicating a high pressure 
that generates a low flow, is the result of more obstructed voiding than a 
graph near the X-axis. Visual evaluation of a pressure-flow graph allows 
for a rough estimation of grade of obstruction. However, for an objective 
and quantitative definition of the pressure-flow relationship we used the 
passive urethral resistance relation analysis and urethral resistance factor 
URA. With passive urethral resistance relation analysis, a quadratic curve, 
the passive urethral resistance relation curve, is fitted to the lowest 
pressure part of the pressure-flow graph which is normally the phase of 
voiding subsequent to maximum flow (figure 1). 1 0 , 1 1 The detrusor pressure 
at maximum flow during the urodynamic investigation was recorded. The 
passive urethral resistance relation parameter minimal urethral opening 
pressure during micturition was observed at the end of voiding. The 
theoretical cross-sectional urethral lumen was computed from the slope of 
the passive urethral resistance relation curve.11 A steep curve with a slight 
angle to the pressure axis reflected a narrow urethral cross-sectional area. 
Griffiths et al. found a statistical correlation between theoretical cross-
sectional urethral lumen and minimal urethral opening pressure during 
voiding.12 This correlation was used to decrease both parameters to 1 
urethral resistance factor URA. URA quantifies obstruction by computing a 
preset curve with a fixed theoretical cross-sectional urethral lumen to 
minimal urethral opening pressure during voiding ratio, through the point of 
detrusor pressure at maximum flow. 
The digitally stored pressure and flow data were translated to a 
urodynamic analysis computer program developed by the research centre 
at our department. This program provides a semiautomatic pressure-flow 
study analysis with passive urethral resistance relation and urethral 
resistance factor analysis. The minimal urethral opening pressure during 
micturition and theoretical cross-sectional urethral lumen were calculated 
automatically based on the manually adjusted passive urethral resistance 
relation curves. Correction for flow artifacts was performed when necess­
ary. We also added a nonparametric analysis of obstruction with clinical 
classes according to the linear passive urethral resistance relation pressure-
flow nomogram (figure 1).1 1 The linear passive urethral resistance relation 
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Figure 1 . Passive urethral resistance relation curves of studied population. 
Detrusor pressure (cm. water) is projected on Y-axis and flow (ml. per 
second) is shown on X-axis. Indicated are passive urethral resistance 
relation curves based on mean urodynamic values of patients without 
(lower quadratic curve), with moderate (middle quadratic curve) and 
with obvious (upper quadratic curve) bladder outlet obstruction. Also 
indicated are 7 linear passive urethral resistance relation obstruction 
classes according to Schäfer et al.11 + , points of mean detrusor 
pressure at maximum flow. 
(L-PURR) was determined by drawing a straight line between the detrusor 
pressure at maximum flow and the minimal urethral opening pressure 
during micturition points on the pressure-flow curve. The position of this 
line defined the outlet condition in a simple manner and afforded classifica-
tion of the severity of bladder outlet obstruction. Urodynamic variables 
analyzed included free maximum flow rate, free voided volume, residual 
volume after free flowmetry and free voided percentage according to free 
flowmetry, bladder capacity at cystometry, maximum flow at urodynamic 
investigation, detrusor pressure at maximum flow, minimal urethral open-
ing pressure during micturition, theoretical cross-sectional urethral lumen, 
urethral resistance factor LIRA, residual volume after urodynamic pressure-
flow study and voided percentage at pressure-flow study according to 
pressure-flow study. Variables were investigated for the entire group of 
patients and for subgroups categorized without (L-PURR class 0 or 1), with 
moderate (L-PURR class 2 or 3) or with obvious (L-PURR class 4 or more) 
bladder outlet obstruction. Statistical analysis was performed using the 
Wilcoxon matched pairs signed rank test for analysis of numerical data and 
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the Kruskal-Wallis 1-way analysis of variance to compare baseline charac­
teristics among groups. The Spearman correlation coefficient was calcu­
lated to correlate bladder capacity and detrusor pressure at maximum flow. 
Results 
From January 1992 to November 1994, 750 new patients with 
lower urinary tract symptoms and benign prostatic enlargement were 
referred to our clinic for evaluation: 17 % were treated with transurethral 
thermotherapy, 20 % were treated surgically (laser, transurethral or open 
prostatectomy, bladder neck-incision), 37 % received medication (σΐ 
blockers or 5a-reductase inhibitors), 2 percent were treated with intermit­
tent or suprapubic catheterisation, and 178 (24%) chose watchful waiting. 
Four of the latter 178 patients were excluded from analysis because the 
initial L-PURR category could not be assessed. No pressure-flow study was 
done in 1 patient because he was unable to produce any f low at the initial 
intended voiding. Three other patients lost the transurethral (pressure 
recording) catheter during the initial voiding. The baseline characteristics of 
all 174 patients studied, and subgroups, without (44 % ) , with moderate 
(36 %) and with obvious (20 %) bladder outlet obstruction are indicated in 
table 1. In patients with obvious bladder outlet obstruction, the baseline 
mean prostatic volume was significantly larger (p = 0.02), while mean 
free voided volume (p = 0.01), free maximum flow rate (p < 0.01), 
bladder capacity (p < 0.01) and maximum flow at urodynamic investiga­
tion (p < 0.01 ) were significantly smaller. A total of 53 patients were not 
urodynamically évaluable at month 6 because they were lost to followup 
(31), refused the second urodynamic evaluation (19), began pharma-
cological treatment (2) or underwent surgery (1). In figure 2 the initial I-
PSS total symptom score and initial detrusor pressure at maximum flow, 
labeled according to the reason for dropping out before month 6, are 
plotted for each individual. This scatterplot indicates that for these vari-
ables patients who were lost to followup or who refused the second 
clinical and pressure-flow study evaluation were heterogeneously distrib-
uted amongst those who completed watchful waiting for 6 months. 
We evaluated 121 patients clinically and urodynamically after 6 
months (median 26 weeks, mean 3 1 , range 19-116) of watchful waiting 
(figure 3). Analysis of the pressure-flow relationship on the clinical 
nomogram11 showed that 47 % of these patients were without, 35 % had 
moderate and 18 % had obvious bladder outlet obstruction. Mean 
urodynamic variables, and median symptom scores at baseline and after 6 
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Table 1 . Mean ± so and median (rmnçe) (for symptom scores and /¡near passive 
urethra/ resistance relation category) baseline characteristics in 174 
patients, and for subgroups without, with moderate and with obvi-
ous bladder outlet obstruction. 
Linear Passive Urethral Resistance Relation Class 
Age (years) 
PSA (ng/ml) 
Prostate volume (cc) 
Total l-PSS score 
l-PSS nocturia score 
l-PSS QoL score 
Free void. vol. (ml) 
Free Umax (ml/sec) 
Free res. vol. (ml) 
Free void. pere. (%) 
Bladder capacity (ml) 
Urod. Qmax (ml/sec) 
Urod. res. vol. (ml) 
Urod. void. perc.(%) 
P^Qmax (cm. water) 
Pvokimin (cm. water) 
A*«, (mm2) 
URA (cm. water) 
L-PURR 
0 and 1 
(n = 77) 
65 ± 8 
2.5 ± 2.2 
37 ± 13 
13 (1-311 
2 (0-5) 
4 (0-6) 
324 ±1Θ9 
14.0 ± 5.Θ 
3 9 ± 59 
8 9 ± 15 
4 6 7 ± 132 
10.6 ± 4.2 
3 9 ± 74 
9 2 ± 15 
3 1 . 0 ± 12.2 
14.4 ± 7.2 
6.21 ± 3.08 
18.5 ± 10.4 
1 (0-11 
2 and 3 
(n = 63) 
6 3 ± 8 
2.7 ± 2.3 
37 ± 14 
1 3 (2-281 
2 (0-5) 
3.5 (0-6) 
3 3 6 ± 204 
13.2 ± 4 . 8 
5 3 ± 73 
8 6 ± 17 
4 7 0 ± 125 
8.3 ± 2.8 
6 2 ± 87 
8 7 ± 18 
54.9 ± 12.7 
26.3 ± 9.7 
3.63 ± 1.27 
30.6 ± e.o 
2 (2-3) 
4 and 6 
(n = 34) 
6 5 ± β 
4.7 ± 5.5 
4 9 ± 22* 
1 3 (2-33) 
2 (0-5) 
3 (1-5) 
2 3 0 ± 108* 
1 0 . 0 ± 3.8* 
6 3 ± 82 
8 2 ± 18* 
3 8 3 ± 9Θ* 
6.5 ± 3.2* 
8 0 ± 102 
8 0 ± 24 
8 7 . 9 ± 20.8* 
4 3 . 8 ± 21.7* 
2.23 ± 0.9Θ* 
5 0 . 2 ± 10.6* 
4 (4-6)* 
O t o 6 
(η = 174) 
6 4 ± 8 
3.0 ± 3.3 
3 9 ± 16 
13 (1-33) 
2 (0-5) 
3 (0-6) 
3 1 0 ± 176 
12.9 ± Б.з 
4 9 ± 70 
8 7 ± 16 
4 5 1 ± 127 
8.9 ± 3.9 
5 4 ± 85 
8 8 ± 18 
50.9 ± 25.6 
24.6 ± 16.3 
4 . 5 0 ± 2.74 
29.1 ± 14.9 
2 (0-6) 
Statistically significant difference (p < 0.05) in baseline character­
istics among 3 groups without, with moderate and with obvious 
bladder outlet obstruction. 
l-PSS: International Prostate Symptom Score. 
l-PSS QoL score: l-PSS Quality of Life Score. 
Urod. Qmax: maximum flow at urodynamic study. 
Urod. res. vol.: residual volume after urodynamic study. 
Urod. void, pere: voided percentage at pressure-flow study. 
Р а й т а х : detrusor pressure at maximum flow. 
Pvo¡dm¡n: minimum urethral opening pressure. 
A,·»: theoretical cross-sectional urethral lumen. 
URA: urethral resistance factor. 
L-PURR: linear passive urethral resistance relation class. 
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Figure 2. Scatterplot of reasons for dropping-out of study during first 6 months 
for each individual. Initial detrusor pressure at maximum flow (cm. 
water) is shown on Y-axis and total l-PSS is shown on X-axis. Indi­
cated are patients who completed watchful waiting (W.W.) for 6 
months, were lost to followup, refused their second urodynamic and 
clinical evaluation (2nd eval.), began pharmacological treatment or 
underwent surgery. 
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Figure 3. Percentage of patients (Y-axis), and time between first and second 
urodynamic study in weeks (X-axis). 
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Table 2. Mean ± so and median (range) (symptom scores and linear passive 
urethral resistance relation category! variables at baseline and after 6 
months of watchful waiting in 121 patients who completed the 
second urodynamic investigation. Legend see table 1. 
Baseline Month 6 Wilcoxon 
ρ Value 
% Second 
voiding 
Larger Smaller 
Total l-PSS score 
l-PSS nocturia score 
l-PSS QoL score 
13 (1-33) 
2 (0-6) 
3 (o-e) 
11 (1-30) 
1 (0-6) 
2 ιο-β) 
< 0.01 
< 0.01 
< 0.01 
33 
13 
6 
64 
34 
51 
Free voided vol. (ml) 
Free Umax (ml/sec) 
Free residual vol. (ml) 
Free voided pere. (%) 
314 ± 1Θ7 
13.2 ± 6.0 
48 ± Θ4 
87 ± 1Θ 
257 ± 146 
12.1 ±4.e 
34 ± se 
89 ± 15 
0.01 
0.03 
0.21 
0.93 
40 
38 
37 
42 
59 
58 
44 
43 
Bladder capacity (ml) 
Urod. Qmax (ml/sec) 
Urod. residual vol. (ml) 
Urod. voided pere. (%) 
P^Qmax (cm. water) 
Pvoidmin (cm. water) 
A««, (mm2) 
URA (cm. water) 
L-PURR 
460 ±123 
8.9 ± 3.6 
58 ± 89 
87 ± 20 
50.6 ± 24.5 
24.1 ± 14.8 
4.34 ± 2.23 
28.2 ± 13.6 
2 (0-5) 
435 ± 144 
8.8 ± 3.7 
46 ± 96 
90 ± 20 
46.9 ± 21.0 
21.3 ± 14.0 
4.38 ± 2.20 
26.9 ± 12.6 
2 (0-4) 
0.02 
0.29 
0.16 
0.10 
0.02 
0.10 
0.97 
0.35 
0.30 
41 
57 
25 
38 
41 
40 
48 
44 
27 
59 
38 
38 
23 
59 
58 
52 
51 
35 
Also indicated are the percentages of patients with a larger or smaller value at the 
2nd voiding. Ρ values indicate the comparison of results at baseline versus month 6. 
months of watchful waiting for the 121 patients who completed watchful 
waiting for 6 months, are indicated in table 2, as are the percentages of 
patients with a larger or smaller result at the second voiding. At the 
second free flowmetry, 59 % of the patients voided with a smaller volume 
and, consequently, 58 % voided with a decreased free maximum flow rate 
compared to the first free flowmetry. There was almost no difference in 
mean maximum flow at urodynamic investigation (0.1 ml. per second) but 
a significant number of patients (59%) voided with a lower detrusor 
pressure at maximum flow rate the second time. Bladder capacity and 
detrusor pressure at maximum flow decreased statistically significant at 
the second voiding. Calculation with the Spearman correlation coefficient 
showed that there was no significant correlation (r = -0.15, ρ = 0.10) 
between bladder capacity and detrusor pressure at maximum flow. Fur-
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thermore, patients with a smaller voided volume at the second urodynamic 
investigation (59 %) had a mean decrease in detrusor pressure at maxi-
mum flow of 3.9 cm. water, while those with a larger voided volume (42 
%) had a mean decrease of detrusor pressure at maximum flow of 2.1 cm. 
water. When the theoretical urethral area and urethral resistance factor 
URA were considered, no significant mean differences were shown at the 
second voiding. A statistical significant number of patients had an 
improved total l-PSS, an improved l-PSS nocturia score and an improved I-
PSS quality of life score after 6 months of watchful waiting. However, 
mean improvement was clinically not relevant. 
Table 3 shows the mean individual absolute differences, that is the 
positive difference resulting from the subtraction of both voidings. 
Themean absolute difference plus or minus standard deviation in maximum 
flow at urodynamic investigation between both voidings was 2.3 ± 2 . 1 
ml. per second. Values of extreme, large and small differences are shown 
in this table, as well as the number of patients exceeding these differ-
ences. In 50 patients (42 %) the difference in maximum flow at 
urodynamic investigation between both voidings was more than 2.0 ml. 
per second and in 36 (30 %) there were only slight differences (less than 1 
ml. per second). Mean maximum flow at urodynamic investigation in 
patients with extreme differences did not change significantly. In the entire 
group mean maximum flow at urodynamic investigation was 8.9 ± 3.8 ml. 
per second initially and 8.8 ± 3.7 ml. per second at the second study. In 
the group with extreme differences mean maximum flow at urodynamic 
investigation was 8.9 ± 3.9 ml. per second initially, and 9.4 ± 3.8 ml. 
per second at the second study. When evaluating patients with extreme 
differences of detrusor pressure at maximum flow, it appeared that they 
had either an extreme small or an extreme large detrusor pressure at maxi-
mum flow at the initial voiding. Patients with extreme differences in 
theoretical cross-sectional urethral lumen were mainly those with an 
extreme large theoretical cross-sectional urethral lumen at the initial 
voiding. When we performed the statistical analysis without the patients 
with extreme values as indicated in table 3, the mean results remained 
unchanged, indicating that extreme differences in the entire group of 
patients occurred at the same magnitude in the negative and positive 
directions. 
In table 4, the clinical and urodynamic parameters at baseline and 
after 6 months of watchful waiting are shown for 121 patients, 
grouped by L-PURR classification. In patients without bladder outlet 
obstruction total l-PSS, l-PSS nocturia score and the l-PSS quality of 
lifescore improved significantly. These improvements were slight and 
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clinically not relevant. In the group with moderate bladder outlet obstruc-
tion the improvements in total l-PSS and l-PSS quality of life score were 
also statistically significant but clinically irrelevant. In the group with 
obvious bladder outlet obstruction a significant improvement in total l-PSS, 
l-PSS nocturia score and l-PSS quality of life score could not be shown. 
Mean free voided volume and free maximum flow rate were decreased at 
the second voiding but the differences were not statistically significant in 
the 3 groups. Compared to the first result, the second mean detrusor 
pressure at maximum flow was 5.2 cm. water larger (p = 0.18) in the 
group without bladder outlet obstruction, 9.7 cm. water smaller (p < 
0.01) in the group with moderate obstruction and 14.1 cm. water smaller 
(p = 0.01) in the group with obvious bladder outlet obstruction. When 
patients with extreme differences in detrusor pressure at maximum flow 
(table 3) were excluded, the differences in mean detrusor pressure at 
maximum flow were not significant. The second mean detrusor pressure at 
maximum flow in the group without bladder outlet obstruction was then 
1.7 cm. water larger (p = 0.46) and in the group with moderate obstruc-
tion it was 9.0 cm water smaller (p < 0.01), while in the group with 
obvious bladder outlet obstruction the second mean detrusor pressure at 
maximum flow was 5.6 cm. water smaller (p = 0.11). 
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Figure 4. Scatterplot indicates initial detrusor pressure at maximum flow (cm. 
water) on Y-axis and initial total l-PSS on X-axis for all patients with 
followup longer than 6 months, according to last treatment: watchful 
waiting, pharmacological treatment, transurethral microwave 
thermotherapy (TUMT) or surgery. 
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Compared to the first result, the second mean minimal urethral 
opening pressure during voiding and urethral resistance factor were 0.5 
and 2.8 cm. water larger in the group without bladder outlet obstruction (p 
= 0.99 and ρ » 0.02, respectively), and 4.9 and 3.1 cm. water lower in 
the group with moderate bladder outlet obstruction (p = 0.03 and ρ = 
0.08, respectively). In the group with obvious bladder outlet obstruction 
the second mean minimal urethral opening pressure during voiding and 
urethral resistance factor were 5.1 and 7.0 cm. water smaller (p = 0.52 
and ρ = 0.02, respectively). Mean theoretical cross-sectional urethral 
lumen did not change significantly. The second mean theoretical cross-
sectional urethral lumen was 0.35 mm.2 smaller in the group without 
bladder outlet obstruction (p = 0.23), 0.47 mm.2 larger in the group with 
moderate obstruction (p = 0.29) and 0.24 mm.2 larger in the group with 
obvious bladder outlet obstruction (p = 0.14). Although the median linear 
passive urethral resistance relation in the group without bladder outlet 
obstruction remained unchanged (class 1), the second linear passive 
urethral resistance relation category was larger in 22 patients, smaller in 
10 and remained unchanged in 22. This difference was statistically 
significant (p = 0.01). In the group with moderate bladder outlet obstruc­
tion the median linear passive urethral resistance relation classification 
remained unchanged (class 2). The second linear passive urethral resis­
tance relation category in these patients was greater in 10, smaller in 18 
and remained the same in 13 (p = 0.05). In the group with obvious 
bladder outlet obstruction the median linear passive urethral resistance 
relation changed from 4 (range 4 to 5) to 3 (range 2 to 4), which was 
significant. Of these patients 14 had a smaller linear passive urethral 
resistance relation at the second voiding, 7 remained unchanged and none 
had a larger value (p < 0.01). 
After evaluation at month 6, 102 patients (84%) continued watch­
ful waiting, 9 began pharmacological treatment, 4 underwent transurethral 
microwave thermotherapy and 6 underwent surgery. Thereafter, 66 
patients were followed for a median of 31.4 weeks (range 1 to 97), during 
which time 2 underwent surgery and 2 began pharmacological treatment. 
In figure 4 the initial detrusor pressure at maximum flow and total l-PSS 
are indicated for each individual, with a followup of longer than 6 months, 
labeled according to the last treatment policy: surgery in 9, transurethral 
thermotherapy in 4, pharmacological treatment in 16 and watchful waiting 
in 114. This figure indicates that all patients who underwent surgery or 
who received transurethral thermotherapy had a large initial detrusor 
pressure at maximum flow (all but 1 had an initial detrusor pressure at 
maximum flow of more than 55 cm. water), and that patients who 
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received pharmacological treatment had a small initial detrusor pressure at 
maximum flow (all but 1 had an initial detrusor pressure at maximum flow 
of less than 55 cm. water). Initial total l-PSS values were heterogeneously 
distributed among the different treatment options. 
Discussion 
Urodynamic investigation with pressure-flow study evaluation and 
symptom scores enabled us to investigate the relationship between 
objective and subjective efficacy of treatment. Previously, when the 
therapeutic choice was limited to surgery or watchful waiting, pressure-
f low evaluation was simply used to diagnose bladder outlet obstruction. 
Because new, less invasive treatment modalities are now available, precise 
grading of obstruction is increasingly important in the evaluation of treat-
ment efficacy.13 The clinical nomogram used in our study has 7 obstruction 
categories, and is more detailed than a diagnosis of obstruction or no 
obstruction.11 Pressure-flow evaluation is able to provide a continuous 
numeric scale of obstruction and, therefore, is even more refined. Further-
more, stratification of therapeutic options based on the individual, accu-
rately assessed, grade of obstruction has recently become available.14,15 
For a reliable assessment of grade of obstruction on a numeric scale, it is 
essential that the test result is accurate and reproducible. The accuracy 
and reproducibility of a test can be determined by repeating it directly after 
the test has been done, and by repeating it at different times or with 
different equipment depending on the circumstances. Rosier et al showed 
that the test result of pressure-flow studies is reproducible, with only 
slight variability when the filling and voiding session during a single 
urodynamic pressure-flow study is repeated.8 We studied the intra-individ-
ual variability of the test results of symptom scores and pressure-flow 
studies when the test was repeated after 6 months without treatment. 
When evaluating the total investigated group of patients and 
comparing our results with those of Rosier et al,9 the mean changes in 
detrusor pressure at maximum flow, maximum flow at urodynamic investi-
gation and urethral resistance factor were comparable. In the study of 
Rosier et al 63 % of the patients voided the second time with a smaller 
detrusor pressure at maximum flow, and the mean difference of 3.0 cm. 
water was statistically significant.9 In our study 59 % of the patients 
voided the second time with a smaller detrusor pressure at maximum f low, 
and the mean difference of 3.7 cm. water was statistically significant. 
However, the mean difference in theoretical cross-sectional urethral lumen 
in the study of Rosier et al was 0.36 mm.2, which was statistically signifi-
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cantly larger the second time,9 while in our study there was only an insig­
nificant difference of 0.04 mm.2. Regarding the variations of pressure-flow 
study variables in our study, the percentage of patients with extreme or 
large differences of urodynamic pressure-flow study variables was greater 
but the mean pressure-flow study variables were not relevantly different 
(table 3). However, there was a statistically significantly smaller detrusor 
pressure at maximum flow and bladder capacity at the second evaluation 
(table 2). However, the magnitude of the changes in detrusor pressure at 
maximum flow and bladder capacity was slight and the clinical relevance 
must be questioned. A smaller bladder capacity may theoretically result in 
decreased pressure at micturition with a smaller detrusor pressure at maxi­
mum flow. Therefore, we calculated the Spearman correlation coefficient 
in our patients. There appeared to be no significant correlation (r = -0.15, 
ρ = 0.10) between bladder capacity and detrusor pressure at maximum 
flow. Furthermore, 62 patients with a smaller voided volume at the second 
urodynamic investigation had a mean decrease in detrusor pressure at 
maximum flow of 3.9 cm. water, while those with a larger voided volume 
at the second urodynamic investigation had a mean decrease of 2.1 cm. 
water. This finding indicates that in our study it is not likely that a smaller 
bladder capacity is the important factor resulting in a decreased detrusor 
pressure at maximum flow. Rosier et al studied relatively more patients 
with an increased grade of bladder outlet obstruction and, therefore, we 
must be cautious when drawing conclusions from a comparison of, in 
essence, 2 different populations.9 The greater variability found in our study 
could be due to the variations in the dynamic component as described by 
Caine.18 Caine suggested that a combination of mechanical and dynamic 
components has a significant impact on lower urinary tract symptoms. The 
mechanical component, that is the enlarged prostate gland, does not 
spontaneously decrease with time.17 In contrast, the dynamic component 
is subject to rapid changes depending on a variety of factors that influence 
sympathetic activity. Among these factors, stress, cold, and use of 
sympathomimetic agents can increase clinical symptoms, indicating that 
these dynamic components probably involve the smooth muscle tone in 
the prostate, prostate capsule and bladderneck.18-'8 With a longer interval 
between investigations the dynamic component may have a greater impact 
on the differences between the test results. 
The values at baseline confirm that patients with obvious bladder 
outlet obstruction have decreased maximal flow rates. In our study 
patients with obvious bladder outlet obstruction also had significantly 
decreased free voided volumes and a significantly smaller bladder capacity. 
In the obvious bladder outlet obstruction group a free voided volume of 
133 
Watchful Waiting 
230 ± 1 0 8 ml. indicates that, although they are instructed to present to 
the outpatient clinic with a full bladder, a considerable percentage of 
patients have an initial voided volume of less than 150 ml., which is a cut-
off point frequently used as a selection criterion in clinical trials. Evidently, 
some patients with obvious bladder outlet obstruction do not enter these 
trials, while the largest urodynamic treatment responses are reported in 
those with low maximal flow rates.19 Consequently, the study results may 
not be linearly extrapolated to the population. In fact, clinical trials in 
patients with a free voided volume of 150 ml. or more may underestimate 
the urodynamic treatment responses that could be detected in the popula-
tion. 
At the second free flowmetry study 59 % of the patients voided 
with a smaller volume and, consequently, 58 % voided with a decreased 
free maximum flow rate compared to the first study. When comparing the 
free voided volumes with free maximum flow rate using the Liverpool 
nomograms, it appeared that the mean values of the first voiding, that is 
voided volume of 314 ml. and free maximum flow rate 13.2 ml. per 
second, correspond with the 7th percentile, while the mean values of the 
second voiding, that is voided volume 257 ml. and free maximum flow rate 
of 12.1 ml. per second, correspond with the 8th percentile of the healthy 
men investigated.20 This finding indicates that the changes in flow rates 
were merely a result of changes in voided volumes. 
The prostatic volume in patients with obvious bladder outlet 
obstruction was significantly higher, confirming the statistically significant 
although moderate correlation between prostate size and bladder outlet 
obstruction.69 
After 6 months of watchful waiting, total l-PSS was significantly 
less in 64 % of the patients, l-PSS nocturia score was significantly less in 
34 % and l-PSS quality of life score was significantly less in 51 %, 
confirming that subjective differences do not always correlate with objec-
tive differences in urodynamic variables.7 In patients without bladder outlet 
obstruction all subjective tests were statistically significantly improved 
after 6 months of watchful waiting. In patients with moderate bladder 
outlet obstruction, only total l-PSS and l-PSS quality of life score were 
statistically significantly improved. One may argue that the subjective 
difference after 6 months of watchful waiting in patients without and with 
moderate bladder outlet obstruction was statistically significant but 
clinically irrelevant, although it is remarkable that in those with obvious 
obstruction no subjective improvement was shown. There was not even a 
tendency for improvement in total l-PSS and l-PSS nocturia score. This 
finding confirms the results of the Veterans Affairs Cooperative Study on 
transurethral resection of the prostate versus watchful waiting.21 In this 
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study the symptomatic patients were randomized for either watchful 
waiting or surgery. In the watchful waiting group 30 to 40 % of the 
patients showed symptomatic improvement. This group may, in fact, be 
patients without bladder outlet obstruction (44 % of our patients). The 
authors concluded that watchful waiting is usually a safe alternative for 
men who are less bothered by urinary difficulty or who wish to delay 
surgery. We agree with their conclusion because we have shown that in 
patients with obvious bladder outlet obstruction symptoms may not 
improve but certainly they do not worsen. Moreover, the urodynamical 
status after 6 months of watchful waiting in patients with obvious bladder 
outlet obstruction does not seem to worsen. However, the long-lasting 
urodynamical effect in patients with obvious bladder outlet obstruction is 
still uncertain. Hopefully we will be able to extend our study and to repeat 
the investigations in some patients who remained on watchful waiting to 
evaluate the natural history of lower urinary tract symptoms and benign 
prostatic enlargement with or without bladder outlet obstruction. However, 
with time more patients will be lost to followup or treated as shown in 
figure 4. 
At our centre, patients with a large initial detrusor pressure at 
maximum flow were treated with transurethral thermotherapy or surgery, 
while those with a low initial detrusor pressure at maximum flow were 
treated pharmacologically. The initial symptom scores were heterogen-
eously distributed among the different treatment options. Apparently, for 
the physicians at our centre the results of pressure-flow studies rather 
than symptom scores have an important role in determining the choice of 
therapy (figure 4). 
The changes in mean pressure-flow study variables between the 3 
linear passive urethral resistance relation groups were remarkably different. 
Patients without bladder outlet obstruction had changes indicating more 
obstruction, while those with bladder outlet obstruction initially had less 
obstruction. The increases of mean urethral resistance factor and mean 
linear passive urethral resistance relation in patients without bladder outlet 
obstruction were slight but statistically significant. The decreases in mean 
detrusor pressure at maximum flow and mean minimal urethral opening 
pressure during voiding in patients with moderate bladder outlet obstruc-
tion were significant, and the decreases in mean detrusor pressure at 
maximum flow, urethral resistance factor and linear passive urethral 
resistance relation in patients with obvious bladder outlet obstruction were 
significant. Even mean residual volume and mean voided percentages at 
pressure-flow study improved significantly in patients with obvious bladder 
outlet obstruction. The difference in mean detrusor pressure at maximum 
135 
Watchful Waiting 
flow in patients with obvious obstruction was 14.1 cm. water, which 
comes close to the suggested clinically relevant cutoff point for differences 
in pressure classes of 15 cm. water.9 These findings could be explained by 
regression towards the mean, a statistical phenomenon in which, if a 
followup sample is chosen based on extreme scores, the retest scores will 
tend to be closer to the population mean than the initial scores. As sug­
gested by Caine," numerous varying factors may influence the dynamic 
part of the obstruction, and these factors may occasionally combine to 
produce a result that is either extremely large or extremely small. When 
measurements are repeated, it is unlikely that components that involve a 
random element should combine again in this extreme fashion. Large 
values accordingly tend to decrease, while small values tend to increase. 
Just as these extreme values tend to regress to the population mean on 
reexamination, patients with chronic but fluctuating conditions tend to 
seek medical attention in the 'bad' periods during exacerbations. 
Consequently, patients are more prone to improve than to deteriorate 
further regardless of the treatment the physician institutes. 
We compared the previously reported urodynamic treatment 
efficacy of new instrumental and noninvasive therapies to the physiological 
variability reported in our study. After laser prostatectomy, an individual 
mean improvement of detrusor pressure at maximum flow of 37 cm. water 
was reported.22 This result is unequivocal and larger than the expected 
physiological variability. After transrectal high intensity focused ultrasound 
and transurethral thermotherapy of the prostate, statistically significant 
improvements in mean detrusor pressure at maximum flow of 11 and 10 
cm. water have been reported.23,24 Based on our results, these findings 
could be obtained simply by repeating the urodynamic pressure-flow evalu­
ation after 6 months without therapy. Tammela and Kontturi reported a 
mean decrease in detrusor pressure at maximum flow of 39 cm. water 
after finasteride treatment for 6 months and a mean increase of detrusor 
pressure at maximum flow of 3 cm. water in the placebo treated group, 
indicating a significant response to treatment.26 The results of this study 
conflict with our results. Considering the large mean detrusor pressure at 
maximum flow in the study by Tammela and Kontturi (120 cm. water), the 
majority of the patients studied had severe bladder outlet obstruction, and 
we would also expect a decrease in detrusor pressure at maximum flow in 
the placebo treated group.26 The urodynamic response in a study evaluat­
ing the efficacy of doxazosin, an σ1 selective blocker, although signifi­
cantly better compared to placebo treatment, was slight (improvement in 
detrusor pressure at maximum flow 5 cm. water) and within physiological 
variability.28 These findings indicate that mean differences among therapy 
groups must be regarded critically, particularly when the reported differ-
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enees are slight and possibly within physiological variability. The variability 
of pressure-flow parameters in our study was greater than in a previous 
study when the filling and voiding session during a single urodynamic 
pressure-flow study was repeated. However, mean pressure-flow parame-
ters were only slightly different. This finding indicates that the dynamic 
component of obstruction actually exists and should be considered in the 
evaluation of new treatment modalities for patients with lower urinary 
tract symptoms and benign prostatic enlargement. 
Conclusions 
We demonstrated that patients without bladder outlet obstruction 
experienced statistically significant but slight symptomatic improvement 
after 6 months of watchful waiting. Symptoms of patients with obvious 
bladder outlet obstruction did not improve significantly. From a clinical and 
diagnostic viewpoint, the reproducibility of mean pressure-flow study 
results after 6 months of watchful waiting was evident. However, there 
was an important intra-individual variability. Patients with extreme values 
at the initial pressure-flow study tended to experience regression towards 
the mean of the population at the second evaluation. Patients with obvious 
bladder outlet obstruction showed a significant decrease in detrusor 
pressure at maximum flow of 14 cm. water, a significant decrease of 
urethral resistance factor of 7 cm. water and a significant decrease of 1 
obstruction class on the linear passive urethral resistance relation 
nomogram, indicating less severe bladder outlet obstruction. Mean differ-
ences among therapy groups must be regarded critically, particularly when 
the reported differences are slight and possibly within their physiological 
variability. Due to the physiological variability caused by the dynamic 
component of obstruction any clinical trial evaluating a new treatment 
modality should include a control arm that allows quantification of this 
physiological variability. 
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Terazosin: International Terazosin Trial 
Abstract 
Objectives: To evaluate the long-term efficacy and safety of terazosin in 
the treatment of benign prostatic hyperplasia (BPH). 
Patients and methods: Thirty-three sites in 13 countries enrolled men 
with BPH who had an International Prostate Symptom Score (l-PSS) ¿ 12. 
After a 2-week, no-treatment lead-in period and a 24-week, single-blind 
treatment period, patients responding to terazosin were randomly assigned 
to receive either terazosin or placebo for a 24-week, double-blind with-
drawal period. 
Results: Of the initial 427 patients enrolled, 378 were évaluable, 273 of 
whom completed the single-blind period, of which 186 patients were 
randomized. During the single-blind treatment period, l-PSS, quality of life 
score (QoL), peak flow rate (Qmax), and nocturia score (Noe) improved 
significantly (p <. 0.05). During the double-blind withdrawal period, l-PSS, 
QoL, Qmax, and Noe deteriorated significantly in the placebo group 
compared with the terazosin group. The most common adverse event 
resulting in premature termination from the study was dizziness. There 
were no clinically important mean reductions in diastolic blood pressure 
(DBP) for patients normotensive at baseline. Terazosin significantly 
reduced mean DBP in hypertensive patients during the single-blind period 
and maintained the reduction during the double-blind period. 
Conclusions: Treatment with terazosin has a beneficial effect on BPH, 
continuing for at least 12 months, and can be safely considered for medium-
to long-term use in those who benefit. 
Introduction 
Benign prostatic hyperplasia (BPH) is a condition that affects many 
men after middle age. A meta-analysis of 10 autopsy studies shows that 
approximately 50% of men aged 60 years or older have histological 
evidence of BPH; the percentage rises to nearly 80% for men aged 80 
years or older.1 
Patients suffering from BPH have conventionally been treated by 
surgical resection of the enlarged prostate gland. Since it is known that σ,-
adrenoceptors are present in the bladder neck and prostate smooth 
muscle,2 σ,-blocking agents have been successfully used to relieve symp­
toms and improve urinary flow rates in patients with BPH. Terazosin is a 
long-acting σ,-selective blocking agent that was originally used for the 
treatment of arterial hypertension. The effects of terazosin on symptom 
scores and urinary flow rates have been previously documented.3"'0 
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This randomized, placebo-controlled, double-blind, multicentre 
study was performed to evaluate the long-term efficacy and safety of 
terazosin in the treatment of patients with BPH. While many terazosin 
studies have focused primarily on changes in symptom scores and flow 
rates, this study examines four additional aspects of terazosin therapy: 1 ) 
changes in patient quality of life (QoL); 2) the effect of randomized with-
drawal following an initial treatment period; 3) the effect of terazosin on 
prostate-specific antigen (PSA) in a prospective study; and 4) the effect of 
terazosin on blood pressure in normotensive and hypertensive patients, 
whether or not the patients were controlled with other antihypertensive 
therapy. 
Patients and methods 
Patients 
Men ¿ 45 years old with BPH were to be enrolled in the study if 
they had an International Prostate Symptom Score (l-PSS) 2: 1 2 , " a peak 
urinary flow rate (Qmax) between 5 and 15 ml/s, a voided volume ¿ 1 0 0 
ml, no urinary tract infection (determined by urine analysis), and a residual 
volume < 300 ml (determined by ultrasound). Diagnosis of BPH was based 
on medical history, physical examination (including digital palpation of the 
prostate), and assessment of symptoms listed on the l-PSS form. PSA was 
measured to aid the diagnosis of prostate cancer (an exclusion criterion).. 
The study included normotensive patients (diastolic blood pressure (DBP) 
< 90 mm Hg), untreated hypertensive patients whose DBP was ^ 115 
mmHg, and hypertensive patients treated with antihypertensive agents 
other than verapamil. Investigators could adjust at their discretion the 
dosage of antihypertensive agents. 
The study excluded hypotensive patients, as well as patients taking 
or recently having received experimental drugs or other medications that 
might interfere with the study (eg, σ-blockers, anti-androgens, 
gonadotrophin-releasing hormone analogues, and herbal extracts). Also 
excluded were patients who had suffered a myocardial infarction or 
transient ischaemic attack within the past 6 months, and patients having 
histories of cerebrovascular accidents, fainting spells, blackouts, known or 
suspected prostate cancer, urethral stricture, gross haematuria, insulin-
dependent diabetes mellitus, renal or hepatic impairment, and certain 
genito-urinary disorders (eg, urinary tract infection). Patients having 
received pelvic radiation or prior surgery for BPH or bladder-neck obstruc-
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tion were also excluded. In addition, patients known to be hypersensitive 
to or non-responsive to σ,-blockers were not included in the study. 
Criteria for the evaluability of patients for efficacy analysis were 
determined prior to initiation of the study. After the study was completed, 
patient evaluability was assessed prior to breaking the study blind. 
Treatment schedule 
This study was divided into three successive parts (figure 1): 1) a 
2-week, no-treatment lead-in period; 2) a 24-week, single-blind treatment 
period; and 3) a 24-week, randomized, double-blind withdrawal period for 
patients responding to treatment. Responders were those patients whose 
l-PSS decreased ¿ 30% from baseline and whose Qmax increased a 
10% from baseline to the end of the single-blind treatment period. 
Investigators screened patients for selection criteria at the initial 
visit. After the 2-week lead-in period, baseline values were established for 
the following study variables: l-PSS, QoL, Qmax, voided volume, nocturia 
score (Noe), PSA level, blood pressure, and pulse rate. After baseline 
values were established, qualifying patients received at the evening of this 
visit an initial dose of 1 mg terazosin and then 2 mg daily for the next 13 
days. Patients then received daily doses of 5 mg for 4 weeks followed by 
10 mg for another 4 weeks. Patients not tolerating the 10 mg dose then 
had their dosage decreased to 5 mg. At week 26, responders were 
randomly assigned to continue receiving the same maintenance dose (5 or 
10 mg) of terazosin that they had been given during the single-blind 
treatment period or to begin receiving placebo. The randomization schedule 
was prepared by computer and was performed by the statisticians inde-
5 
10 mg 10 mg 
Placebo 
5 mg 
Placebo 
1 
Week -2 0 2 6 10 18 26 34 42 50 
Visit 1 2 3 4 5 β 7 β 9 10 
I—I—I 1 1 1 1 1 1 1 
Lead-in Single-blind Randomized withdrawal 
period period period 
Figure 1. Study design. 
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pendently of the clinical group. All study medications were taken at 
bedtime; placebo tablets were identical to terazosin tablets in colour, 
shape, size and appearance. Clinical supplies were provided by Abbott 
Laboratories, International Division. 
For the first 4 weeks of the study, patients were seen every other 
week. For the next 8 weeks, patients were seen every fourth week. For 
the last 40 weeks, patients were seen every eighth week. 
Study procedures 
Prior to all study procedures, each patient gave informed consent. 
Patients were evaluated at baseline and at each visit using an l-PSS form. 
Seven questions on the evaluation form constituted l-PSS (range 0-35) . 
One of these seven questions constituted Noe (range 0-5) . (A Noe of 0-4 
directly represents the average number of times per night that a patient 
got out of bed to urinate; a Noe of 5 represents five or more times per 
night.) A separate question constituted QoL (range 0-6) . Higher scores 
indicate worse symptoms and quality of life. Vital signs, including blood 
pressure and pulse rate, were also evaluated at baseline and at each visit 
thereafter. Uroflowmetry variables, including peak and mean urinary flow 
rates and total voided volume, were electronically measured at baseline, at 
26 weeks, and at each visit thereafter. The total volume voided during 
each uroflowmetric measurement was required to be ^ 100 ml. 
Additional study procedures included a PSA assay, evaluation of 
treatment failure, and urine analysis. Blood samples were obtained for PSA 
assays at baseline, at week 26, and at the last visit; these samples were 
drawn prior to digital palpation of the prostate. PSA levels were measured 
using IMx testing kits (Abbott Laboratories, North Chicago, Illinois, USA). 
During the single-blind period, to determine the statistical signifi-
cance of observed differences for l-PSS, QoL, Qmax, and Noe, a t-test on 
mean change from baseline to final visit was used. During the double-blind 
period, statistical significance of differences between treatment groups for 
l-PSS, QoL, Qmax, Noe, vital signs, and PSA was determined using a one-
way analysis of variance. The carry-forward convention was used for I-
PSS, QoL, Qmax, and Noe. Fisher's exact test comparison was used for 
adverse events. 
Demographics 
Four hundred and twenty-seven patients were enrolled in the 
single-blind treatment period from 33 sites in 13 countries. Of those 
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patients, 49 were not évaluable because they either failed to meet inclu-
sion criteria, were disqualified because of exclusion criteria, had no valid 
baseline, or had no évaluable visits. Of the 378 évaluable patients, 273 
completed the single-blind treatment period; the other 105 patients were 
lost to follow up or withdrew due to adverse events. Of those who 
completed the single-blind study period, 186 patients from 29 sites in 11 
countries qualified for randomization into the double-blind withdrawal 
period. Nonqualification was largely due to insufficient improvement in 
symptom score and/or Qmax. Eleven patients were erroneously random-
ized and thus were not évaluable. Of the 175 évaluable, randomized 
patients, 149 completed the double-blind period. Among the 26 patients 
who withdrew from the study during the double-blind period, the l-PSS 
measures of 19 patients were carried forward from the termination visit 
and included in efficacy analysis. The l-PSS for one of the patients who 
completed the double-blind period was invalid and was therefore excluded; 
this resulted in 167 évaluable patients for l-PSS analysis. 
After having their terazosin dosage escalated to a 10 mg dose 
during the single-blind treatment period, 86.9% (152/175) of patients who 
were later randomized continued at that dosage while 13.1 % (23/175) had 
their dosage reduced to 5 mg. At entry to the single-blind period the mean 
age for all patients was 63.6 years. 
Results 
Single-blind efficacy 
The four primary efficacy variables in this study were l-PSS, QoL, 
Qmax, and Noe. During the single-blind treatment period, terazosin pro-
duced statistically significant improvements from baseline to the final visit 
in all four variables. These improvements were shown not only in patients 
who qualified for the double-blind period, but also for all patients who 
completed the single-blind period (table 1). There were no differences in 
responses between patients who were later randomized to terazosin 
compared with those randomized to placebo. 
Regarding the onset of action of terazosin, 51.3% (138/269) of all 
patients completing the single-blind period experienced ^ 30% improve-
ment in l-PSS by week 2; by week 10 this percentage increased to 82.2% 
(208/253) and by week 26 to 85.2% (219/257). 
While 67.0% (175/261) of all patients completing the single-blind 
period experienced improvement in nocturia (12 patients whose baseline 
Noe was 0 were excluded from this result), 9 8 . 1 % (51/52) of patients 
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Table 1 . Mean changes in efficacy variables from baseline to the final visit of 
the single-blind period. 
Patients who were later randomized 
into the double-blind period 
Symptom score 
Quality of life score 
Qmax (ml/s) 
Nocturia score 
η 
175 
175 
159 
175 
Mean baseline 
19.1 
3.7 
9.7 
2.6 
Mean change 
-12.4* 
-2.0· 
4.7· 
-1.3* 
% change 
64.9 
53.6 
47.8 
50.6 
All patients completing the single-blind period 
Symptom score 
Quality of life score 
Qmax (ml/s) 
Nocturia score 
η 
273 
273 
239 
273 
Mean baseline 
18.5 
3.6 
9.8 
2.4 
Mean change 
-10.7· 
-1.7* 
3.1· 
-1.0· 
% change 
57.7 
47.2 
31.8 
42.9 
•Statistically significant (p s 0.05) difference from baseline. 
whose baseline Noe was 4 or 5 experienced improvement. (Improvement 
in nocturia was defined as a reduction of Noe by at least 1.) 
Double-blind efficacy 
During the double-blind withdrawal period, the mean changes in I-
PSS, Noe, QoL, and Qmax were significantly less for the terazosin group 
compared with the placebo group (table 2). Except for Noe at the final 
visit, the differences between groups for all four efficacy variables were 
statistically significant (p <. 0.05) at all three visits of the double-blind 
period (figures 2-4). Also, from the start of the double-blind period to the 
final visit, the changes in QoL and Qmax were not statistically significant 
in the terazosin group. In the placebo group, changes were statistically 
significant (p <, 0.05) for all four efficacy variables. 
As estimated by the Kaplan-Meier method, the cumulative rate of 
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relapse at 180 days in the placebo group (61.6%) was statistically greater 
(p £ 0.05) compared with the terazosin group (25.2%) (figure 5). Relapse 
was defined as a patient's withdrawal from the study because of lack of 
response to treatment or as a patient's l-PSS increasing by ^ 50% of the 
improvement experienced during the single-blind period. A clinically 
important difference in relapse rates appeared as early as 70 days, when 
the rates were 36.9% and 10.8% for the placebo and terazosin groups, 
respectively. Also, the number of patients withdrawing from the study due 
to failure to respond was 11 in the placebo group and one in the terazosin 
group. 
The efficacy data reported above reflect the results for évaluable 
patients, not for intent-to-treat patients. However, there were no differ-
ences between the two sets of results. 
Table 2. Mean changes in efficacy variables from baseline at each visit of the 
double-blind period. 
Efficacy variable 
Symptom score 
Quality of life score 
Qmax (ml/s) 
Nocturia score 
Patient 
group 
Placebo 
Terazosin 
Placebo 
Terazosin 
Placebo 
Terazosin 
Placebo 
Terazosin 
η 
83 
84 
83 
84 
74 
76 
83 
84 
Mean 
Week 
26 
6.5 
6.9 
1.6 
1.9 
14.8 
13.7 
1.2 
1.3 
week 34 
mean 
change 
4.4· 
1.3 
1.0* 
0.1 
-3.7* 
-0.7 
0.6· 
0.2 
week 42 
mean 
change 
4.5* 
1.8 
0.8* 
0.1 
-2.7* 
-0.4 
0.6* 
0.3 
week 50 
mean 
change 
4 . 1 · 
1.7 
0.7* 
0.2 
-2.7* 
-0.6 
0.5 
0.2 
* Statistically significant (p ¿ 0.05) difference between treatment groups. 
Single-blind safety results 
The three primary safety variables in this study were blood pres-
sure, PSA levels, and adverse event reporting. 
Of patients evaluated for blood pressure during the single-blind 
period, 57.4% (233/406) had a normal baseline DBP (< 90 mmHg) and 
42.6% (173/406) had a higher than normal baseline DBP (^ 90 mmHg). 
The group with normal DBP included normotensive patients and well-
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controlled hypertensive patients. The group with higher than normal DBP 
included untreated and treated hypertensive patients. 
Terazosin produced no clinically significant mean blood-pressure 
changes in patients with a normal baseline DBP (normotensives and well-
controlled hypertensives). However, for patients with a higher than normal 
baseline DBP, mean blood-pressure changes were clinically and statistically 
significant (p £ 0.05). Such changes were seen by week 2, when DBP 
decreased from a mean of 93.9 mmHg to 85.5 mmHg amongst patients 
receiving no additional antihypertensives (n = 133); among patients 
receiving additional antihypertensives (n = 40), DBP decreased from 95.0 
mmHg to 87.3 mmHg. 
For patients who completed the single-blind period, the mean 
change in PSA level from baseline to final visit was not statistically 
significant for the total group, nor for any one age group (table 3). 
The most common adverse events reported for all patients (n = 
427) during the single-blind period were dizziness (21.1%), headache 
(12.6%), asthenia (6.6%), pharyngitis (5.2%), somnolence (4.9%), back 
pain (4.2%), flu syndrome (3.7%), and abdominal pain (3.0%). Adverse 
events caused 20.4% of patients to withdraw from the study. The most 
common adverse events causing termination from the single-blind period 
were dizziness (6.8%), headache (2.1%), asthenia (1.9%), somnolence 
(1.2%), dyspnoea (1.2%), and arrhythmia (0.9%). 
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Table 3. Mean changes in PSA levels single-blind period. 
Patient age group 
40-49 years 
50-59 years 
60-69 years 
70-79 years 
80- years 
All patients 
η 
8 
74 
127 
57 
4 
2 7 1 * 
Mean baseline 
(ng/ml) 
1.2 
2.5 
3.4 
3.7 
3.4 
3.2 
Mean change 
(ng/ml) 
-0.1 
0.0 
0.2 
-0.3 
1.6 
0.03 
* One patient was not categorized by age group. 
Double-blind safety results 
Of the patients evaluated for blood pressure, 6 2 . 2 % (125/201) had 
a normal DBP ( < 90 mmHg) at baseline (visit 2) and 37.8% (76/201) had 
a higher than normal DBP ( ^ 90 mmHg) at the same visit. Hypertensive 
patients randomized to placebo continued to receive the antihypertensive 
treatment they had been receiving during the single-blind treatment period 
or they received no antihypertensive treatment. 
From the start of the double-blind period to the final visit, there 
were no clinically significant mean DBP changes in either the terazosin or 
the placebo group. These findings were shown in normotensive, well-
controlled hypertensive, and non-controlled hypertensive patients, regard­
less of concurrent antihypertensive treatment. Further, with one exception, 
none of the changes were statistically significant (p <. 0.05). DBP results 
of the double-blind period are summarized in Table 4. 
An additional safety variable was pulse rate. Mean changes in pulse 
rate from baseline to the final visit were not statistically significant 
between randomized groups. 
The mean change in PSA level from the start of the double-blind 
period to the final visit was not statistically significant for either random­
ized group. In the placebo group (n = 72), the mean PSA level increased 
from 3.0 ng/ml at the start of the double-blind period to 3.3 ng/ml at the 
final visit; in the terazosin group (n = 73), mean PSA level increased from 
3.5 ng/ml to 3.7 ng/ml. Further, there were no clinically significant 
changes in mean PSA level in any age group during the double-blind 
period. 
Seventy-nine patients reported adverse events during the double-
blind period - 40 in the placebo group and 39 in the terazosin group. In the 
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Table 4. Double-blind mean changes in diastolic blood pressure (DBP). 
η Mean Mean Mean 
Week 26 Week 50 Change 
Patients with DBP < 90 mmHg at baseline 
No antihyper­
tensives 
Using 
antihypertensives 
No antihyper­
tensives 
Using 
antihypertensives 
Placebo 51 
Terazosin 51 
Placebo 9 
Terazosin 14 
Patients with DBP a 
Placebo 26 
Terazosin 30 
Placebo 13 
Terazosin 7 
77.8 
76.7 
77.8 
76.4 
80.8 
76.1 
79.4 
77.1 
90 mmHg at baseline 
81.2 
82.8 
79.8 
87.1 
84.8 
82.8 
82.6 
81.7 
3.0· 
-0.6 
1.7 
0.7 
3.7 
0.0 
2.8 
-5.4 
* Statistically significant (ρ s 0.05) difference from week 26, 
but not clinically significant. 
placebo group (n = 102), the most common adverse events were pharyn­
gitis (3.9%), hypertension (2.9%), urinary retention (2.9%), and flu 
syndrome (2.0%). In the terazosin group (n = 105), the most common 
adverse events were pharyngitis (3.8%), dizziness (2.9%), dyspepsia 
(2.9%), flu syndrome (2.9%), and urinary retention (2.9%). Seven patients 
in the terazosin group and 9 in the placebo group were discontinued 
because of adverse events (angina pectoris, dizziness (n = 2), hepatitis, 
pneumonia, somnolence, and urinary retention in the terazosin group; and 
kidney calculus, kidney pain, myocardial infarct, second-degree 
atrioventricular block, syncope, urinary retention (n = 3), and urinary tract 
infection in the placebo group). 
Discussion 
The design of the present study reflects clinical practice by ident­
ifying a group of patients who responded beneficially to terazosin during a 
6-month period when all patients with lower urinary tract symptoms, an 
enlarged prostate gland, and a poor urinary stream took the drug. The 
advantage of initiating medical treatment in patients with BPH is its 
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reversibility: it can be stopped when patients do not respond or when side-
effects occur. In clinical practice, a trial of treatment is often appropriate, 
and only those patients who benefit should continue taking the drug. A 
decision should then be made whether treatment should continue 
indefinitely or whether stopping would be possible without relapse; a 
beneficial effect might attenuate with prolonged treatment. This study's 
protocol was designed to investigate these issues. 
We treated a heterogenous group of patients with lower urinary 
tract symptoms, enlargement of the prostate, and poor urinary flow rate. 
The fact that 175 of 378 évaluable patients were eligible to enter the 
second part of the study suggests that approximately half of the men 
treated with terazosin might find it suitable for long-term use. This propor-
tion is almost certainly lower than what would be expected in clinical 
practice, however, because of the stringent trial protocol, which required 
improvements in Qmax as well as in l-PSS. A substantial number of 
patients not meeting the Qmax requirement had a sufficient l-PSS improve-
ment: 58% (219/378) experienced ^ 30% l-PSS improvement by the end 
of single-blind period. 
The percentage of patients who experienced dizziness was rather 
high in comparison with previous experience with terazosin.12'16 The ways 
in which adverse events were collected may have contributed to this 
discrepancy: centres reporting high numbers were required by their ethical 
committees to enquire specifically about this symptom, whereas in centres 
reporting lower numbers patients were asked if they had experienced any 
ill effects. It should be noted that less than one third of the patients 
reporting dizziness had discontinued treatment, which suggests that the 
majority of dizziness events were tolerable and transient. 
Patients who responded during the single-blind period were ran-
domized for the double-blind period into two groups, one continuing on 
terazosin and one being withdrawn from active treatment and placed on 
placebo. Patients withdrawn from terazosin experienced a significant 
deterioration in l-PSS and Qmax, while those continuing on terazosin 
maintained their improved Qmax, with only a small, clinically insignificant 
deterioration in l-PSS. The deterioration in the placebo group did not, 
however, return to baseline, suggesting that 1) there is variability in the 
evolution of BPH (symptoms fluctuate over time and patients have a high 
chance to enter the trial when they experience a period with severe lower 
urinary tract symptoms); 2) there is a continuing placebo effect, and 3) the 
full effect of withdrawal of terazosin takes longer than 24 weeks. Another 
more speculative suggestion could be that 6 months of σ-blockade might 
reduce the sensitivity of the σ-adrenergic receptor. All these suggestions 
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are applicable for the effects on DBP, which paralleled the findings in BPH 
symptoms and flowmetry. 
While this study's minimum required voided volume of 100 ml is 
lower than the standard 150 ml level, at entry to this study's single-blind 
period there were no statistically significant differences between the mean 
Qmax of patients whose voided volume was 100-149 ml (9.2 ml/s, η = 
99) and of patients whose voided volume was a 150 ml (10.3 ml/s, η = 
279). 
In this study terazosin was taken at night rather than the conven­
tional daytime dosing regimen. Nocturia improved in 67% (175/261) of 
patients compared with only 4 3 % (51/119) in a previous study using 
daytime dosing. However, historical comparisons of this type are unreli­
able; furthermore, a different symptom score was used in the daytime 
dosing study. Despite this, these results may warrant a further comparison 
of the effects of daytime and bedtime dosing on nocturia. 
Studies have shown that therapy with 5o-reductase inhibitors such 
as finasteride lowers PSA levels by around 5 0 % , thereby possibly masking 
a diagnosis of prostate cancer.17 In the present study, terazosin did not 
affect PSA levels. (It should be noted that 1 patient unexpectedly was 
diagnosed with carcinoma of the prostate during the single-blind period of 
this study.) 
Previous studies have demonstrated the efficacy of terazosin as a 
treatment for the symptoms of BPH.3-10 In the first part of this study, 
nearly half of the patients benefitted sufficiently to justify long-term 
treatment. During the second phase, this effect continued; withdrawal led 
to a recurrence of symptoms. The authors of this study conclude that 
terazosin has a beneficial effect on BPH continuing for at least 12 months 
and can safely be considered for medium- to long-term use in those who 
benefit. 
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Terazosin: urodynamic results ITT 
Abstract 
Purpose: We evaluated the urodynamic and clinical effects of terazosin in 
patients with symptomatic benign prostatic hyperplasia (BPH). 
Material and Methods: A total of 45 patients who participated in a 
multicentric trial was evaluated with urodynamic pressure-flow studies 
before and after 26 weeks of treatment. 
Results: Maximum flow rate and symptom score improved significantly in 
22 patients with and 11 without bladder outlet obstruction who completed 
26 weeks of treatment. In patients with bladder outlet obstruction, the 
condition was significantly reduced and in patients without obstruction, 
significant urodynamic changes could not be detected. 
Conclusion: Terazosin treatment results in symptomatic relief and 
improved urinary flow in patients with and without bladder outlet obstruc­
tion and in significant improvement in patients with urodynamically proved 
obstruction. 
Introduction 
Benign prostatic hyperplasia (BPH) develops in almost half of all 
men older than 50 years.1 Traditionally, the first choice of treatment in 
patients with symptomatic BPH was prostatectomy. The incidence of 
postoperative complications (5% to 10%), 2 treatment failures (25%) 3 and 
reoperations (10%) 4 after prostatectomy, and the knowledge that this 
condition is not inevitably of a rapidly progressive, deteriorating nature 
have led to the development of new safe and effective nonoperative 
treatments. 
In 1976 Caine et al demonstrated that phenoxybenzamine, a 
nonselective σ1-2 blocker, could be effective for the treatment of patients 
with BPH.6 However, the widespread use of this compound was limited by 
the appearance of a significantly high incidence of side effects. With the 
introduction of prazosin, an σ1 selective blocking agent, similar efficacy 
but fewer side effects were shown.6 Since then, several reports have 
documented the beneficial effects of new selective σ1 blockers in patients 
with symptomatic BPH.7·8 
Terazosin is a long-acting σ1 selective blocking agent that was 
originally used in the treatment of patients with hypertension. The effects 
of terazosin on symptom scores and urinary flow rates in patients with 
symptomatic BPH have been documented in several studies.7,9 The report­
ed incidence of side effects is low. Side effects are related to the а 
adrenergic blocking effect and include headache, dizziness and asthenia. 
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An advantage of terazosin over prazosin is that the longer half-life allows 
for a once daily dosage regimen. Terazosin administered at bedtime 
minimizes the percentage of patients who experience tiredness and 
dizziness during the day, and increases the percentage of responders who 
have severe nocturia.10 
Besides evaluation of symptom score and free urine f low, we 
examined at 1 center the outcome of pressure-flow studies on the treat-
ment of patients with symptomatic BPH who participated in a multicenter 
international randomized withdrawal trial (International Terazosin Trial: ITT) 
designed to evaluate the long-term safety and efficacy of terazosin. 
Patients and methods 
We report the urodynamic and clinical results of terazosin therapy 
in patients with symptomatic BPH who were included in a multicenter 
international randomized withdrawal trial at our centre in Nijmegen. The 
results of the multicenter trial have been reported previously.9 Sympto-
matic BPH was diagnosed in all patients by medical history, physical 
examination (including digital palpation and ultrasonographic examination 
of the prostate), blood analysis, baseline International Prostate Symptom 
Score (l-PSS) of 12 or more and a maximum free urinary flow rate of 5 to 
15 ml. per second inclusive, with a total voided volume of 100 ml. or more 
and a post-void residual volume of less than 300 ml. Prostatic volume was 
calculated using the planimetrie method on an ultrasound scanner with a 
multiplane 3-dimensional rectal transducer. All patients were considered 
neurologically normal based on history, symptoms and physical examinati-
on (no motor, sensory or reflex deficits). 
After symptomatic BPH was diagnosed clinically patients began 
treatment with terazosin administered at bedtime and increasing to a 
maximum dose of 10 mg. per day at 6 weeks. During part 1 of the study 
urodynamic pressure-flow tests before and after 26 weeks of treatment 
with terazosin were used to evaluate urodynamic changes. Urinary sedi-
ment and culture were negative at the time of pressure-flow studies. To 
control patient compliance, plasma terazosin levels were measured at 26 
weeks of treatment. According to the study protocol, at 26 weeks of 
therapy patients were categorized based on the symptomatic response and 
free flow result into those who did and did not respond to treatment. 
Responders, that is patients with an l-PSS improvement of 30% or more 
from baseline and an increase in maximum free urinary flow rate of 10% or 
more from baseline, were then randomly allocated to maintain the dosage 
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of terazosin or to receive placebo. The patients then entered part 2 of the 
study (24 weeks), during which they were seen at 8-week intervals to 
receive the double-blind medication and to record symptoms and free 
urinary flow rates. 
The pressure-flow studies were performed with an 8F transurethral 
lumen catheter with an intravesical microtip pressure sensor for bladder 
pressure recordings. Abdominal pressure was recorded intrarectally with 
an 8F microtip sensor catheter. Before cystometry the bladder was 
emptied through the lumen of a transurethral catheter to quantify residual 
volume after free uroflowmetry. Thereafter, the bladder was filled with 
water of 20°C with a filling speed of 50 ml. per minute with the patient 
supine. In consideration of the micturition diary, free uroflowmetry and 
residual urine volume, care was taken to fill the bladder until the maximum 
bladder capacity was reached and filling was stopped when the patient 
expressed a strong urge to void. To provide an objective and precise 
grading of obstruction, pressure-flow graphs were fitted with a passive 
urethral resistance relation curve at the lowest pressure part of the 
graph.11 Minimal detrusor pressure during micturition and computed 
theoretical cross-sectional urethral area were calculated automatically 
based on the manually adjusted passive urethral resistance relation 
curves.11 The detrusor pressure at maximum flow during the urodynamic 
investigation was recorded. Correction for flow artifacts was performed 
when necessary. The parameter urethral resistance relation URA was 
determined by fitting the pressure-flow plot at the point of maximum flow 
(at detrusor pressure at maximum flow). Urethral resistance relation was 
computed to classify patients on a continuous, 1-parameter scale of 
obstruction.12 The linear passive urethral resistance relation was deter-
mined by drawing a straight line between the 2 points on the pressure-
flow curve that corresponded to the detrusor pressure at maximum flow 
and the minimal detrusor pressure during voiding.13 The position of this 
straight line defined the outlet condition in a simple way and afforded 
classification of the severity of outlet obstruction. Urodynamic parameters 
analyzed were maximum free urinary flow rate, free voided volume, 
maximum flow during urodynamic investigation, detrusor pressure at 
maximum flow, minimal detrusor pressure during voiding, theoretical cross-
sectional urethral area and urethral resistance relation for all patients, for 
those without obstruction (linear passive urethral resistance relation less 
than 3) and for those with obstruction (linear passive urethral resistance 
relation 3 or more).14 We investigated the possible differences in treatment 
effects between the obstruction and no obstruction groups using previ-
ously defined response criteria for each urodynamic parameter and symp-
tom score (table 1). We also examined possible differences in initial 
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urodynamic parameters between the patients who did and did not respond 
to treatment according to the definition of the study protocol. Statistical 
analysis was performed using the Wilcoxon matched pairs signed rank test 
and the Wilcoxon rank sum W test for analysis of numerical data, and the 
chi-square test for the comparison of categorical data. 
Table 1. Percentages of urodynamic and symptomatic responders in the 
obstruction and no obstruction groups after 26 weeks of terazosin 
treatment. 
Maximum free flow rate: 
increase ^ 10 % 
increase a: 50 % 
Free voided volume: 
increase a: 50 ml. 
Minimal detrusor pressure during 
voiding: 
decrease i 10 cm. water 
Maximum urodynamic flow rate: 
increase a: 2 ml./sec. 
Detrusor pressure at maximum 
% Obstruction 
(22 pts.) 
59 
32 
23 
55 
36 
64 
% No obstruction 
(11 pts.) 
91 
18 
45 
22 
45 
36 
ρ Value* 
0.06 
0.41 
0.18 
0.09 
0.61 
0.14 
flow: 
decrease s 10 cm. water 
Theoretical cross-sectional ure- 36 14 0.27 
thral area: 
increase a: 1 mm.2 
Urethral resistance relation 55 0 < 0.01 
decrease a: 10 cm. water 
Total l-PSS symptom score: 
decrease a: 30 % 67 100 0.03 
decrease ;> 50 % 57 64 0.72 
Responders· 41 91 < 0.01 
* Chi-square test 
• Responders are those who, after 26 weeks of treatment, have an increase in 
maximum free flow rate a: 1 0 % and a decrease in total l-PSS a: 30%. 
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Results 
A total of 45 patients (mean age 64 years, range 50-76) began 
treatment with terazosin increasing to a maximum dose of 10 mg. per day 
at 6 weeks. The ultrasonographically detected prostatic volume ranged 
from 20 to 94 cc (mean 44). A total of 30 patients (64%), including 3 
unable to void during the pressure-flow investigation, was categorized as 
having obstruction and 12, including the 3 unable to void during the initial 
investigation, stopped treatment during part 1 of the study due to dizzi­
ness in 2, asthenia in 4, cardiac arrhythmia in 1, dyspnea in 2, poor 
compliance in 2 and progressive complaints with a urinary tract infection in 
1. Of the patients 33, including 22 (67%) with obstruction, underwent 
pressure-flow studies before and after 26 weeks of terazosin treatment. 
The initial l-PSS total symptom score and initial detrusor pressure at 
maximum flow labeled according to the reason for dropping out before 
week 26 and response status according to the definition of the study 
protocol at 26 weeks of treatment, are plotted for each individual in figure 
1. Patients who dropped out of the study because of toxicity had sympto­
matic and urodynamic values that were heterogeneously distributed 
amongst those who completed the first 26 weeks of therapy. Mean 
urodynamic parameters and symptom scores at baseline for the initial 45 
patients, and at baseline and after 26 weeks of treatment for 33 patients, 
divided in 2 subgroups with and without obstruction are shown in table 2. 
Maximum free urinary flow rate and l-PSS symptom score improved signifi­
cantly in the entire group of patients (mean 2.3 ml. per second and 10 
points respectively; ρ < 0.01 and ρ < 0.01 respectively). In the obstruc­
tion group the mean maximum free urinary flow rate improved by 1.6 ml. 
per second, which was not statistically significant (p = 0.06). However, 
mean improvement in maximum flow during urodynamic investigation (1.9 
ml. per second) was significant (p = 0.01). In the no obstruction group 
mean improvement in maximum free urinary flow rate (3.6 ml. per second) 
was statistically significant (p = 0.01) but mean improvement in maximum 
flow during urodynamic investigation (1.6 ml. per second) was not (p = 
0.32). Symptom scores improved significantly in both groups (p < 0.01 
with and ρ < 0.01 without obstruction). 
Mean pressure-flow parameters of maximum flow during 
urodynamic investigation, minimal detrusor pressure during voiding, 
detrusor pressure at maximum flow, theoretical cross-sectional urethral 
area and urethral resistance relation in the obstruction group significantly 
improved after 26 weeks of terazosin treatment. In the patients without 
obstruction significant changes could not be detected. Figure 2 shows the 
improvements in urethral resistance relation and l-PSS symptom score 
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axis) and total l-PSS (X-axis) for each individual, labeled according to 
reasons for dropping out of study during first 26 weeks of treatment 
and response status according to definition of study protocol at 26 
weeks of treatment. UTI, urinary tract infection. 
ω 
я 39 
5 
E 
и 
h- 23 
Ζ 
LU 
5 
LU 
Ь 7-
СП 
2 
è ·• 
3 
-25 
о 
• 
о 
о 
А 
А 
• 
о 
О 
о 
• 
А * 
о 
А 
£ 
о 
о 
А 
А 
no obstruction group 
obstruction group 
15 25 
Figure 2. 
l-PSS IMPROVEMENT 
Improvement in urethral resistance relation (URA) in cm. water (Y-
axis) and l-PSS symptom score (X-axis) plotted for each individual 
patient with and without obstruction who completed 26 weeks of 
terazosin therapy. 
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Table 2. Urodynamic and symptomatic results at baseline for the initial 45 pa­
tients, and at baseline and 26 weeks after starting terazosin treat­
ment for 33 patients divided into subgroups of 11 without and 22 
with obstruction. Legend see chapter 6, table 1. 
Free Qmax (ml/s) 
Baseline 
Week 2 6 
ρ Value 
Free void. vol. (ml) 
Baseline 
Week 2 6 
ρ Value 
Free res. vol. (ml) 
Baseline 
Week 2 6 
ρ Value 
Pvoidmin (cm. water) 
Baseline 
Week 2 6 
ρ Value 
Urod. Qmax (ml/s) 
Baseline 
Week 2 6 
ρ Value 
P ^ Q m a x (cm. water) 
Baseline 
Week 2 6 
ρ Value 
A * » (mm2) 
Baseline 
Week 2 6 
ρ Value 
URA (cm. water) 
Baseline 
Week 2 6 
ρ Value 
Total l-PSS score 
Baseline 
Week 2 6 
ρ Value 
Initial group 
(45 pts.) 
9.1 ± 2.7 
-
2 2 4 ± 98 
-
6 2 ± 87 
-
3 7 . 2 ± 22.0 
-
7.3 ± 3.6 
-
7 0 . 7 ± 32.0 
-
3.2 ± 3.2 
-
4 2 . 1 ± 18.4 
-
19.7 ± 6.6 
-
3 3 patients completing 2 6 weeks terazosin 
Total group 
9.0 ± 2.8 
11.3 ± 4 . 4 
< 0.01 
2 0 3 ± 81 
2 1 5 ± i n 
0.97 
67 ± 99 
6 0 ± 81 
0 . 8 2 
38.7 ± 24.2 
29.5 ± 1Θ.Β 
0 . 1 3 
7.1 ± з.в 
8.9 ± 5.2 
0.01 
7 2 . 7 ± 34.2 
5 9 . 4 ± 28.2 
0.01 
3.2 ± з.в 
3.9 ± 2.4 
< 0.01 
4 3 . 6 ± 19.8 
3 4 . 2 ± 17.7 
< 0.01 
2 0 . 1 ± 6.9 
9.7 ± 5.4 
< 0.01 
No Obstr. 
(11 pts.) 
9.7 ± 2.8 
13.3 ± 3.8 
0.01 
2 2 4 ± 129 
2 4 4 ± 98 
0.66 
2 2 ± 2 4 
5 5 ± 56 
0 . 1 2 
2 0 . 3 ± 9.5 
2 3 . 0 ± 18.0 
0 . 4 4 
9.0 ± 4.2 
10.6 ± 8.1 
0 . 3 2 
4 3 . 4 ± 9.2 
4 4 . 6 ± 18.8 
0 . 7 9 
3.4 ± 1.7 
3.7 ± 1.4 
0 . 5 0 
2 5 . 2 ± 8.9 
2 4 . 2 ± 12.4 
0.51 
21.1 ± 7.3 
8.6 ± 5.4 
< 0.01 
Obstruction 
(22 pts.) 
8.6 ± 2.9 
10.2 ± 4 . 3 
0.06 
192 ± 8 8 
2 0 0 ± 1 1 7 
0.76 
7 6 ± 111 
6 6 ± 90 
0.36 
4 6 . 3 ± 24.5 
33.3 ± 18.9 
0.04 
6.2 ± 2.9 
8.1 ± 4.8 
0.01 
87.3 ± 32.8 
66.7 ± 29.5 
0.01 
2.3 ± 0.9 
3.7 ± 2.5 
< 0.01 
51.9 ± 17.7 
38.8 ± 18.5 
< 0.01 
19.6 ± 5.3 
10.3 ± 6.4 
< 0.01 
Comparison of baseline versus week 26 values (mean ± standard deviation) using 
Wilcoxon matched pairs signed rank test. 
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plotted for each patient who completed 26 weeks of therapy. The majority 
of obstruction patients had symptomatic and urodynamic improvement 
after 26 weeks of terazosin treatment. Symptomatic improvement in the 
group without obstruction was comparable with that of the group with 
obstruction. The changes in urethral resistance relation in the no obstruc­
tion group were not great and the majority were within physiological 
variability. 
Table 1 shows the number of responders according to the study 
protocol, and the number of responders for each urodynamic parameter 
and symptom score in both groups. Of 22 patients with and 11 without 
obstruction 13 (59%) and 10 (91%), respectively, had a 10% or greater 
increase in maximum free urinary flow rate (p = 0.06). In comparison, 7 
of 22 patients (32%) with and 2 of 11 (18%) without obstruction had 
greater differences in maximum free urinary flow rate (50% or more)(p = 
0.41). A total of 12 of 22 patients (55%) with and none without obstruc­
tion had a decrease in urethral resistance relation of 10 cm. water or more, 
and this difference was statistically significant (p < 0.01). The number of 
patients classified as responders according to the study protocol definition 
was significantly greater in the group without obstruction (p < 0.01). 
Passive urethral resistance relation curves based on mean urodynamic 
values for both groups at baseline and after 26 weeks of treatment are 
shown in figure 3. 
Pd.u 
(cm H20I 
Pdflf 
lem H20) 
Flow ImJ/uol Flow ІшІ/исІ 
Figure 3. Passive urethral resistance relation curves based on mean urodynamic 
values for obstruction (a) and no obstruction (b) groups at baseline (1) 
and after 26 weeks of treatment (2). + , mean detrusor pressure at 
maximum flow. Pdetr, detrusor pressure. 
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Table 3 provides an overview of the mean initial urodynamic 
parameters between the groups who did and did not respond to treatment. 
The mean urodynamic parameters of theoretical cross-sectional urethral 
area, urethral resistance relation and linear passive urethral resistance 
relation were significantly different, indicating that patients without 
obstruction were more likely to respond to treatment according to the 
study protocol definition compared to those with obstruction (figure 1). 
After the first 26 weeks of treatment 19 of 33 patients were 
categorised as responders according to the protocol definition and were 
randomized to receive further treatment. For the next 24 weeks, 5 
obstruction and 4 no obstruction responders were randomized to maintain 
the dosage of terazosin, and 4 obstruction and 6 no obstruction respon-
ders received placebo. During part 2 of the protocol 3 patients (1 random-
ized to continue terazosin and 2 receiving placebo) interrupted treatment 
because of progressive complaints. Table 4 shows the mean values of 
maximum free urinary flow rate and symptom scores for all patients, as 
well as for those with versus without obstruction and randomized to 
receive placebo versus terazosin. During part 2 of the study symptom 
scores deteriorated significantly in the placebo group (p = 0.02), whereas 
the improved symptom scores in the terazosin group were maintained. A 
mean terazosin level of 114 ng./ml. (range 66-187) 26 weeks after 
beginning therapy showed good drug compliance in the study population. 
The most frequent treatment related side effects were mild head-
ache, dizziness and asthenia. Usually, these side effects were mild and 
transient. Six patients stopped treatment because of such events. In one 
patient treatment was stopped because of progressive complaints after 8 
weeks of therapy that later were found to be related to a culture proved 
urinary tract infection. Dyspnea and cardiac arrhythmia were other reasons 
for cessation of treatment but these events were not considered to be 
treatment related. 
Discussion 
Traditionally, an important objective method to assess the effect of 
a new treatment modality in BPH is urinary flow measurement. However, 
there is a great variability in consecutive measurements of uroflowmetry. 
Golomb et al evaluated the variability of urinary flow in 32 patients with 
BPH and 16 healthy volunteers.16 The variability between consecutive 
maximum flow rates was observed in the BPH group from at least 1 
standard deviation (5.7 ml. per second) in 28 of 32 patients to at least 2 
standard deviations in 15 of 32. Furthermore, on voiding nomograms the 
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highest recorded maximum flow rate was greater than the 2 standard devi­
ation plot, while the lowest maximum flow rate was less than the 2 
standard deviation plot. It is obvious that this great variability in 
measurements of uroflowmetry has a marked negative impact on the 
power of statistical tests to assess a difference in the intra-individual and 
interindividual urinary flow rate. Furthermore, it largely increases sample 
size requirements to achieve statistical power. These difficulties were 
Table 3. Initial clinical and urodynamic values for patients with and without 
response according to the study protocol definition. 
Mean ± standard deviation 
Maximum free flow rate 
(ml./sec.) 
Free voided volume (ml.) 
Residual volume (ml.) 
Minimal detrusor pressure during 
voiding (cm. water) 
Maximum urodynamic flow rate 
(ml./sec.) 
Detrusor pressure at maximum 
flow (cm. water) 
Theoretical cross-sectional ure­
thral area (mm.2) 
Urethral resistance relation (cm. 
water) 
Linear passive urethral resis­
tance relation 
Total l-PSS symptom score 
Response 
(19 pts.)# 
10.2 ± 3.6 
216 ± 105 
46 ± 68 
34.0 ± 25.0 
8.6 ± 4.0 
66.5 ± 37.1 
4.2 ± 4.8 
36.3 ± 19.4 
2.6 ± 1.5 
21.2 ± 6.5 
No Response 
(14 pts.) 
8.0 ± 2.4 
197 ± 67 
95 ± 124 
44.5 ± 22.9 
5.2 ± 1.6 
81.0 ± 29.0 
2.0 ± 0.7 
52.9 ± 16.2 
3.9 ± 1.0 
18.6 ± 4.9 
ρ Value* 
0.11 
0.86 
0.20 
0.05 
< 0.01 
0.05 
0.03 
< 0.01 
< 0.01 
0.31 
* Increase in maximum free flow rate of & 10% and decrease in total l-PSS of 
2 30% after 26 weeks of treatment. 
• Wilcoxon rank sum W test. 
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already recognised in 1982 by Drach et al, who suggested to adjust the 
maximum urinary flow rate for varying age and volume voided.16 Presently, 
it is accepted that the poor urinary stream in 20 to 25% of patients with 
symptomatic BPH is due to a hypoactive detrusor muscle.3 This fact 
emphasizes the relative importance of urinary flow measurement in 
assessing the effect of a treatment modality in patients with symptomatic 
BPH, especially in small groups. 
During the international consultation on BPH in 1993 it was advised 
that, if obstruction is the end point of the study, pressure-flow studies 
before and after treatment should be used in the evaluation of new 
therapies.17 Pressure-flow studies enable us to investigate the relationship 
between subjective efficacy of treatment and objective voiding parame-
ters. Moreover, the use of pressure-flow studies may help to select 
patients for a given treatment and, therefore, dropout and over treatment 
percentages may decrease considerably. 
Patients may be selected for a given treatment using the linear 
passive urethral resistance relation diagram, a classification of the degree 
of bladder outlet obstruction.14 This diagram is divided into 7 bands, 
labeled 0 to 6, representing increasing severity of obstruction. Bands 0 and 
1 represent an unobstructed, bands 2 and 3 a minimally obstructed, and 
bands 4 to 6 an increasingly severe obstructed outlet condition.13,14 In 
patients with a linear passive urethral resistance relation of 0 or 1 , cat-
egorized as without obstruction, the poor urinary stream is caused by a 
hypoactive detrusor muscle. These patients have little chance to benefit 
from transurethral resection of the prostate.14 Pharmacotherapy in this 
group must have been used frequently but to our knowledge efficacy 
results in this specific group of patients have not been reported, probably 
because they were not identified by pressure-flow analyses. 
Between unobstructed and obviously obstructed groups, with poor 
urinary streams and high intravesical pressures noted by a linear passive 
urethral resistance relation of 4 or more, there is a gray zone of patients 
with a linear passive urethral resistance relation of 2 and 3 who have 
minimal bladder outlet obstruction. We divided the gray zone of patients 
with minimal obstruction into 2 groups: 1) those with a linear passive 
urethral resistance relation of 2 or less were classified as without ob-
struction and 2) those with a linear passive urethral resistance relation of 3 
or more were classified as with obstruction. With this classification we 
were able to show differences in clinical and urodynamic treatment 
responses between the 2 groups. 
In the obstruction group all mean values for maximum flow during 
urodynamic investigation, minimal detrusor pressure during voiding, 
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detrusor pressure at maximum flow, theoretical cross-sectional urethral 
area and urethral resistance relation after 26 weeks of terazosin improved 
significantly. From a theoretical viewpoint, the mechanism of voiding using 
an σ1 adrenergic blockader is changed towards a better outlet distensibility 
during voiding and, thus, becomes more efficient. The first effect of a 
decrease in outlet obstruction is presumably a change in the balance of 
bladder outlet and detrusor contraction towards a lower pressure 
micturition with improved efficacy. Theoretically, the increase in maximum 
urinary flow rate might not be as high as may be expected, which may be 
partly attributed to a decrease in voiding detrusor pressure. More efficient 
voiding can also be shown by lower post-void residual volumes but this 
could not be demonstrated by our patients who had a low mean residual 
volume of 62 ml. with a high standard deviation of 87 ml. In our study 
more efficient micturition after terazosin is clearly evident in the obstruc­
tion group in which urodynamic parameters improved significantly, particu­
larly the improvement in maximum urinary flow rate. A significant change 
in theoretical cross-sectional urethral area together with a significant 
change in minimal detrusor pressure during voiding indicates that terazosin 
has relaxed the bladder outlet so that more efficient voiding can occur. 
The patients without obstruction showed no significant urodynamic 
changes. Ironically, the group with the highest percentage of patients 
showing slight improvements in free flow and symptoms had no 
urodynamic obstruction. When we evaluated greater improvements in free 
flow and symptoms, there was no significant difference between the 
percentage of patients in either group (table 1), which demonstrates that 
in our patients without obstruction statistically significant improvements in 
symptoms or free flow were not confirmed by significant improvements of 
urodynamic variables. This finding suggests that the way we analyze 
efficacy in the majority of pharmacotherapy studies for BPH (that is 
improvements in symptoms and maximum free urinary flow rate) is not 
entirely representative of the urodynamic mechanism of action. Moreover, 
the results of urodynamic studies in men who received treatment for BPH 
depend on the percentage of included patients who actually have obstruc­
tion. In other words, a high percentage of patients without obstruction will 
mask the urodynamic effect that is clearly shown in those with obstruc­
tion. Tammela and Kontturi reported a mean decrease of detrusor pressure 
at maximum flow of 39 cm. water after finasteride treatment for 6 months 
and a mean increase of detrusor pressure at maximum flow of 3 cm. water 
in the placebo treated group, indicating a significant urodynamic response 
to treatment.18 Such a large urodynamic response can only be expected in 
patients with severe outlet obstruction. Considering the high mean 
detrusor pressure at maximum flow values in the study of Tammela and 
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Kontturi (mean detrusor pressure at maximum flow 120 cm. water), the 
majority of the included patients had severe bladder outlet obstruction. The 
urodynamic response in a study evaluating the efficacy of doxazosin, an 
σ1 selective blocker, although significantly better compared to placebo, 
was slight (improvement of detrusor pressure at maximum flow 5 cm. 
water).* Mean detrusor pressure at maximum flow in the doxazosin study 
was 78 cm. water indicating that a higher percentage had less severe 
obstruction compared to the study of Tammela and Kontturi. These 
findings imply that mean urodynamic differences between therapy groups 
must be regarded critically. 
The maximum flow during urodynamic investigation is lower than 
the maximum free urinary flow rate and this difference is systematic, 
probably due to the transurethral catheter and the different type of investi­
gation. The large variability in consecutive measurements in urinary flow 
measurement is also illustrated in this study. In all patients significant 
improvements in maximum flow during urodynamic investigation (1.8 ml. 
per second) and maximum free urinary flow rate (2.3 ml. per second) could 
be detected, which is in accordance with the results of the multicenter trial 
in which 239 patients completing the first 26 weeks of therapy had a 
significant improvement in maximum free urinary flow rate of 3.2 ml. per 
second.9 The differences in our study were statistically significant only for 
maximum free urinary flow rate in the no obstruction group and maximum 
flow during urodynamic investigation in the obstruction group. In the no 
obstruction group the power to detect a true difference of 2.0 ml. in 
maximum flow during urodynamic investigation at a significance level a of 
0.05 was only 2 1 % . In the obstruction group the power to detect a true 
difference of 2.0 ml. in maximum free urinary flow rate at a significance 
level a of 0.05 was only 6 4 % . Evidently, more patients are needed in 
these subgroups to detect a significant difference in these parameters. 
Symptoms obviously responded well to terazosin in both groups. 
This symptomatic response can be differentiated from a placebo response, 
since symptoms during part 2 of this study deteriorated significantly in the 
placebo group, whereas the improved symptom score at week 26 in the 
terazosin group was maintained until the end of the study. In our study 
terazosin resulted in significant symptomatic relief and significant improved 
urinary flow in the majority of patients. Terazosin also resulted in improved 
efficiency of micturition and a significant decrease in bladder outlet 
obstruction in the majority of patients with urodynamically proved obstruc­
tion. As indicated in the multicenter trial9 and our study (figures 1 and 2), 
few patients do not benefit symptomatically or urodynamically from 
terazosin treatment. To date laboratory studies have indicated that in the 
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human prostate the relative expression of o l e adrenergic receptor sub­
types is predominant.18 A large interindividual variation of o1c expression 
in BPH specimens could explain why not all men react favorably to treat­
ment with σ1 selective blocking agents.20 Future laboratory studies should 
be directed towards the search for more prostate specific σ1 receptor 
subtypes, which would allow development of new σ1-subtype selective 
blocking agents resulting in increased therapeutic efficacy and fewer side 
effects. 
We have shown that a stratified analysis, based on urodynamic 
classification of bladder outlet obstruction, provides meaningful insight into 
the working mechanism of terazosin in patients with symptomatic BPH. 
We also have shown that significantly more patients without obstruction, 
in whom no significant urodynamic changes could be detected, had slight 
improvements in maximum free urinary flow rate and symptom score 
compared to those with obstruction, which demonstrates that in 
pharmacotherapy studies that include many patients without obstruction 
clinical response to treatment is not necessarily identical to urodynamic 
response. 
Further prospective clinical investigations in patients classified 
according to the grade of obstruction are necessary to provide the still 
needed information on the role of bladder outlet obstruction in the evalu­
ation of pharmacological therapy, and the capability of urodynamic and 
clinical parameters to predict a favorable response to new treatments. 
Only then can the treatment of symptomatic BPH be individualized accord­
ing to the pathophysiology, complaints, and expectations of the patient. 
Conclusions 
Terazosin results in significant symptomatic relief and improved 
urinary flow in patients with and without bladder outlet obstruction. 
Terazosin also results in improved efficiency of micturition and significantly 
decreased bladder outlet obstruction in patients with urodynamically 
proved obstruction. 
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Terazosin: A stratified analysis 
Abstract 
Objectives: To evaluate clinical and urodynamic changes in patients with 
and without bladder outlet obstruction (BOO) and to compare the clinical 
and urodynamic results of terazosin treatment between patients with and 
without BOO. 
Methods: In a prospective study, 97 patients who completed a full 
screening program including urodynamic investigation with pressure-flow 
study analysis, started treatment with terazosin. A total of 60 patients 
completed 6 months of treatment and were re-evaluated with international 
prostate symptom scores (l-PSS), uroflowmetry and urodynamic investiga-
tion with pressure-flow study analysis. Patients were stratified using the 
linear passive urethral resistance relation (L-PURR) classification according 
to Schäfer. Patients with a L-PURR of 3 or more were classified as patients 
with and patients with a L-PURR of 2 or less were classified as patients 
without BOO. The clinical and urodynamic changes within and between 
the groups with and without BOO were evaluated. 
Results: Terazosin resulted in significant symptomatic relief (9 points on 
the l-PSS scale, ρ < 0.01) and a significant improvement of free urinary 
flow (3.0 ml/s; ρ < 0.01). In patients with BOO, a statistically significant 
improvement of all urodynamic obstruction variables (p < 0.01) was 
shown. In patients without BOO, a significant improvement of free urinary 
f low (4.4 ml/s; ρ < 0.01), a statistically significant improved bladder 
capacity (increase of 70 ml; ρ = 0.01) and no statistically significant 
changes in urodynamic obstruction variables (p > 0.05) were shown. 
Patients with a hypo-active detrusor were more prone to early dropout. 
When comparing the changes of symptoms (p = 0.89), quality of life (p = 
0.85) and the number of patients with improvements of free uroflow of at 
least 30 % (p = 0.15), there appeared to be no significant difference 
between the groups with and without BOO. 
Conclusions: Although there is a statistically significant difference in 
urodynamic response to terazosin treatment between patients with and 
without BOO, we cannot recommend the use of pressure-flow studies in 
the selection of patients for terazosin treatment because the clinical results 
of treatment appear not to be significantly different between patients with 
and without BOO. It seems more useful, and certainly less expensive and 
less invasive, to start σ1 blocker therapy if, on clinical grounds, the 
urologist considers the patient to be a candidate for σΐ blocker therapy 
and to continue therapy in those who respond. 
178 
Chapter 7.3 
Introduction 
Lower urinary tract symptoms (LUTS) in elderly men are traditional­
ly labelled as prostatism. The term suggests that the enlarged prostate 
gland, causing intravesical bladder outlet obstruction (BOO), is exclusively 
responsible for the LUTS. However, benign prostatic hyperplasia (BPH) is a 
histological diagnosis, and LUTS are not necessarily related to 
urodynamically proven bladder outlet obstruction or histologically proven 
BPH.1,2 LUTS have shown to be prevalent in an age-matched female 
population indicating that the prostate is not required for the occurrence of 
these symptoms.3 It has also been recognized that LUTS are related to 
detrusor instability or detrusor underactivity in an important percentage of 
elderly men.4,6 Obviously, the pathophysiology of LUTS is not always clear 
without an advanced urodynamic pressure-flow study investigation. 
Urodynamic pressure-flow study investigation is the reference standard to 
quantify the grade of BOO in elderly men with LUTS.6 Precise grading of 
obstruction is becoming increasingly important in the evaluation and 
comparison of new therapeutic options in the treatment of patients with 
LUTS. 
Because it is known that σ1-adrenoreceptors are predominantly 
present in the bladder neck and prostate smooth muscle, σ1 -blocking 
agents have successfully been used to relieve symptoms in patients with 
LUTS.79 
Terazosin is a long-acting σ1 -selective blocking agent originally 
used in the treatment of patients with hypertension. The effects of 
terazosin on symptom scores and urinary flow rates in large groups of 
patients with LUTS have been well documented.e,s These studies indicate 
that approximately 60 % of patients respond well on treatment with 
terazosin. So far, it is unknown if it is possible to predict a good response 
on σ1-blocker treatment in the individual patient. Consequently, selection 
of patients who should be preferably treated with an σ1-blocker or one of 
the other treatment modalities is still not based on scientific grounds. 
Earlier studies indicated that inclusion of urodynamic pressure-flow data in 
the preoperative evaluation may improve the overall clinical results, as 
does an indication for transurethral resection of the prostate.6,10,11 Jensen 
showed that symptomatic patients without BOO have a higher likelihood of 
subjective postoperative treatment failure when compared to symptomatic 
patients with BOO.11 It is unknown if a stratification based on the grade of 
BOO has any predictive value for patients who are treated with an σ1-
selective blocking agent. In our study, we investigated possible differences 
in treatment outcome in patients with and patients without BOO who were 
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treated with terazosin. 
Patients and methods 
In 1992, we started a prospective study to evaluate the outcome 
of therapy in patients with LUTS treated with terazosin. Between Septem­
ber 1992 and October 1994, all patients were evaluated at baseline by 
medical history, International Prostate Symptom Score (l-PSS), prostate-
specific antigen analysis, physical examination including digital rectal 
examination, ultrasonographic examination of the prostate, and free urinary 
flowmetry with subsequent ultrasonographic measurement of residual 
urinary volume. Prostate specific antigen was determined using the 
Tandem-Ε PSA assay (Hybritech, San Diego, Calif). Prostate volume was 
calculated using the planimetrie method with a Kretz Combison 330 
ultrasound scanner and a multiplane 3-D rectal transducer (VRW 177AK). 
For free urinary flowmetry the Dantec Urodyn 1000 flowmeter was used. 
For evaluation of the voiding efficiency, the voided percentage, (the 
relative amount of bladder contents that was expelled during micturition) 
was calculated. All patients were considered neurologically normal, based 
on history, symptoms and physical examination (no motor, sensory or 
reflex deficits). Patients in whom a prostatic carcinoma or other disease 
beyond the prostate could be expected which could possibly influence their 
LUTS (for example, urethral stricture or bladder neck contracture), were 
evaluated more extensively first (by prostate biopsy or urethra-cystoscopy) 
and excluded if these diseases were confirmed. Excluded were patients 
previously treated with transurethral (laser) resection of the prostate, 
transurethral microwave thermotherapy, or 5o-reductase inhibitors. 
Patients treated with a blockers within 4 weeks before the baseline 
pressure-flow study was performed were also excluded. There were no 
explicit urodynamic pressure-flow study selection criteria. After the clinical 
diagnosis was established, patients were informed about the treatment 
options. When the patient experienced moderate symptoms or the patient 
was bothered by his symptoms, terazosin treatment was recommended in 
addition to other minimal invasive therapies. Patients started treatment 
with an increasing dose, to a maximum of 10 mg per day terazosin at 6 
weeks of treatment, administered at bed time. Every patient's dose was 
titrated up to 10 mg, but patients not tolerating the 10 mg-dose had their 
dosage decreased to 5 mg. Urodynamic pressure-flow studies before and 
after 6 months of treatment with terazosin were used to evaluate 
urodynamic changes. Urinalysis and culture were negative at the time of 
pressure-flow studies. After 6 months of treatment, patients were re-
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evaluated both clinically and urodynamically. 
Urodynamic pressure-flow studies were performed with an 8F 
transurethral lumen catheter equipped with an intravesical microtip pres­
sure sensor for bladder pressure recording. Abdominal pressure was 
recorded intrarectally with an 8F microtip sensor catheter (MTC®. Drager, 
Germany). Before cystometry, the bladder was emptied through the lumen 
of the transurethral catheter. The bladder was filled with water of 2 0 ° С at 
a rate of 50 ml per minute; with the patient in supine position. In consider­
ation of the micturition diary, free uroflowmetry and residual urine, care 
was taken to fill the bladder until the maximum bladder capacity was 
reached. Filling was stopped when the patient expressed a very strong 
urge to void. Commercially available equipment (UD 2000®; MMS, 
Enschede, the Netherlands) was used to record the pressure and flow 
data. Digitally stored data were translated to a urodynamic analysis 
computer program developed at our own department. This program 
provides a half automatic pressure-flow study analysis with passive 
urethral resistance relation (PURR) and urethral resistance factor (URA). 
To provide an objective and precise grading of obstruction, pres­
sure-flow graphs were fitted with a PURR curve at the lowest pressure 
part of the graph.12 The minimal urethral opening pressure during 
micturition (Pvok^J and theoretical cross-sectional urethral lumen (A t h M) 
were calculated automatically, on basis of these manually adjusted PURR 
curves.12 The pressure at maximum flow during the urodynamic investiga­
tion (P^Qmax) was recorded. Correction for flow artifacts was performed 
when necessary. URA was determined by fitting the pressure-flow plot at 
the point of maximum flow (at P^Qmax). URA was used to classify 
patients on a continuous, one-parameter scale of obstruction.13 We also 
added a nonparametric analysis of obstruction with clinical classes accord­
ing to the linear PURR (L-PURR) pressure-flow nomogram.14 The linear 
PURR was determined by drawing a straight line between the P^Qmax 
and the PvokJ^ points on the pressure-flow curve. The position of this line 
defined the outlet condition in a simple way and allowed classification of 
the severity of BOO. The following urodynamic variables were analyzed 
from free flowmetry: free Qmax; free voided volume; residual volume after 
free flowmetry and free voided percentage. Bladder capacity was analyzed 
from cystometry. Finally, the following were analyzed from pressure-flow 
study: maximum flow during urodynamic investigation (urod Qmax); 
P^Qmax; Pvo¡dmin; Ath.0; URA; residual volume after urodynamic pressure-
flow study (urod residual volume) and voided percentage during pressure-
flow study (urod voided percentage) for the whole group of patients and 
for subgroups of patients who were categorised as patients with BOO (L-
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PURR of 3 or more) and patients categorised as patients without BOO (L-
PURR less than 3).16 
All statistical tests were two-sided and carried out at the 5% 
significance level. For numerical variables (such as symptom scores, 
quality of life scores, free flow parameters and urodynamic parameters) 
within-treatment changes were assessed using the paired t-test or the 
Wilcoxon matched-pairs signed-ranks test; between-treatment group 
changes using the t-test for independent samples or the Mann-Whitney Li-
test. The number of patients with an increase of voided volume of 50 ml 
or greater and with an improvement of Qmax of 10% or more from 
baseline in the groups with and without BOO were compared using the chi-
square test. 
Results 
From september 1992 to October 1994, 97 patients started 
treatment with terazosin. The baseline characteristics of 97 patients, and 
for subgroups with and without BOO, who were included in the study are 
indicated in table 1. This table indicates that patients without BOO had, in 
addition to the significantly different urodynamic variables, a significant 
higher free Qmax and a significant higher free voided percentage. 
Twenty-eight (29%) patients stopped terazosin treatment before 
the evaluation at month 6 because of side-effects (n = 13), no response to 
therapy (n = 12), or symptoms improving "spontaneously" (n = 3). The 
most frequent treatment-related side effects were mild headache, dizziness 
and asthenia. Usually, these side effects were mild and transient. Of the 
13 patients who experienced side effects, 9 stopped treatment because of 
treatment-related side effects: dizziness (n = 2), asthenia (n = 4), palpita-
tions (n = 1), peripheral edema (n = 1) and paraesthesia (n=1). Dyspnea 
(n = 2), cardiac arrhythmia (n = 1), and visual disturbances (n = 1) were the 
reasons why the 4 other patients who experienced side effects stopped 
treatment: these events were not considered to be treatment related. Nine 
other patients were not available at 6 months because they were lost to 
follow-up (n = 4) or they refused their second clinical and urodynamic 
pressure-flow study evaluation (n = 5). Sixty patients, of whom 30 (50%) 
were classified as patients with BOO, were evaluated clinically and 
urodynamically before and after 6 months (median 28, range 17-45 
weeks) of treatment. 
The mean variables listed in table 1 were compared between the 
group that continued taking terazosin for 6 months and the group that 
stopped taking terazosin before 6 months. Patients who stopped terazosin 
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Table 1 . Mean baseline characteristics of 97 patients included in the study 
(standard deviation in parentheses). P-value indicates the signifi­
cance of the comparison between the baseline characteristics 
between the groups with (L-PURR 2 3) and without (L-PURR < 3) 
BOO. Legend see chapter 6, table 1. 
Age (years) 
PSA (ng/ml) 
Prostate volume (cc) 
total l-PSS 
l-PSS QoL score 
Free voided vol. (ml) 
Free Qmax (ml/s) 
Free residual vol. (ml) 
Free voided pere. (%) 
Bladder capacity (ml) 
Urod. Qmax (ml/s) 
Urod. resid. vol. (ml) 
Urod.void.perc. (%) 
P^Qmaxfcm water) 
P v « ^ (cm water) 
Кш> (mm2) 
URA (cm water) 
L-PURR 
Whole group 
(n = 97) 
62(9) 
3.8 (3.8) 
38 (18) 
19.1 (5.9) 
4.1 (1.2) 
265 (136) 
10.5 (5.5) 
73 (120) 
81 (18) 
424(134) 
7.7(4.1) 
113(157) 
77 (28) 
57.5 (29.8) 
29.1 (18.1) 
3.7 (2.7) 
35.2 (19.3) 
2.4 (1.5) 
Patients with 
L-PURR < 3 
(n = 53) 
61 (9) 
3.4 (3.5) 
34(16) 
18.9 (5.8) 
4.0(1.2) 
296 (154) 
11.6 (6.5) 
58 (86) 
85 (15) 
437 (144) 
9.4 (4.5) 
79(146) 
85 (25) 
39.8 (16.2) 
18.4(9.2) 
4.9 (3.1) 
22.5 (7.7) 
1.3(0.7) 
Patients with 
L-PURR «» 3 
(n = 44) 
63(8) 
4.5(4.1) 
42 (20) 
19.8 (5.8) 
4.2 (1.2) 
231 (100) 
9.0 (3.7) 
94 (154) 
77 (20) 
400(118) 
5.5 (2.0) 
142 (147) 
69 (26) 
80.5 (27.6) 
42.8 (17.7) 
2.1 (0.8) 
51.7 (17.3) 
3.9 (0.9) 
p-value 
0.31 
0.29 
0.06 
0.47 
0.70 
0.06 
<0.01 
0.06 
0.02 
0.28 
< 0.01 
< 0.01 
< 0.01 
< 0.01 
< 0.01 
< 0.01 
< 0.01 
< 0.01 
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before 6 months were statistically significantly younger (mean age ± sd: 
58 ± 9 years) when compared with patients who continued taking 
terazosin up to 6 months (64 ± 8 years, ρ < 0.01). The mean bladder 
capacity in those who discontinued terazosin was higher (458 ± 1 2 5 ml) 
when compared with those who continued treatment up to 6 months (403 
± 136 ml) (p = 0.03). When comparing the mean Р о к ^ (23.3 ± 15 
versus 32.3 ± 18.8 cm water; ρ =0.01), the mean URA (29.3 ± 14.1 
versus 38.6 ± 21.1 cm water; ρ = 0.04) and the mean L-PURR category 
(1.9 ± 1 . 4 versus 2.7 ± 1.5; p = 0.02) between those who stopped 
terazosin treatment and those who continued it for 6 months, respectively, 
the mean values of those who stopped were significantly smaller, indicat­
ing that patients without BOO had a higher likelihood of stopping terazosin 
for various reasons before month 6. 
Table 2 outlines the mean symptom scores and mean urodynamic 
variables at baseline and after 6 months of treatment of the 60 patients 
who completed terazosin treatment for 6 months, the patients are divided 
into two subgroups, those with and without BOO. Also indicated in this 
table is the comparison of the changes in these variables between the 
groups with and without BOO. Mean total l-PSS improved significantly in 
both groups: from 19.7 to 10.6 in the group without BOO and from 20.1 
to 11.1 in the group with BOO (for both groups, ρ < 0.01). The mean I-
PSS quality of life score improved significantly in both groups: from 4.1 to 
2.0 in the group without BOO and from 4.1 to 2.3 in the group with BOO 
(for both groups, ρ < 0.01). The mean symptom and quality of life related 
changes between the groups without and with BOO were not significantly 
different (p = 0.89 and ρ = 0.85, respectively). In patients without BOO, 
mean free Qmax improved significantly by 4.4 ml/s (p < 0.01 ), mean free 
voided volume increased by 24 ml (p = 0.52), and mean free residual 
volume did not change significantly (p = 0.24). In the patients with BOO, 
mean free Qmax improved significantly by 1.6 ml/s (p = 0.04), mean free 
voided volume decreased by 32 ml (p = 0.15) and mean free residual 
volume decreased significantly from 110 ml to 59 ml (p = 0.03). The 
mean change of free Qmax was significantly higher in the group without 
BOO when compared with the group with BOO (p = 0.01). This could 
have been related to an increase of voided volume of 24 ml in the group 
without BOO and a decrease of voided volume of 32 ml in the group with 
BOO. The statistical significant difference in the change of free Qmax 
between the groups with and without BOO was evaluated further. Small 
improvements in free Qmax (10 % or more from baseline) were found 
significantly more frequently in patients without BOO (77%) than in 
patients with BOO (48%) (p = 0.02). This higher number of patients with 
a small improvement of free Qmax could be related with an increase in free 
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Table 2. Mean characteristics, at baseline and after 6 months of terazosin 
treatment, for the 60 patients who completed the second 
urodynamic evaluation, divided into subgroups of patients, with and 
without BOO. P-vaiues in the columns regarding patients with and 
without BOO indicate the significance of the comparison of baseline 
versus month 6 within groups. P-value* between groups indicates 
the significance level of the comparison of the changes in the 
variables from baseline to month 6 between the groups with and 
without BOO. Legend see chapter 6, table 1. 
Patients without BOO 
(L-PURR < 3) 
η = 30 
Patients with BOO 
(L-PURR a: 3) 
η = 30 
p-value* 
total l-PSS Baseline: 19.7 (6.4) 
Month 6: 10.6 (6.7) 
Change: 9.5 (7.1) 
p-value: < 0.01 
Baseline: 20.1 (5.8) 
Month 6: 11.1 (5.7) 
Change: 9.7 (7.0) 
p-value: < 0.01 
0.89 
l-PSS QoL score Baseline: 4.1 (1.2) 
Month 6: 2.0(1.3) 
Change: 2.0 (1.2) 
p-value: < 0.01 
Baseline: 4.1 (1.1) 
Month 6: 2.3 (1.4) 
Change: 1.9 (1.8) 
p-value: < 0.01 
0.85 
Free voided vol. (ml) Baseline: 286 (163) 
Month 6: 311 (173) 
Change: 24(191) 
p-value: 0.52 
Baseline: 219 (99) 
Month 6: 189 (70) 
Change: 32 (111) 
p-value: 0.15 
0.17 
Free Qmax (ml/s) Baseline: 11.4 (8.2) 
Month 6: 15.9 (8.2) 
Change: 4.4 (4.7) 
p-value: < 0.01 
Baseline: 8.3 (2.7) 
Month 6: 9.9 (3.5) 
Change: 1.6 (3.4) 
p-value: 0.04 
0.01 
Free resid. vol. (ml) Baseline: 59 (99) 
Month 6: 45 (129) 
Change: 11 (63) 
p-value: 0.24 
Baseline: 110(177) 
Month 6: 59 (85) 
Change: 53 (176) 
p-value: 0.03 
0.23 
Free void. pere. (%) Baseline: 85 (14) 
Month 6: 91 (14) 
Change: 6 (15) 
p-value: 0.07 
Baseline: 74 (22) 
Month 6: 82 (22) 
Change: 8 (22) 
p-value: 0.10 
0.94 
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Table 2. (com.) Patients without BOO 
(L-PURR < 3) 
(n = 30) 
Patients with BOO 
(L-PURR :» 3) 
(η = 30) 
p-value* 
Bladder capac. (ml) 
Urod Qmax (ml/s) 
Urod resid. vol. (ml) 
Urod void. pere. (%) 
P^QmaxIcm water) 
PïMd__ (cm water) 
(mm2 
URA (cm water) 
L-PURR 
Baseline: 420(145) 
Month 6: 485 (192) 
Change: 70(135) 
p-value: 0.01 
Baseline: 9.7 (5.1) 
Month 6: 11.3 (5.6) 
Change: 1.6 (4.6) 
p-value: 0.02 
Baseline: 84 (151) 
Month 6: 72 (134) 
Change: 12 (161) 
p-value: 0.62 
Baseline: 84 (24) 
Month 6: 88 (22) 
Change: 4 (26) 
p-value: 0.35 
Baseline: 42.5 (16.0) 
Month 6: 44.4 (19.4) 
Change: 1.9 (24.5) 
p-value: 0.70 
Baseline: 21.1 (9.8) 
Month 6: 19.1 (13.6) 
Change: 2.0 (15.6) 
p-value: 0.51 
Baseline: 5.3 (3.7) 
Month 6: 5.8 (3.0) 
Change: 0.5 (3.3) 
p-value: 0.11 
Baseline: 23.7 (8.0) 
Month 6: 21.8 (10.6) 
Change: 1.9 (9.7) 
p-value: 0.07 
Baseline: 1.4 (0.7) 
Month 6: 1.2 (1.0) 
Change: 0.3 (1.0) 
p-value: 0.30 
Baseline: 388 (128) 
Month 6: 402 (127) 
Change: 14(123) 0.06 
p-value: 0.93 
Baseline: 5.3 (2.2) 
Month 6: 7.2 (3.5) 
Change: 1.9 (2.7) 0.73 
p-value: < 0.01 
Baseline: 158 (158) 
Month 6: 95 (114) 
Change: 64(85) 0.12 
p-value: < 0.01 
Baseline: 65 (28) 
Month 6: 79 (22) 
Change: 14(19) 0.01 
p-value: < 0.01 
Baseline: 81.6 (30.3) 
Month 6: 62 6 (29.4) 
Change: 19.0 (37.1) 0.01 
p-value: < 0.01 
Baseline: 43.6 (19.1) 
Month 6: 29.8 (17.5) 
Change: 13.8 (22.3) 0.02 
p-value: < 0.01 
Baseline: 2.1 (0.8) 
Month 6: 3.3 (2.0) 
Change: 1.2 (1.6) 0.57 
p-value: < 0.01 
Baseline: 53.5 (19.6) 
Month 6: 37.7 (17.3) 
Change: 15.8 (15.8) < 0.01 
p-value: < 0.01 
Baseline: 3.9 (1.0) 
Month 6: 2.8 (1.6) 
Change: 1.3 (1.2) < 0.01 
p-value: < 0.01 
186 
Chapter 7.3 
voided volume in patients without BOO. Forty-seven percent of the 
patients without BOO had an increase of free voided volume of at least 50 
ml, whereas of those in the group with BOO, only 14 % had an increase of 
free voided volume of 50 ml or greater (p < 0.01). When comparing the 
number of patients with larger improvements of free Qmax (30 or 50 % or 
more from baseline), there were no significant differences between the 
two groups. Sixty percent of the patients without BOO and 41 % of the 
patients with BOO had an increase of free Qmax of 30 % or more from 
baseline (p = 0.15) and 43 and 34 %, respectively, had an increase of 
free Qmax of 50 % or more from baseline (p = 0.49). The mean free 
voided percentage improved from 85 to 91 % in the group without BOO 
and from 74 to 82 % in the group with BOO; changes within and between 
these groups were not significant. 
The evaluation of the pressure-flow study variables urod Qmax, 
P^Qmax, Pvoidmin, A^«,, URA and L-PURR in the patients with BOO 
revealed statistically significant improvements of all mean variables after 6 
months of terazosin treatment (table 2). Significant changes of pressure-
flow study variables in patients without BOO could not be detected, 
except for mean urod Qmax which improved significantly with 1.6 ml/s (p 
= 0.02). The mean bladder capacity in patients without BOO improved 
from 420 to 485 ml, which was statistically significant (p = 0.01). When 
evaluating the mean urodynamic changes between the groups with and 
without BOO, the changes for the variables urod voided percentage, 
P^Qmax, Pvo¡dmin, URA and L-PURR were significantly higher in the group 
with BOO. In figure 1 the improvements of P^Qmax and total l-PSS are 
plotted for each patient who completed 6 months of treatment. The 
patients with BOO tended to have a larger urodynamical improvement 
when compared with patients without BOO. However, the symptomatic 
improvement is in the same range in both groups. 
In table 3 the mean changes in symptoms, quality of life, free 
uroflow variables and urodynamic variables are compared between the 
group of patients who improved urodynamically (that is the group that had 
a L-PURR decrease of 1 point or more on the Schäfer nomogram) and the 
group who did not. Only the changes in the inter-related urodynamic 
variables P^Qmax, Pvoid^, URA and L-PURR were significantly higher in 
the group that improved urodynamically. The mean changes in symptoms, 
quality of life and free uroflow variables were not significantly different 
between those who improved urodynamically and those who did not. 
After 6 months, 54 out of 93 patients (58%) continued terazosin 
treatment. The others were treated with trans urethral microwave 
thermotherapy (n = 4), trans urethral laser ablation of the prostate (n = 9), 
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other medication (n = 7) or unknown procedures of medications (n = 4) or 
they were followed with the watchful waiting policy (n = 15). 
Discussion 
During the World Health Organization international consultation on 
BPH in 1993, it was advised that, if obstruction is the endpoint of the 
study, pressure-flow studies before and after treatment should be used in 
the evaluation of new therapies.10 Pressure-flow studies enable us to 
investigate the relationship between subjective efficacy of treatment and 
objective voiding parameters. Moreover, the use of pressure-flow studies 
may help to select patients for a given treatment; therefore, dropout and 
overtreatment percentages may decrease considerably.11,17 
With respect to the efficacy of terazosin in the group with BOO, we 
showed that all mean values P^Qmax; Pvo¡dmin; A ^ ; and URA improved 
significantly after 6 months of treatment with terazosin. From a theoretical 
viewpoint, the mechanism of voiding using an σ1-adrenergic blockader is 
changed toward better outlet distensibility during voiding; thus, it becomes 
more efficient. The first effect of a decrease in outlet obstruction is 
presumably a change in the balance of bladder outlet and contraction 
towards a lower pressure micturition with improved efficacy. Theoretically, 
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Figure 1 . Urodynamic and symptomatic results for each individual patient who 
completed 6 months of terazosin therapy, labelled according to the 
BOO class, with [solid circle] (L-PURR a 3) and without [asterisk] 
BOO (L-PURR < 3). Improvement of P,j.,Qmax in cm. water on the Y-
axis, defined as P^Qmax at baseline minus P^.Qmax at month 6, and 
improvement of total l-PSS symptom score on the X-axis, defined as 
total l-PSS at baseline minus total l-PSS at month 6. 
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Table 3. Comparison of the changes after terazosin treatment for 6 months 
between the group who improved urodynamica/ly (L-PURR decrease 
of at least 1 point! and the group that did not (standard deviation in 
parentheses). Legend see chapter 6, table 1. 
total l-PSS 
l-PSS QoL score 
Free voided volume (ml) 
Free Qmax (ml/s) 
Free residual volume (ml) 
Free voided percentage (%) 
Bladder capacity (ml) 
Urod Qmax (ml/s) 
Urod residual volume (ml) 
Urod voided percentage (%) 
P^Qmax (cm water) 
Pvoidmi) (cm water) 
A«.,, (mm2) 
URA (cm water) 
L-PURR 
L-PURR decrease 
a: 1 
(n = 35) 
8.7 (5.2) 
1.9 (1.5) 
3(141) 
3.1 (5.0) 
48 (164) 
9(21) 
29 (119) 
2.4 (3.1) 
55 (134) 
12 (22) 
24.5 (26.7) 
17.1 (18.9) 
1.1 (2.6) 
17.2 (11.8) 
1.6 (0-8) 
L-PURR decrease 
< 1 
(n = 25) 
10.7 (8.7) 
2.1 (1.5) 
-14 (181) 
3.1 (3.3) 
12(71) 
4 ( 1 5 ) 
60 (147) 
0.9 (4.3) 
13 (123) 
5(23) 
-13.8 (27.5) 
-5.0 (13.3) 
0.5 (2.7) 
-2.9 (9.7) 
-0.3 (0.6) 
p-value 
0.30 
0.70 
0.68 
0.98 
0.31 
0.94 
0.33 
0.13 
0.21 
0.43 
< 0.01 
< 0.01 
0.48 
< 0.01 
< 0.01 
the increase in Qmax might not be as high as may be expected, which 
may be partly attributed to a decrease in P^Qmax. More efficient voiding 
can also be shown by lower post-void residual volumes, but this could not 
be demonstrated by our patients; they had a low mean residual volume of 
59 ml with a high standard deviation of 99 ml. A significant larger Α ^
β 
together with a significant decrease of Pvoid^ indicates that terazosin has 
relaxed the bladder outlet so that more efficient voiding can occur. 
In the patients without BOO, statistically significant changes of 
urodynamic variables could not be shown, except for free Qmax, urod 
Qmax and bladder capacity. When evaluating the present study, we have 
to realize that this study is a non controlled one, so we have to be careful 
in drawing far-reaching conclusions with respect to efficacy. Exact 
quantification of the urodynamic effect of treatment is only possible with a 
double-blind placebo-controlled study. This is mainly due to a large placebo 
effect that exists in patients treated with an σ1-blocker such as terazosin. 
In a large randomized, double blind study Roehrborn et al showed an 7.6 
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point improvement in symptom score in the terazosin-treated group, 
whereas in patients treated with a placebo, symptom score improved by 
only 3.7 points. The improvements in free Qmax were an increase of 2.2 
ml/s in the terazosin-treated group and an increase of 0.8 ml/s in the 
placebo-treated group.18 
At baseline, patients with BOO had a significant different voiding 
mechanism with lower voided percentages and lower maximum flow rates 
when compared with the group without BOO (table 1). Because terazosin 
treatment improves the obstruction classification, some patients will shift 
from the group with BOO to the group without BOO and this could result 
in a favourable improvement of free Qmax. 
In the present study, dropout percentages were relatively higher 
than those reported in literature. Lepor reported that, of 494 patients 
enrolled in a 42-month, open-label, multicenter study of terazosin, 213 
(43%) withdrew prematurely, 55 (11%) because of lack of effectiveness, 
96 (19%) because of adverse events, and 62 (13%) because of adminis­
trative reasons.8 It could be that the 3 8 % dropout rate in the present study 
(37 from 97 patients dropped out the study before 6 months) is relatively 
higher because we offered patients with moderate symptoms or patients 
who are bothered by their symptoms the choice between an σ1-blocker 
treatment or other minimally invasive therapies. With a wide variety of 
minimal invasive treatment options, patients and urologists may more 
easily change their original treatment decision, compared with a situation 
where, after σΐ -blocker treatment, the only options are watchful waiting or 
prostatectomy. 
Patients without BOO were more prone to early dropout for various 
reasons when compared with patients with BOO. In patients with a L-
PURR of 0 or 1, the poor urinary stream is caused by a hypo-active 
detrusor muscle. These patients benefit little from transurethral resection 
of the prostate.11 It could be that the unobstructed patients are also less 
likely to benefit from σ1-blockers. This may be consistent with the 
assumption that it is unlikely that the detrusor function is improved by 
these drugs. 
Our study design may be criticized for lack of a placebo control 
group and for potential selection bias. However, the mean changes of peak 
flow rates and symptom scores observed in this open label study were 
comparable to the data from a randomized study.19 Earlier studies have 
indicated that the expected improvement of mean free Qmax after 6 
months of treatment with terazosin is between 2.4 and 3.1 ml/s.88,18·19 In 
our study, the mean improvement of free Qmax in the total group of 
patients was 3.0 ml/s. One may question the clinical relevance of 3.0 ml/s 
improvement of free Qmax. This study indicates that, besides the 
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improved free Qmax, more variables may change after terazosin therapy. 
In the present study, unobstructed patients had a statistically significantly 
increased bladder capacity. Patients with BOO had a statistically signifi-
cantly decreased residual volume. As a result of these changes, another 
micturition pattern may develop that could result in a significant improve-
ment of the l-PSS, especially when taking into account that the questions 
of the l-PSS questionnaire are concerned with bladder emptying, fre-
quency, intermittency, urgency, nocturia, weak stream and hesitancy. All 
of these symptoms may improve as a result of improved free Qmax, 
bladder capacity, or residual volume. 
When companng the changes after 6 months of therapy between 
the patients with and without BOO, the changes in symptoms and quality 
of life were not significantly different (table 2). An improvement of free 
voided volume of 50 ml or more occurred significantly more frequently in 
the group without BOO. A larger voided volume in the group without BOO 
could result in a higher number of patients with slight improvements in free 
Qmax. When comparing the free voided volumes with the free Qmax, 
using the Liverpool nomograms, it appeared that the values of the first 
voiding in the group without BOO - a voided volume of 286 ml and a free 
Qmax of 11.4 ml/s - correspond with the 5th percentile whereas the 
values of the second voiding - a voided volume of 311 ml and a free Qmax 
of 15.9 ml/s - correspond with the 17th percentile of the healthy males 
investigated.20 For the group with BOO, the values of the flows correspond 
with the 5th and 10th percentile for the first and the second voiding, 
respectively. This indicates that, despite the different voided volumes, the 
free Qmax increases, probably as a result of therapy. When we evaluated 
the number of patients with greater improvements in free Qmax, there was 
no significant difference between groups with and without BOO, which 
demonstrates that, in our patients without BOO, statistically significant 
improvements in free Qmax were not confirmed by significant improve-
ments of urodynamic variables. Significant changes in urodynamic vari-
ables were only shown in the group with BOO. This finding suggests that 
the way we analyze efficacy in most pharmacotherapy studies for BPH 
(that is, improvements in symptoms and small improvements of Qmax) 
does not depend on the urodynamic mechanism of action. Therefore, we 
cannot recommend the use of pressure-flow studies in the selection of 
patients for terazosin treatment in daily urological practice because the 
changes of symptoms and quality of life between the groups with and 
without BOO were not significantly different. Moreover, the number of 
patients with improvements of free uroflow of at least 30% appeared not 
to be significantly different between groups with and without BOO. Hence, 
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it seems more useful and certainly less expensive and less invasive to start 
σ1-blocker therapy if, on clinical grounds, the urologist considers the 
patient to be a candidate for σ1 -blocker therapy and to continue therapy in 
those who are satisfied. 
However, it is unknown what the long-lasting effect of BOO on the 
bladder is for patients who are satisfied with their treatment but who 
remain urodynamically obstructed. Do they have a higher likelihood of 
developing complications on the long term, such as obstructive 
nephropathy, urinary retention, infection, bleeding, bladder stones or other 
complications that adversely affect their well-being ? Is there a difference 
in the probability of developing complications when compared with 
patients without BOO ? Further follow up and more prospective, well-
controlled investigations are necessary to provide the still lacking informa­
tion on the long-lasting effects and complications of pharmacological 
treatment. 
Conclusions 
We have shown that a stratified analysis, based on the urodynamic 
classification of BOO, provides insight into the working mechanism of 
terazosin in patients with and without BOO. Patients with a hypo-active 
detrusor muscle may be more prone to dropout early when compared with 
patients who have a normal detrusor function. We also showed that after 
6 months of terazosin treatment, the changes of symptoms and quality of 
life and the number of patients with improvements of free uroflow of 30 % 
or greater appeared not to be significantly different between the groups 
with and without BOO. Therefore, we cannot recommend the use of 
pressure-flow studies in daily urological practice if, on clinical grounds, the 
urologist considers the patient to be a candidate for σ1 -blocker therapy. It 
seems more useful and certainly less expensive and less invasive, to start 
terazosin therapy for patients and to stop therapy in those who are not 
satisfied. In the dissatisfied patients, pressure-flow studies could be of 
help in selecting patients for more invasive treatments. In patients who are 
satisfied with their treatment, terazosin could be continued. However, as 
the long-term complications of pharmacological treatment in patients with 
bladder outlet obstruction are not well known, we recommend to follow up 
these patients on a regular basis. 
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Abstract 
Objectives: We investigated the symptomatic and urodynamic effects of 
several non-invasive and minimally invasive treatment modalities to 
quantify these effects and to compare subjective and objective results 
within groups with various degrees of obstruction. 
Methods: In a prospective study at one centre, 487 patients who com-
pleted a full screening program including urodynamic investigation started 
treatment with: watchful waiting, terazosin, transurethral microwave 
thermotherapy or laser treatment of the prostate and were reevaluated 
symptomatically and urodynamically after 6 months of therapy. The 
symptomatic and urodynamic results of 87 patients from another centre 
who underwent a transurethral resection of the prostate and who had their 
second urodynamic evaluation 6 months postsurgery were also included. 
Results: In patients without bladder outlet obstruction (BOO), improve-
ment in maximum flow and symptom scores with little change in the 
degree of obstruction was most apparent whilst a decrease of detrusor 
pressure at maximum flow was observed mainly in patients with BOO. The 
urodynamic effect but not the symptomatic effect of treatments depended 
on the initial grade of BOO. Urodynamic changes were more marked in the 
minimally invasive treatment groups compared to the non-invasive treat-
ment groups. 
Conclusions: In symptomatic patients with BPH, symptomatic improve-
ment in the short-term does not seem to depend on changes in urodynamic 
parameters. Future well controlled studies focussing on the durability of 
symptomatic and urodynamic effects will be needed to illustrate the 
relative potential of urodynamic and other clinical parameters to predict a 
favourable response to current and innovative treatments. 
Introduction 
Bladder outlet obstruction (BOO) in men due to benign prostatic 
hyperplasia (BPH), has presented a great clinical problem for many years. It 
has been estimated that BPH affects approximately 45 % of men at 60 
years of age1 and some estimate the prevalence to be approximately 80% 
by the age of 80.2 The incidence and clinical significance of BPH have 
been increasingly difficult to evaluate, since the indications for therapeutic 
intervention have shifted from attempts to preserve life to those improving 
quality of life. Also, as we move into an era where alternatives to surgery 
are increasingly used to treat BPH, the time has come to consider which 
diagnostic criteria should be established before any pharmacological, 
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minimally invasive or invasive treatment can be recommended. To assess 
patient's complaints subjective parameters can be used such as symptom 
scores and/or objective parameters such as voiding studies. Most urolo­
gists agree that only patients with bladder outlet obstruction should 
undergo surgical intervention but nevertheless the decision for surgery is 
usually based primarily on the nature and severity of symptoms. 
Despite an increasing number of reports on the relationships 
between symptoms and bladder outlet obstruction, the correlation 
between these entities remains unproved.3 Also the correlation between 
subjective efficacy of treatment and objective (voiding parameters) effi­
cacy is not clear. 
We investigated symptomatic and urodynamic effects of several 
non-invasive and minimally invasive treatment modalities to quantify these 
effects and to compare the subjective and objective results of treatment 
within the various obstruction groups according to the linear passive 
urethral resistance relation (L-PURR) nomogram.4 
Patients and methods 
In 1992, a prospective study was initiated in our prostate centre to 
evaluate the outcome of therapy in patients with lower urinary tract 
symptoms (LUTS) treated with non-invasive or minimally invasive treat­
ment modalities. All patients were evaluated at baseline by medical 
history, International Prostate Symptom Score (l-PSS), physical examin­
ation including digital rectal and ultrasonographic examination of the 
prostate, and free urinary flowmetry with subsequent ultrasonographic 
measurement of residual urinary volume. Prostate volume was calculated 
using the planimetrie method with a Kretz Combison 330 ultrasound 
scanner and a multiplane 3-D rectal transducer (VRW 177AK). For free 
urinary flowmetry the Dantec Urodyn 1000 flowmeter was used. All 
patients were considered neurologically normal, based on history, symp­
toms and physical examination (no motor, sensory or reflex deficits). 
Patients in whom a prostatic carcinoma or other diseases beyond the 
prostate, possibly influencing their LUTS (e.g. urethral stricture or bladder 
neck contracture) could be expected were evaluated more extensively first 
e.g. by prostate biopsy or urethro-cystoscopy and excluded if these 
diseases were confirmed. Excluded were patients previously treated with 
transurethral (laser) resection of the prostate, transurethral microwave 
thermotherapy, or 5a-reductase inhibitors. Patients treated with a blockers 
within 4 weeks of the baseline pressure-flow study being performed were 
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also excluded. 
Following this assessment patients were informed about the 
treatment options available at our prostate centre: watchful waiting (WW), 
pharmacological therapy, transurethral microwave thermotherapy (TUMT), 
laser therapy of the prostate and transurethral prostatectomy (TURP). 
Therapy was recommended depending on the severity of symptoms and 
the grade of bladder outlet obstruction (BOO). For example, when a 
urodynamic investigation showed no BOO and the patient experienced 
minimal symptoms, or he was not bothered by his symptoms, WW was 
recommended besides pharmacological treatment.6 On the other hand, 
patients sometimes preferred WW even when BOO was confirmed. For 
those who were treated with terazosin treatment was started with an 
increasing dose, to a maximum of 10 mg per day at 6 weeks of treatment, 
administered at bed time." When BOO was confirmed urodynamically, 
minimal invasive treatment modalities were recommended and the possibil-
ity of pharmacological treatment and WW was discussed with the patient 
whereafter the patient and the physician decided on the appropriate 
treatment. For those who were treated with TUMT the high energy 2.5 
software was used.7 In patients who were treated with laser 
prostatectomy a side fire laser technique was used.8 The results of the few 
patients who underwent a TURP are not reported here. 
Urodynamic pressure-flow studies were performed according to the 
procedure described before.6 The following urodynamic variables were 
analyzed. From free flowmetry: free maximum flow (free Qmax); free 
voided volume; residual volume after free flowmetry. From pressure-flow 
study: detrusor pressure at maximum flow (p^Qmax); urethral resistance 
factor (URA) and L-PURR obstruction category.4 
I-PSS and cystometry with pressure-flow studies before and at 6 
months after treatment were performed to evaluate symptomatic and 
urodynamic changes. Urinalysis and culture were negative at the time of 
pressure-flow studies. 
Also the symptomatic and urodynamic results of 99 patients who 
underwent a TURP of whom 87 had their second conventional urodynamic 
evaluation 6 months postsurgery in the Freeman Hospital, Newcastle upon 
Tyne, United Kingdom were included. The results of patients from this 
centre have been described before.8 The patients in this centre were 
selected differently. The indications for operation were symptoms of poor 
flow, hesitancy, dribbling micturition, or incomplete bladder emptying with 
or without additional symptoms of frequency, nocturia, urgency, or urge 
incontinence. All patients had a maximum urinary flow rate < 15 ml. per 
second when measured in the outpatient department. There were no 
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explicit urodynamic pressure-flow study selection criteria. The patients 
were evaluated at baseline by medical history, a standard symptom 
questionnaire based on that described by Frimodt-МфІІег et al,1 0 physical 
examination including digital rectal examination of the prostate with 
estimation of the prostatic volume, and free urinary flowmetry with 
subsequent ultrasonographic measurement of residual urinary volume. All 
patients were considered neurologically normal, based on history, symp­
toms and physical examination. Patients were excluded if they were 
already on a waiting list (because those waiting for some time might not 
have been representative), if they had an acute urinary retention or if they 
had clinically apparent prostatic cancer. 
Descriptive statistics were used to give an overview of the reported 
symptomatic and urodynamic changes after (starting) treatment for sub­
groups of patients who were categorised as patients without BOO (L-PURR 
ÍS 1) patients categorised as moderate BOO (L-PURR = 2,3) and patients 
categorised as patients with severe BOO (L-PURR 2: 4). Within-treatment 
changes (before and 6 months after treatment comparison) were assessed 
using the Wilcoxon matched-pairs signed-ranks test. Differences in 
medians for the changes across the obstruction categories within treat-
ment groups were tested with the Kruskal Wallis One Way ANOVA test. 
Approval for the studies was obtained locally from the Newcastle 
District Ethical Committee as well as from the Medical Ethical Committee 
of the University Hospital of Nijmegen. 
Results 
From January 1992 to November 1995, 1015 new patients with 
lower urinary tract symptoms and benign prostatic hyperplasia were 
referred to the Nijmegen clinic for evaluation: 25 % were treated with 
transurethral thermotherapy, 20 % were treated surgically (laser, 
transurethral or open prostatectomy, bladder neck-incision), 30 % received 
medication (σ1 blockers or 5o-reductase inhibitors), 2 % were treated with 
intermittent or suprapubic catheterisation, and 23 % chose WW. For this 
analysis the results of the first consecutive 178 men who were followed 
with WW, 97 men who were treated with terazosin, 180 men who were 
treated with TUMT, 114 men who were treated with laser therapy and 99 
men from the Freeman Hospital who were treated with TURP were taken 
into account. In the total population, 27 % dropped out the study before 
the second investigation at 6 months. The main reason was that they were 
not available for evaluation because they refused the second urodynamic 
199 
Non-invasive and minimally invasive treatments 
and clinical investigation. A total of 487 men was investigated clinically 
and urodynamically before and 6 months after (the start of) treatment; 
121 men were followed with WW,6 60 men received terazosin,9 136 men 
underwent TUMT, 83 men were treated with laser prostatectomy and 87 
had a TURP. 
In table 1 the baseline characteristics of the studied population are 
indicated across the various obstruction groups investigated. Table 2 
presents the changes of the variables 6 months after (starting) therapy. 
As indicated in table 2 and figure 1, in patients without BOO (L-
PURR = 0,1), the changes in p^Qmax after therapy were minimal and 
below the suggested clinical relevant cut-off point of 15 cm. water.11 The 
improvements in free maximum flow were minimal (between 3 and 4 
ml./s.) in the terazosin, the TUMT and TURP treated group. In the WW 
group, symptom scores improved significantly at 6 months (intragroup ρ < 
0.01) but the magnitude of improvement was not clinically relevant. In the 
terazosin, TUMT and TURP treated group, symptom scores at 6 months 
improved statistically significantly (intragroup ρ < 0.01) with a median of 
47 to 57 %. 
In patients with moderate BOO (L-PURR = 2,3), p^Qmax 
decreased slightly ( < 10 cm. water) after WW and terazosin, and 
decreased significantly ( > 15 cm. water) in the TUMT, the laser and the 
TURP treated group. Free maximum flow improved in all but the WW 
group, particularly after laser and TURP ( > 8 ml./s.). In all groups particu­
larly in the terazosin, TUMT, laser and TURP treated group, symptom 
scores at 6 months improved significantly (intragroup ρ < 0.01). 
In patients with severe BOO (L-PURR ^ 4), p^Qmax decreased 
statistically significantly (intragroup ρ < 0.01) in all groups. In the WW 
group, the improvement was close to the suggested clinically relevant cut­
off point of 15 cm. water. Qmax improved significantly except in the WW 
and terazosin treated group. At 6 months, symptom scores remained 
stable in the WW group and improved significantly (intragroup ρ < 0.01) 
in the other treatment groups. 
The urodynamic effects of the specific therapies are indicated in 
figure 1. Evidently, patients with severe obstruction after TURP moved into 
the unobstructed area on the Abrams-Griffiths nomogram. The changes 
following the non-invasive and minimally invasive treatments were less 
clear. 
Table 2 indicates that stratification based on the L-PURR nomogram 
according to Schäfer was able to predict the interrelated urodynamic 
outcome of therapy (figure 1a-c) but not the symptomatic outcome of 
therapy. Also this stratification did not seem to predict the outcome of free 
flow. An exception was the severe obstruction group treated with 
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Figure 1 . Urodynamic changes 6 months after (starting) therapy for patients 
who were initially unobstructed (L-PURR s 1; figure 1a), who had 
moderate obstruction (L-PURR = 2,3; figure 1b) and for those who 
had severe bladder outlet obstruction (L-PURR & 4; figure 1c). The 
basis of the arrow represents the baseline p^Qmax (Y-axis) at maxi-
mum flow during urodynamic investigation (X-axis). The top of the 
arrow represents this situation 6 months after (starting) treatment. 
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terazosin which, despite statistically significant improvements of symp-
toms and p^Qmax did not seem to benefit with regard to free maximum 
flow. Also in the TUMT treated groups with no or moderate obstruction 
the change in free maximum flow was significantly lower although the 
improvement in symptoms was considerable. 
Discussion 
The decision to treat and the selection of therapy are the result of 
the clinicians' diagnosis and the patients preference. In the past, phys-
icians performed prostatectomy mainly for LUTS. Nowadays, 
prostatectomy is indicated most clearly in patients with recurrent urinary 
retention or evidence of obstructive uropathy in the upper urinary tract as 
a result of chronic urinary retention. Besides prostatectomy, physicians 
and symptomatic patients now have a variety of less invasive treatment 
modalities to choose from. One key issue is whether the physician should 
focus on relieving symptoms or relieving urodynamically proven obstruc-
tion. Unfortunately, LUTS, prostate size, free uroflowmetry parameters and 
the amount of post-void residual urine are associated with obstructive 
voiding but the correlation with the grade of obstruction is poor.12'18 An 
imprecise relationship between symptoms and urodynamic findings was 
recently reported by Ezz el Din et al who, in one centre, evaluated the 
relationship between urodynamic findings and the International Prostate 
Symptom Score and specific questions in 803 patients. It was concluded 
that these methods measure different aspects of the clinical condition that 
should be viewed separately in the evaluation and treatment decision of 
the elderly male patient presenting with LUTS.3 
The stratified analysis in the present study has demonstrated that 
the urodynamic effect of various treatments depends on the initial grade of 
BOO. In patients without BOO the increase in Qmax was most predomi-
nant, whilst a decrease of p^Qmax was principally observed in patients 
with BOO. Symptomatic changes of various therapies were not significant-
ly different among the different obstruction classes. These observations 
are in line with previous reports. We have recently shown that 
urodynamics and symptom scores are unable to delineate which patients 
are at risk when left untreated.6 Patients with severe obstruction on 
urodynamics did not worsen in the short-term; on the contrary, they were 
more likely to improve than to deteriorate urodynamically. Symptoms in 
this specific group of patients did not change significantly. On the other 
hand, patients without BOO became more obstructed urodynamically 
despite the fact that their symptoms improved significantly.5 The present 
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study confirms the discrepancy between subjective and objective efficacy 
of treatment. 
Our study design may be criticized for lack of control and potential 
selection bias. For an exact comparison and quantification of the 
urodynamic and symptomatic effects of specific treatments, a randomized 
controlled study design would be preferable. However, this was not 
possible in our situation. Many of the differences between non controlled 
studies can be explained by the selection of patients or by varying tech-
niques of measurement. Our group of patients may be a specifically 
selected group of patients. With a wide variety of treatment options the 
group of patients who choose for a specific treatment in Nijmegen may be 
different when compared to the situation that the only treatment options 
are WW and prostatectomy as in the group of patients who underwent a 
TURP in Newcastle. Nevertheless, some information can be gleaned from 
this study. 
The present study suggests that symptomatic efficacy in the short-
term in the majority of studies for patients with LUTS suggestive for BOO 
does not seem to depend on decreasing obstruction. Hence other factors, 
such as morbidity of treatment, long-term outcome, patient preference and 
socio-economic aspects will determine the suitability of the alternatives to 
TURP, which remains the 'gold standard'. In patients within various 
obstruction classes, urodynamic improvement was greatest in the minimal-
ly invasive treatment groups compared to the non-invasive treatment 
groups. Specifically, the urodynamic effects in the laser treated group 
appeared to be larger than in the TUMT treated group and in the severely 
obstructed patients the highest urodynamic improvement was obtained 
with TURP (figure 1). The urodynamic effects may be related to the 
ablative power of the treatment which is obviously larger in TURP than in 
laser and TUMT respectively. Speculatively, in symptomatic patients with 
BOO, the durability of symptomatic improvement may be related to the 
urodynamic effects of treatment and thus with the ablative effect of 
treatment. 
Since earlier studies have indicated that inclusion of pressure-flow 
data in the preoperative evaluation and patient selection for interventional 
therapies such as TURP and TUMT may improve the overall clinical 
results,9,17-18 it is our opinion that symptoms alone should not be used as 
the main indication for deciding on the appropriate (minimal) invasive 
treatment options. Future well controlled studies focussing on the durabil-
ity of symptomatic and urodynamic effects will be needed to illustrate the 
relative potential of symptoms, urodynamic and other clinical parameters 
to predict a favourable response to current and innovative treatments. 
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Conclusions 
The present study indicated that the urodynamic effect of several 
treatments depended on the initial grade of BOO. Symptomatic improve-
ment did not differ significantly among the different obstruction classes. 
Urodynamic changes were more marked in the minimally invasive treat-
ment groups compared to the non-invasive treatment groups. The present 
study suggests that in symptomatic patients with BPH, symptomatic 
improvement in the short-term does not seem to depend on changes in 
urodynamic parameters. 
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Summary and conclusions 
Summary and conclusions 
The significance of micturition variables in the assessment of 
patients with lower urinary tract symptoms (LUTS) was investigated in 
chapter 2-5 of this thesis. 
In chapter 2, international differences in the reporting of LUTS and 
related bother was investigated in 1271 patients from 12 countries who 
participated in the International Continence Society - 'Benign Prostatic 
Hyperplasia' (ICS-'BPH') study. The International Prostate Symptom Score 
(l-PSS) questionnaire has been demonstrated to correlate strongly with the 
patients' degree of bother from their urinary condition. From the ICS-'BPH' 
questionnaire, it appeared that the most frequently reported symptoms are 
not necessarily the most bothersome. The most frequently reported 
symptoms were those associated with the voiding phase, the most 
bothersome symptoms were those associated with the storage phase or 
those associated with incontinence. Country of origin was significantly 
associated with half of the symptoms measured, including both storage 
and voiding symptoms of both high and low prevalences. Controlling for a 
range of potential confounding variables had very little effect on these 
relationships. There were not such marked differences for 
bothersomeness, although the symptoms where there were international 
differences were all voiding symptoms. The results of studies in particular 
countries, therefore, may not be generally applicable in other countries. In 
particular, it may be important to take into account different patterns of 
selection of patients and reporting of symptoms and bothersomeness in 
interpreting the results of studies using common questionnaires. It is likely 
that the use of symptom scores will conceal this variation, necessitating 
either the consideration of individual symptoms (as in the ICS-'BPH' 
questionnaire) or the development of country-specific scoring systems. An 
alternative would be to focus on bother, which appeared much less 
sensitive to international differences. 
In chapter 3, the relationship between a wide range of symptoms 
from the ICS-'BPH' questionnaire and the results of urodynamic pressure-
flow studies was reported in 933 patients participating in the ICS-'BPH' 
study who had évaluable pressure-flow studies. It was confirmed that 
there was little or no correlation between a wide range of storage and 
voiding symptoms and the results of pressure-flow studies. Subjective and 
objective micturition variables measure different aspects of the clinical 
condition that should be viewed separately in the evaluation and treatment 
decision of the patient presenting with LUTS. 
In chapter 4, a study is reported in 150 patients who were sub-
jected to a standardized screening program including l-PSS, transrectal 
ultrasound of the prostate with ultrasonographic measurement of the 
transition zone volume of the prostate and urodynamic investigation with 
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pressure-flow study. There were very small differences between the 
correlations of total prostate volume, transition zone volume and transition 
zone index and symptoms as well as free flow and pressure-flow variables. 
Obviously, symptoms and bladder outlet obstruction are mainly determined 
by other factors than prostate and, specifically, transition zone volume. 
In chapter 5, a computerized method of validation of 
uroflowcurves, developed for clinical research purposes, was described. 
For the validation process of this computerized method of uroflow vali-
dation, we used 90 randomly chosen flows with different types of artifacts 
from 35 patients out of 9 centres participating in a clinical trial with 
alfuzosin. These flows were scanned into a computer whereafter auto-
mated artifact detection and correction was performed according to pre-
established rules implemented in the software. The results were compared 
with the manual artifact correction by three experts who used the same 
artifact detection and correction rules as implemented in the software. 
When comparing the results of the experts, a considerable interobserver 
variation was shown. The variability of the maximum flow values after 
computerized artifact correction was less than the variability of the 
maximum flow values reproduced by the flowmeter and also less than the 
variability of the manually corrected flows. This may lead to lower sample 
size requirements especially in studies where the primary objective is to 
assess a small (± 1 ml/s) difference in mean maximum flow between 
groups. 
In chapter 5, a new portable home-based uroflowmetry system was 
used to investigate variability and circadian changes of uroflow. The first 
manuscript introduces the portable home-based uroflowmetry system: P-
flow®. A total of 67 patients used the home-based uroflowmeter and the 
results were compared with uroflowmetry in the out-patient department. 
There was a good correlation between the uroflow results obtained when 
voiding at home and at the out-patient department. The highest measured 
maximum flow and voided volume were obtained with the home-based 
uroflowmeter system. However, the mean of all consecutive home-based 
maximum flow and voided volume measurements were lower than those 
obtained by single-void uroflowmetry in the out-patient department. This 
was not surprising because the sole aim at the out-patient department was 
to have the bladder as full as possible, while at home the timing of 
micturition was related to other daily activities. It was concluded that 
home-based uroflowmetry provides reliable voiding results which are 
comparable with those obtained in the out-patient department. However, 
when multiple samples are available the problem arises which sample(s) 
should be used for the evaluation particularly if the reported circadian 
211 
Summary and conclusions 
changes are of clinical relevance. 
These circadian changes of uroflow have been evaluated in the 
second manuscript dealing with the portable home-based uroflowmetry 
system. A total of 170 patients with lower urinary tract symptoms sugges-
tive of bladder outlet obstruction used a home-based uroflowmeter and 
produced a total of 1670 correctly measured flows at home. These 
patients also underwent a screening program with free urinary flowmetry 
in the hospital and a urodynamic pressure-flow study. It appeared that, in 
all obstruction categories, the mean voided volume of the flow produced 
between midnight and 6 h a.m. was significantly greater compared with 
the flows produced in the afternoon and evening. The smallest mean 
voided volume at home is produced in the afternoon. Despite this signifi-
cantly smaller voided volume in the afternoon, the maximum flow pro-
duced at home in the afternoon in moderately and severely obstructed 
patients was significantly greater than that produced in the morning. It 
was concluded that the circadian rhythm of uroflow has to be taken into 
account in the evaluation of the efficacy of treatment, especially in 
obstructed patients. 
In chapter 6-8, the impact of noninvasive, minimally invasive and 
invasive treatments on subjective and objective micturition variables was 
quantified and compared within groups with various degrees of bladder 
outlet obstruction (BOO). 
In chapter 6, the physiological variability of symptoms and pres-
sure-flow study variables was assessed in 121 patients who underwent 
clinical and urodynamic pressure-flow study evaluation before and after a 
period of 6 months of watchful waiting. It was demonstrated that, after 6 
months of watchful waiting, patients without BOO experienced statistically 
significant but slight symptomatic improvement. Symptoms of patients 
with obvious BOO did not improve significantly. From a clinical and diag-
nostic viewpoint, the reproducibility of mean pressure-flow study results 
after 6 months of watchful waiting was evident. However, there was an 
important intra-individual variability. Patients with extreme values at the 
initial pressure-flow study tended to experience regression towards the 
mean of the population at the second evaluation. Patients with obvious 
BOO showed a significant decrease in detrusor pressure at maximum flow 
of 14 cm. water, a significant decrease of urethral resistance factor of 7 
cm. water and a significant decrease of 1 obstruction class on the linear 
passive urethral resistance relation nomogram, indicating less severe BOO. 
It was concluded that mean differences among therapy groups must be 
regarded critically, particularly when the reported differences are slight and 
possibly within their physiological variability. It was also concluded that 
due to the physiological variability caused by the dynamic component of 
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obstruction, any clinical trial evaluating a new treatment modality should 
include a control arm that allows quantification of this physiological 
variability. 
Chapter 7 dealed with the results of terazosin treatment in patients 
with LUTS. The first manuscript describes the long-term efficacy and 
safety of terazosin in 427 symptomatic patients who started terazosin in 
the International Terazosin Trial (ITT), a clinical trial in which 33 centres in 
13 countries enrolled patients with an initial total l-PSS of 12 or more. 
After a 2-week, no-treatment lead-in period and a 26-week, single-blind 
treatment period, patients responding to terazosin were randomly assigned 
to receive either terazosin or placebo for a 24-week, double-blind with­
drawal period. During follow up, patients were evaluated with symptom 
scores and uroflowmetry at the out-patient department. During the single-
blind period, symptoms, quality of life score and maximum flow improved 
significantly. During the double-blind withdrawal period, symptoms, quality 
of life score and maximum flow deteriorated significantly in the placebo 
group compared with the group that continued terazosin. The deterioration 
in the placebo group did not, however, return to baseline, suggesting that 
1) there is variability in the evolution of LUTS (symptoms fluctuate over 
time and patients have a high chance to enter the trial when they experi­
ence a period with severe LUTS), 2) there is a continuing placebo effect, 
and 3) the full effect of withdrawal of terazosin takes longer than 24 
weeks. Another more speculative suggestion could be that 6 months of 
σ1 -blockade might reduce the sensitivity of the σ-adrenergic receptor. 
The second manuscript described the group of patients participat­
ing in the ITT in the university hospital Nijmegen. Besides the follow up 
investigations as described before, these patients also underwent a 
urodynamic pressure-flow study at baseline and at week 26 of treatment. 
Terazosin treatment resulted in symptomatic relief and improved urinary 
flow in patients with and without BOO and in significant improvement in 
patients with urodynamically proven obstruction. Patients without 
urodynamically proven obstruction showed no significant urodynamic 
changes. Ironically, the group with the highest percentage of patients 
showing slight improvements in free flow and symptoms had no 
urodynamic obstruction. This finding suggested that the way we are used 
to analyze efficacy in the majority of pharmacotherapy studies for patients 
with LUTS (that is improvements in symptoms and maximum free urinary 
flow) is not entirely representative of the urodynamic mechanism of action. 
The third manuscript described the results of treatment in 97 
symptomatic patients treated with terazosin in the university hospital 
Nijmegen. Of the 97 patients who started with terazosin, 60 completed 6 
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months of treatment and were reevaluated with l-PSS, uroflowmetry and 
urodynamic investigation with pressure-flow study analysis. The clinical 
and urodynamic changes within and between the groups with and without 
BOO were evaluated. Patients with a hypo-active detrusor were more 
prone to early drop out. Overall, terazosin resulted in significant sympto­
matic relief (9 points on the l-PSS scale, ρ < 0.01) and a significant 
improvement of free urinary flow (3.0 ml/s; ρ < 0.01). In patients with 
BOO, a statistically significant improvement of all urodynamic obstruction 
variables (p < 0.01) was shown. In patients without BOO, a significant 
improvement of free urinary flow (4.4 ml/s; ρ < 0.01), a statistically 
significant improved bladder capacity (increase of 70 ml; ρ = 0.01) and no 
statistically significant changes in urodynamic obstruction variables (p > 
0.05) were shown. When comparing the changes of symptoms (p = 
0.89), quality of life (p = 0.85) and the number of patients with improve­
ments of free uroflow &: 30 % (p = 0.15), there appeared to be no 
significant difference between the groups with and without BOO. It was 
concluded that although there is a statistically significant difference in 
urodynamic response to terazosin treatment between patients with and 
without BOO, we cannot recommend the use of pressure-flow studies in 
the selection of patients for terazosin treatment because the clinical results 
of treatment appeared not to be significantly different between patients 
with and without BOO. It seemed more useful and it would certainly be 
less expensive and less invasive to start σ1 blocker therapy if, on clinical 
grounds, the urologist considers the patient to be a candidate for σ1 
blocker therapy and to continue therapy in those who respond. 
In chapter 8, the symptomatic and urodynamic effects of the 
noninvasive treatment modalities described in chapter 6 and 7 as well as the 
transurethral microwave thermotherapy (TUMT), transurethral laser ablation of 
the prostate and transurethral resection of the prostate (TURP) were quan­
tified in a total of 574 patients who completed 6 months of treatment and 
were reevaluated with l-PSS, uroflowmetry and a urodynamic pressure-flow 
study at 6 months after (starting) treatment. The analysis was stratified 
according to the degree of obstruction and the subjective and objective 
changes after (starting) treatment were compared between obstruction 
groups. For each treatment modality, symptomatic improvement did not differ 
significantly among the different obstruction classes. Urodynamic changes 
were more marked in the minimally invasive treatment groups compared to 
the non-invasive treatment groups. Specifically, the urodynamic effects in the 
laser treated group appeared to be greater than in the TUMT treated group 
and in the severely obstructed patients the greatest urodynamic improvement 
was obtained with TURP. It was concluded that in patients with LUTS, 
independent from the treatment chosen, symptomatic improvement in the 
short-term does not seem to depend on changes in urodynamic parameters. 
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Future perspectives 
Lower urinary tract symptoms (LUTS) are common in men older 
than 50 years of age.1 By the year 2000, more than 600 million of the 
elderly population will be over 60 years of age and two thirds of them will 
be living in the developed countries. This demographic shift has significant 
implications for the planning and delivery of services for men with LUTS in 
the coming decades. The observation that the prevalence of LUTS in the 
community is greater than the number of men who seek medical or 
surgical help1 , 2 confirms that the perception of LUTS is a personal matter 
that could be dissimilar among men in different age groups and various 
environmental and socio-demographic circumstances. The high prevalence 
of undiagnosed and untreated LUTS in combination with the fact that the 
prevalence of LUTS in the aging community in the developed countries is 
likely to increase, suggests that costs related to the treatment of LUTS 
could escalate considerably as public awareness of the problem increases. 
LUTS in the individual man can have diverse etiologies. They may 
originate from intravesical bladder outlet obstruction caused by the 
enlarged prostate gland, but also from motor or sensory abnormalities of 
detrusor and urethral function,3 or even from changes in habits and 
lifestyle that commonly occur as men age. 
Also the current treatment modalities for the individual man with 
LUTS are diverse. Transurethral resection of the prostate is no longer the 
sole treatment option available. Presently, watchful waiting and a variety 
of medical, minimally invasive and surgical approaches exist for the man 
with LUTS. With regard to medications, there are the σ1-adrenergic 
antagonists (alfuzosin, doxazosin, tamsulosin and terazosin) and the 5-σ-
reductase inhibitors (finasteride). The minimally invasive procedures that 
are now available include transurethral incision of the prostate, laser 
ablation of the prostate, transurethral thermotherapy and there are a 
number of new approaches now under development and being investi­
gated. The most commonly used surgical approaches today are 
transurethral resection of the prostate and transabdominal prostatectomy. 
Although thè most invasive, these latter operations have the greatest 
efficacy. 
The question now is how we will be able to further optimize the 
diagnostic evaluation so that the most optimal treatment for the individual 
man with LUTS can be selected. Before focusing on optimalisation of the 
diagnostic evaluation, we have to decide what are the most important 
aspects associated with the clinical condition of the man with LUTS we 
want to treat. Are we mainly interested in improving symptoms or should 
the aim of treatment be relieving urodynamically proven obstruction ? 
In chapter θ it was shown that the symptomatic change on the 
short term was not significantly different among groups with different 
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degrees of obstruction. From this observation one may conclude that if we 
are only interested in relieving symptoms on the short term, we do not 
have to perform a comprehensive evaluation including urodynamic investi­
gation with pressure-flow analysis. It may be sufficient to exclude cancer 
and to inform the patient of the potential symptomatic benefits and side 
effects associated with the treatment options available. When the main 
aim of treatment is to relieve symptoms, a large placebo factor has to be 
taken into account.46 When consulting the man with LUTS about the 
probability of symptomatic improvement, the practising urologist may use 
the guidelines published by the Agency for Health Care Policy and 
Research which indicate the median probabilities for symptomatic improve­
ment following various treatments.6 These guidelines suggest that 
transurethral resection of the prostate results in considerable higher 
symptomatic improvement (88 %, 95 confidence interval 75-96 %) than 
σΐ-andrenergic antagonists (74 %) and watchful waiting (42 % ) . 6 Other 
studies suggest that one quarter of men fail to improve symptomatically 
following a transurethral resection of the prostate6,7 and this percentage 
may be greater when less invasive therapies are used. 
Several studies have attempted to identify the individuals who are 
more likely to have poorer symptomatic outcomes than others. With symp­
toms alone it is not possible to identify these patients but other variables 
such as a small prostate volume, low detrusor pressures, bladder instability 
and urge incontinence are obviously associated with a poor outcome as a 
result of surgery.8,7 
If the aim is to optimize the diagnostic evaluation so that the most 
optimal treatment for the individual can be selected, it is clear that taking 
into account symptoms only is not sufficient. We have to focus on reliev­
ing urodynamic proven bladder outlet obstruction. With the results of 
pressure-flow studies we are now able to identify patients who are at risk 
for a poor outcome after surgery and transurethral microwave 
thermotherapy of the prostate.ββ Furthermore, with urodynamic pressure-
flow studies we may be able to predict the durability of symptomatic 
improvement (chapter 8) and failure rates may be reduced if only patients 
with bladder outlet obstruction are subjected to therapy.9 The question 
arises whether we have to perform an invasive urodynamic pressure-flow 
study in every man with LUTS who needs therapy. The answer is probably 
no. With less invasive investigations, we may also be able to predict 
whether a man with LUTS has bladder outlet obstruction or not. Reynard 
et al indicated that the specificity and positive predictive value of maxi­
mum flow for predicting bladder outlet obstruction was significantly 
improved by multiple free-flow measurements in the out patient clinic.10 If 
217 
Future perspectives 
the highest maximum flow after 3 voidings was less than 10 ml/s, the 
specificity and positive predictive values for bladder outlet obstruction 
were 90 and 94 % respectively. We agree with Reynard that multiple free­
flow measurements are most efficient for an accurate assessment.10 
Home-based uroflowmetry in this respect is a more convenient tool than 
collecting flows at the out-patient clinic (chapter 5). Rosier et al in a 
retrospective study showed that with the help of a combination of objec­
tive noninvasive measurements (total prostate volume, maximum flow, 
post-void residual volume and voided volume), it was possible to 
distinguish between groups of patients with and without bladder outlet 
obstruction.11 Whether a combination of objective noninvasive measure­
ments is sensitive and specific enough to accurately predict the presence 
of bladder outlet obstruction in the individual patient needs to be con­
firmed. 
Future analyses of studies such as the International Continence 
Society - 'Benign Prostatic Hyperplasia' study12 may be able to provide 
vital information on the relative potential of urodynamic and other clinical 
parameters to predict a favourable response to current and innovative 
treatments. 
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Samenvatting 
Het klinische belang en de plaats van subjectieve en objectieve 
mictie variabelen bij de diagnostiek van patiënten met lagere urineweg-
symptomen wordt in hoofdstuk 2-5 beschreven. 
In hoofdstuk 2 worden internationale verschillen in de prevalentie 
van lagere urinewegsymptomen en gerelateerde hinder onderzocht door de 
gegevens van 1271 patiënten uit 12 landen die deelnamen aan de Interna-
tional Continence Society - 'Benign Prostatic Hyperplasia' (ICS-'BPH') 
studie te analyseren. Eerder onderzoek met de Internationale Prostaat 
Symptoom Score (l-PSS) vragenlijst had al aangetoond dat de ernst van de 
symptomen sterk correleert met de ernst van de symptoom gerelateerde 
hinder. Uit dit onderzoek met de ICS-'BPH' vragenlijst blijkt echter dat de 
meest frequent gerapporteerde symptomen niet persé als de meest hinder-
lijke worden ervaren. De meest frequent gerapporteerde symptomen bleken 
de symptomen te zijn geassocieerd met de ontledigingsfase van de blaas, 
de meest hinderlijke symptomen bleken de symptomen geassocieerd met 
de vullingsfase van de blaas en met incontinentie. Land van herkomst 
bleek significant geassocieerd met de prevalentie van de helft van de 
gemeten symptomen, geassocieerd met de vullingsfase en de ontledigings-
fase van de blaas. Door middel van logistische regressie werd er nagegaan 
wat de invloed was van een reeks potentiële verstorende variabelen op de 
associatie van land van herkomst en de prevalentie van ieder symptoom en 
symptoom gerelateerde hinder. De invloed van deze potentiële verstorende 
variabelen bleek klein te zijn. In tegenstelling tot de associatie van land van 
herkomst en de prevalentie van symptomen bleek de associatie van land 
van herkomst met de symptoom gerelateerde hinder echter veel minder 
duidelijk te zijn. De weinige symptomen waarbij er een significante associa-
tie was tussen land van herkomst en symptoom gerelateerde hinder waren 
symptomen gerelateerd aan de ontledigingsfase van de blaas. Geconclu-
deerd werd dat de resultaten van studies in bepaalde landen niet zonder-
meer geëxtrapoleerd kunnen worden naar andere landen. Bij de interpre-
tatie van de resultaten van internationale studies waarbij algemene vragen-
lijsten worden gebruikt, is het van belang rekening te houden met de 
internationale verschillen in de selectie van patiënten en het melden van 
symptomen en gerelateerde hinder. Tevens is het waarschijnlijk dat het 
gebruik van symptoom scores (de som van de antwoorden op vragen die 
betrekking hebben op de ontledigingsfase en de vullingsfase en evt. ook 
incontinentie) deze variatie maskeert. Dit benadrukt het belang om indivi-
duele symptomen te beschouwen (zoals in de ICS-'BPH' vragenlijst) ofwel 
land-specifieke scoringssystemen te ontwikkelen. Een alternatief hiervoor 
zou kunnen zijn de analyse te concentreren op symptoom gerelateerde 
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hinder welke veel minder gevoelig bleek voor internationale verschillen. 
In hoofdstuk 3 wordt de relatie onderzocht tussen een groot aantal 
symptomen van de ICS-'BPH' vragenlijst en de resultaten van urody-
namische druk-flow metingen door de gegevens van 933 patiënten met 
evalueerbare urodynamische studies die deelnamen aan de ICS-'BPH' 
studie te analyseren. Bevestigd werd dat er géén of een slechte correlatie 
bestaat tussen symptomen die geassocieerd zijn met de ontledigingsfase 
of de vullingsfase van de blaas en de resultaten van urodynamische 
studies. Subjectieve en objectieve mictie variabelen kwantificeren verschil-
lende aspecten van de klinische conditie en moeten afzonderlijk be-
schouwd worden bij de diagnostiek en behandelingsindicatie van patiënten 
met lagere urineweg symptomen. 
In hoofdstuk 4 wordt een studie beschreven waarbij 150 patiënten 
een gestandaardiseerd onderzoekprogramma met de l-PSS vragenlijst, 
transrectaal echografisch onderzoek van de prostaat met meting van het 
volume van de transition zone van de prostaat en urodynamische druk-flow 
metingen, ondergingen. Er waren zeer kleine verschillen tussen de correla-
ties van totaal prostaat volume, het transition zone volume en de transition 
zone index enerzijds en symptomen, de resultaten van de vrije urinestraal-
meting en de urodynamische druk-flow studies anderzijds. Deze correlaties 
waren indien zij statistisch significant waren nog maar matig. Kennelijk 
worden symptomen en blaasuitgangsobstructie voornamelijk bepaald door 
andere factoren dan het totale prostaat volume danwei het transition zone 
volume. 
In hoofdstuk 5 wordt ingegaan op de grote variabiliteit van vrije 
urinestraalmetingen en gezocht naar verklarende factoren hiervoor. In 
hoofdstuk 5.1 wordt een gecomputeriseerde methode voor het automa-
tisch detecteren en corrigeren van artefacten van vrije urinestraalmetingen 
gepresenteerd die ontwikkeld is voor klinische research doeleinden. Voor 
het proces van validatie werden 90 at random gekozen urinestraalmetingen 
met verschillende artefacten van 35 patiënten uit 9 verschillende centra 
die deelnamen aan een klinisch onderzoek met alfuzosine gebruikt. Deze 
urinestraalmetingen werden gescanned in de computer waarna auto-
matische artefact detectie and correctie werd uitgevoerd volgens tevoren 
vastgestelde regels die geïmplementeerd waren in de software. De resulta-
ten werden vergeleken met de handmatige artefact correctie door 3 
experts die dezelfde artefact detectie en correctie regels gebruikten als die 
geïmplementeerd waren in de software. Bij de vergelijking van de resulta-
ten tussen de 3 experts bleek er een belangrijke inter-expert variatie te be-
staan. De variabiliteit van de maximale urinestraal waarden na automati-
sche artefact correctie was minder dan de variabiliteit van de maximale 
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urinestraal waarden die direct afkomstig waren van de urinestraalmeter en 
tevens minder dan de variabiliteit van de - door de experts - handmatig 
gecorrigeerde urinestraalmetingen. Deze geringere variabiliteit kan resulte-
ren in kleinere aantallen benodigde patiënten, vooral in studies waarbij het 
voornaamste doel is een klein ( ± 1 ml/s) verschil in de gemiddelde 
maximale urinestraal waarden tussen groepen aan te tonen. 
In hoofdstuk 5.2 on 5.3 wordt een nieuw systeem voor thuis-
flowmetrie gebruikt om de variabiliteit en circadiane veranderingen van de 
kracht van de urinestraal in kaart te brengen. Het eerste manuscript (H 
5.2) introduceert de draagbare thuis-flowmeter: P-flow*. 67 Patiënten 
gebruikten de thuis-flowmeter en de resultaten werden vergeleken met de 
resultaten zoals die op conventionele wijze verkregen waren: d.m.v. een 
urinestraalmeting m.b.v. een urinestraalmeter op de polikliniek. Er bleek 
een goede correlatie te bestaan tussen de resultaten die verkregen waren 
door gebruik van de thuis-flowmeter en de resultaten zoals die op conventi-
onele wijze ter beschikking waren gekomen. De grootst gemeten kracht 
van de urinestraal en het grootste geplaste volume werden gemeten met 
de thuis-flowmeter. Echter, het gemiddelde van alle achtereenvolgende 
urinestraalmetingen was lager dan dat van de urinestraalmetingen in het 
ziekenhuis. Dit was niet verbazingwekkend want de patiënten worden, 
indien zij een urinestraalmeting in het ziekenhuis moeten ondergaan, 
geadviseerd te komen met een zo vol mogelijke blaas, terwijl thuis het 
tijdstip van de mictie gerelateerd is aan andere, dagelijkse, activiteiten. Eén 
van de voornaamste conclusies was dat d.m.v. thuis-flowmetrie betrouw-
bare urinestraalmetingen gegenereerd kunnen worden die vergelijkbaar zijn 
met de urinestraalmetingen in het ziekenhuis. Echter, wanneer vele urine-
straalmetingen beschikbaar zijn ontstaat het probleem welke urinestraalme-
tingen nu gebruikt moeten worden voor de evaluatie van het effect van 
een mogelijke behandeling, vooral als er een klinisch relevant circadiaan 
ritme van de kracht van de urinestraal bestaat. 
Deze circadiane veranderingen in de kracht van de urinestraal 
worden beschreven in het tweede manuscript (H 5.3) dat betrekking heeft 
op de thuis-flowmeter. 170 Patiënten met lagere urineweg symptomen 
gebruikten de thuis-flowmeter en produceerden in totaal 1670 correct 
gemeten urinestraalmetingen thuis. Deze patiënten ondergingen tevens een 
gestandaardiseerd screeningsprogramma dat bestond uit de l-PSS vragen-
lijst, een conventionele urinestraalmeting in het ziekenhuis en een urodyna-
mische druk-flow meting. Het bleek dat bij alle obstructie categorieën het 
gemiddelde volume van de urinestraalmeting tussen middernacht en 6 h 's 
morgens significant groter was vergeleken met de urinestraalmetingen 
geproduceerd gedurende de middag of avond. Het kleinste gemiddelde 
volume thuis werd geproduceerd gedurende de middag. Ondanks dit 
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significant kleinere volume gedurende de middag was de kracht van de 
urinestraal bij patiënten met een matige en ernstige blaasuitgangsobstruc-
tie 's middags significant groter dan die geproduceerd gedurende de 
ochtend. De voornaamste conclusie was dat circadiane veranderingen van 
de kracht van de urinestraal van belang zijn en dat met deze veranderingen 
rekening gehouden dient te worden bij de evaluatie van de effectiviteit van 
een behandeling, vooral bij patiënten met een matige of ernstige blaasuit-
gangsobstructie. 
In hoofdstuk 6-8, worden de subjectieve en objectieve resultaten 
van niet-invasieve en minimaal invasieve behandelingen gekwantificeerd en 
vergeleken tussen groepen patiënten met verschillende mate van blaasuit-
gangsobstructie. 
In hoofdstuk 6 wordt de fysiologische variabiliteit van symptomen 
en de resultaten van urodynamische druk-flow metingen gekwantificeerd 
door de gegevens van 121 patiënten die zowel klinisch als urodynamisch 
geëvalueerd werden vóór en 6 maanden ná een periode van waakzaam 
afwachten te analyseren. Deze studie toonde ons dat na 6 maanden 
waakzaam afwachten patiënten zonder blaasuitgangsobstructie symptoma-
tisch statistisch significant verbeterden. De verbetering was echter gering 
en klinisch irrelevant. Symptomen van patiënten met ernstige blaasuit-
gangsobstructie veranderden niet significant. De reproduceerbaarheid van 
de gemiddelden van de urodynamische druk-flow variabelen was goed. 
Echter, er was een belangrijke variabiliteit tussen groepen patiënten met 
verschillende mate van blaasuitgangsobstructie. Bij de urodynamische 
evaluatie na 6 maanden neigden patiënten met extreme waarden bij de 
initiële druk-flow meting naar een regressie naar het gemiddelde van de 
onderzoekspopulatie: bij patiënten met een initiële evidente blaasuitgangs-
obstructie bleek na 6 maanden een significante verbetering van de detrusor 
druk bij maximale urinestraal van gemiddeld 14 cm. water, een significante 
verbetering van de urethrale resistance factor van gemiddeld 7 cm. water 
en een significante vermindering van gemiddeld 1 obstructie klasse (L-
PURR), te bestaan hetgeen impliceert dat er, bij deze categorie patiënten, 
na 6 maanden waakzaam afwachten minder blaasuitgangsobstructie 
gemeten wordt. De belangrijkste conclusie was dat gemiddelde subjectief 
en objectief gemeten resultaten van behandelingen tussen behandelgroe-
pen kritisch beschouwd dienen te worden vooral als de waargenomen 
verschillen klein zijn en mogelijk vallen binnen de fysiologische variabiliteit. 
Door deze aanzienlijke fysiologische variabiliteit die waarschijnlijk veroor-
zaakt wordt door de dynamische component van obstructie werd aanbevo-
len om bij ieder klinisch onderzoek waarbij het effect van een specifieke 
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behandeling in kaart wordt gebracht, een controle arm op te nemen zodat 
het mogelijk is deze fysiologische variabiliteit te kwantificeren. 
In hoofdstuk 7 worden de resultaten van behandeling van patiënten 
met lagere urineweg symptomen met terazosine in kaart gebracht. Het 
eerste manuscript (H 7.1) beschrijft de lange termijn resultaten van 
behandeling met terazosine bij 427 patiënten die deelnamen aan de 
Internationale Terazosine Trial (ITT), een klinische trial waarin 33 centra in 
13 landen patiënten recruteerden met een initiële l-PSS score van 12 of 
meer. Na een 2 weken durende inloop periode waarin geen behandeling 
gegeven werd, volgde een 26 weken durende periode waarbij de patiënt, 
single-blind (de arts maar niet de patiënt weet dat de patiënt met terazosi-
ne behandeld wordt), met terazosine behandeld werd. Patiënten die goed 
op de behandeling reageerden werden na 26 weken gerandomiseerd voor 
een 24 weken durende periode waarbij de patiënt dubbel-blind (noch de 
arts, noch de patiënt weet of er met placebo of met terazosine behandeld 
wordt) ofwel de behandeling met terazosine continueerde danwei in plaats 
van terazosine met placebo werd behandeld. Tijdens de single-blind 
periode, verbeterden symptomen, de kwaliteit van leven score en de kracht 
van de urinestraal significant. Tijdens de dubbel-blinde periode verslech-
terden symptomen, de kwaliteit van leven score en de kracht van de 
urinestraal significant in de groep patiënten die met placebo behandeld 
werd maar niet in de groep patiënten die met terazosine behandeld werd. 
De verslechtering van variabelen in de placebo behandelde groep echter, 
was niet zodanig dat de initiële waarden weer bereikt werden. Deze 
bevindingen suggereren dat 1 ) er een variabiliteit bestaat in de evolutie van 
lagere urineweg symptomen (symptomen fluctueren in de tijd en patiënten 
hebben een grotere kans om in een slechte periode in een klinische trial te 
belanden), 2) er bestaat een voortdurend placebo effect, en 3) het duurt 
langer dan 24 weken voordat het effect van 26 weken behandeling met 
terazosine is verdwenen. Een andere meer speculatieve verklaring is dat 6 
maanden van σ1 -blokkade mogelijk de gevoeligheid van de σ-adrenerge 
receptor vermindert. 
Het tweede manuscript (H 7.2) beschrijft de resultaten van de 
groep patiënten die deelnamen aan de ITT in het St. Radboud Ziekenhuis te 
Nijmegen. Behalve de follow up zoals hiervoor beschreven werden deze 
patiënten zowel vóór als 26 weken ná de start met terazosine, middels 
urodynamische druk-flow metingen, geëvalueerd. Behandeling met terazo-
sine resulteerde in symptomatische verbetering en een verbetering van de 
kracht van de urinestraal zowel bij patiënten met als bij patiënten zonder 
blaasuitgangsobstructie. Bij patiënten zonder urodynamisch aangetoonde 
blaasuitgangsobstructie konden geen significante veranderingen van de 
urodynamische obstructie variabelen aangetoond worden. Ironisch genoeg 
226 
was het juist de groep zonder blaasuitgangsobstructie die het hoogste 
percentage patiënten met kleine verbeteringen van de kracht van de urine-
straal en symptomen had. Deze bevinding suggereert dat de wijze waarop 
we de effectiviteit van een behandeling met geneesmiddelen evalueren 
(verbeteringen van symptomen en de kracht van de urinestraal) niet 
afhankelijk is van het urodynamisch meetbare effect van de behandeling. 
Het derde manuscript (H 7.3) beschrijft de resultaten van behande-
ling met terazosine bij 97 patiënten met lagere urineweg symptomen in het 
St. Radboud Ziekenhuis te Nijmegen. Van de 97 patiënten die startten met 
terazosine, completeerden 60 de 6 maanden behandeling waarna zij 
opnieuw werden geëvalueerd met de l-PSS vragenlijst, urinestraalmeting en 
een urodynamisch druk-flow onderzoek. De klinische en urodynamische 
veranderingen binnen en tussen de groepen met en zonder blaasuitgangs-
obstructie werden geanalyseerd. Patiënten zonder blaasuitgangsobstructie 
hadden een groter risico vóór 6 maanden met de behandeling te stoppen. 
In zowel de groep met als de groep zonder blaasuitgangsobstructie resul-
teerde behandeling met terazosine in significante symptomatische verbete-
ring (9 punten op de l-PSS schaal, ρ < 0.01) en een significante verbete­
ring van de kracht van de urinestraal (gemiddeld 3.0 ml/s; ρ < 0.01). Bij 
patiënten met een blaasuitgangsobstructie werd een statistisch significante 
verbetering van alle urodynamische obstructie variabelen (p < 0.01) 
aangetoond. Bij patiënten zonder blaasuitgangsobstructie werd een signifi-
cante verbetering van de kracht van de urinestraal (4.4 ml/s; ρ < 0.01), 
een statistisch significant verbeterde blaas capaciteit (toename van 70 ml; 
ρ = 0.01) en geen statistisch significante veranderingen van urodyna­
mische obstructie variabelen (p > 0.05) aangetoond. Toen de veranderin­
gen van mictie variabelen tussen de groepen met en zonder blaasuitgangs­
obstructie met elkaar vergeleken werden bleek dat er voor wat betreft 
symptomen (p = 0.Θ9), kwaliteit van leven (p = 0.85) en het aantal 
patiënten met een verbetering van de maximale urinestraal ^ 30 % (p = 
0.15), geen significante verschillen tussen deze groepen bestaan. Een van 
de conclusies van dit manuscript was dan ook dat er ondanks een signifi-
cant urodynamisch verschil tussen patiënten met en zonder blaasuit-
gangsobstructie, het gebruik van druk-flow metingen voor de selectie van 
patiënten die met terazosine behandeld moeten gaan worden niet aanbevo-
len kan worden omdat de klinische resultaten van behandeling niet signifi-
cant verschilden tussen patiënten met en zonder blaasuitgangsobstructie. 
Het lijkt zinvoller en is zeker minder invasief en minder kostbaar om σΐ 
blokker therapie te starten als de uroloog, op klinische gronden, de patiënt 
een geschikte kandidaat vindt voor a\ blokker therapie en deze behande-
ling te continueren bij diegenen die goed reageren op de behandeling (een 
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proef behandeling). 
In hoofdstuk 8 worden de symptomatische en urodynamische 
effecten van niet-invasieve vormen van behandeling zoals beschreven in 
hoofdstuk 6 en 7 samen met de minimaal invasieve vormen van behande-
ling transurethrale microgolf thermotherapie (TUMT), transurethrale laser 
ablatie van de prostaat en de transurethrale resectie van de prostaat 
(TURP) gekwantificeerd bij een totaal van 574 patiënten die 6 maanden na 
de (start van) de behandeling geëvalueerd werden met de l-PSS vragenlijst, 
urinestraalmeting en een urodynamische druk-flow studie. De analyse werd 
gestratificeerd naar de mate van initiële blaasuitgangsobstructie en de 
subjectieve en objectieve veranderingen na de (start van) de behandelingen 
werden vergeleken tussen de diverse obstructie groepen. Voor iedere vorm 
van behandeling gold dat in tegenstelling tot de urodynamisch gemeten 
verbetering, de symptomatische verbetering na 6 maanden niet significant 
verschilde tussen de diverse obstructie klassen. Urodynamische verande-
ringen waren meer uitgesproken in de minimaal invasieve behandelgroepen 
vergeleken met de groepen die met niet-invasieve vormen van behandeling 
behandeld werden. De urodynamische effecten in de met laser behandelde 
groep bleken groter te zijn dan die in de TUMT behandelde groep en bij de 
patiënten met een ernstige blaasuitgangsobstructie werd de grootste 
urodynamisch gemeten verbetering gezien bij de patiënten die met een 
TURP behandeld waren. De conclusie van dit hoofdstuk was dat, onafhan-
kelijk van de gekozen behandeling, symptomatische verbetering op de 
korte termijn niet afhankelijk lijkt te zijn van veranderingen in urodynami-
sche obstructie variabelen. 
Toekomstverwachtingen 
Lagere urineweg symptomen komen frequent voor bij mannen 
ouder dan 50 jaar.1 In het jaar 2000 zijn meer dan 600 miljoen mensen 
ouder dan 60 jaar en twee derde van hen leeft in de ontwikkelde landen. 
Deze vergrijzing heeft belangrijke gevolgen voor de planning en levering 
van de gezondheidszorg voor mannen met lagere urineweg symptomen in 
de komende jaren. Het feit dat de prevalentie van lagere urineweg sympto-
men ¡n de populatie groter is dan het aantal mensen dat medisch advies 
vraagt vanwege deze lagere urineweg symptomen1·2 bevestigt dat de 
perceptie van lagere urinewegsymptomen een individuele zaak is die kan 
verschillen tussen verschillende leeftijdscategorieën en groepen met een 
verschillende socio-demografische achtergrond. De hoge prevalentie van 
niet gediagnostiseerde en onbehandelde lagere urineweg symptomen in de 
vergrijzende bevolking van de ontwikkelde landen suggereren dat kosten 
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gerelateerd aan de behandeling van lagere urineweg symptomen snel 
kunnen escaleren indien het probleem gemakkelijker algemeen toegankelijk 
wordt. 
Lagere urineweg symptomen bij het individu kunnen verschillende 
oorzaken hebben. De meerderheid van de lagere urineweg symptomen bij 
de oudere man worden veroorzaakt door een blaasuitgangsobstructie ten 
gevolge van een vergrote prostaat. Lagere urineweg symptomen kunnen 
echter ook een gevolg zijn van motore of sensore stoornissen van de 
musculus detrusor of van de urethra,3 of zelfs van veranderingen in 
gewoonten en leefstijl die nogal eens voorkomen bij de ouder wordende 
mens. 
Ook de huidige vormen van behandeling voor de patiënt met lagere 
urineweg symptomen zijn nogal divers. Transurethrale resectie van de 
prostaat en waakzaam afwachten zijn niet langer de enig beschikbare 
opties. Vandaag de dag zijn er diverse farmacologische, minimaal invasieve 
en chirurgische vormen van behandelingen voor de patiënt met lagere 
urineweg symptomen. Met betrekking tot de farmacologische vormen van 
behandeling, zijn er de o1-adrenerge antagonisten (alfuzosine, doxazosine, 
tamsulosine and terazosine) en de 5-a-reductase inhibitoren (finasteride). 
De minimaal invasieve vormen van behandeling die op dit moment beschik-
baar zijn omvatten transurethrale incisie van de prostaat, laser ablatie van 
de prostaat, transurethrale thermotherapie en er zijn een aantal nieuwe 
minimaal invasieve vormen van behandeling die nu ontwikkeld en getest 
worden. De meest gebruikte chirurgische vormen van behandeling zijn 
transurethrale resectie van de prostaat en transabdominale prostatectomie. 
Deze chirurgische vormen van behandeling zijn het meest invasief en 
hebben de grootste effectiviteit. 
De vraag is nu hoe we in de toekomst in staat zullen zijn de dia-
gnostische evaluatie te optimaliseren zodat direct de meest optimale 
behandeling voor het individu geselecteerd kan worden. Echter, voordat de 
diagnostische evaluatie geoptimaliseerd kan worden moet eerst besloten 
worden welke de belangrijkste aspecten zijn die we willen en kunnen 
behandelen bij de patiënt met lagere urineweg symptomen. Zijn we 
hoofdzakelijk geïnteresseerd in het verbeteren van symptomen of zijn we 
met name geïnteresseerd in het verminderen van urodynamisch aangetoon-
de obstructie van de blaasuitgang ? 
In hoofdstuk 8 werd aangetoond dat, bij een aantal niet-invasieve 
en minimaal invasieve vormen van behandeling, in tegenstelling tot de 
urodynamisch gemeten verbetering, de symptomatische verbetering na 6 
maanden niet significant verschilde tussen de diverse obstructie klassen. 
Op grond van deze waarneming zouden we kunnen concluderen dat, indien 
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we hoofdzakelijk geïnteresseerd zijn in het verbeteren van symptomen op 
de korte termijn, we geen invasief urodynamisch druk-flow onderzoek 
hoeven te verrichten. Het is voldoende om een prostaatcarcinoom uit te 
sluiten en de patiënt te informeren over de potentiële symptomatische 
voordelen en bijwerkingen van de beschikbare vormen van behandeling. 
Als het verbeteren van symptomen het belangrijkste doel is van de behan-
deling, moeten we ons ervan bewust zijn dat symptomen ook significant 
verbeteren door behandeling met een placebo.46 Richtlijnen die gebruikt 
kunnen worden wanneer de patiënt met lagere urineweg symptomen 
geadviseerd wordt over de te verwachten symptomatische verbetering na 
de beschikbare behandelingen zijn de richtlijnen gepubliceerd door de 
Agency for Health Care Policy and Research.6 Deze richtlijnen suggereren 
dat transurethrale resectie van de prostaat resulteert in een aanzienlijk 
betere symptomatische verbetering (88 %, 95 betrouwbaarheids interval 
75-96 %) dan σΐ-adrenerge antagonisten (74 %) en waakzaam afwachten 
(42 % ) . 6 Andere studies suggereren dat een kwart van de patiënten na een 
transurethrale resectie van de prostaat niet symptomatisch verbeteren.e·7 
en dit percentage zou groter kunnen zijn na minder invasieve vormen van 
behandeling. 
Velen hebben getracht patiënten te selecteren die een grote kans 
hebben niet voldoende op de behandeling te reageren. Met symptomen 
alleen zijn deze patiënten niet te selecteren, maar andere variabelen zoals 
een klein prostaat volume, lage detrusor drukken, blaas instabiliteit en urge 
incontinentie zijn duidelijk geassocieerd met een slecht resultaat na chirur-
gische behandeling."·7 
Als het doel is de diagnostiek te optimaliseren zodat de optimale 
behandeling voor het individu geselecteerd kan worden, is het duidelijk dat 
afgaan op een verbetering van symptomen alléén niet voldoende is. We 
zullen ons moeten richten op het verminderen van blaasuitgangsobstructie. 
Met de resultaten van urodynamische druk-flow metingen zijn we nu al in 
staat groepen patiënten te selecteren die een marginale kans hebben op 
een goed resultaat van de behandeling na chirurgie en transurethrale 
microgolf thermotherapie van de prostaat.ββ Bovendien zouden we met de 
resultaten van urodynamische druk-flow metingen in staat kunnen zijn de 
duurzaamheid van de symptomatische verbetering te voorspellen (hoofd­
stuk 8) en de kans op mislukking van de behandeling zou verder geredu­
ceerd kunnen worden indien alleen patiënten met blaasuitgangsobstructie 
behandeld zouden worden.9 De vraag rijst vervolgens of we dan een 
invasief en kostbaar urodynamische druk-flow meting bij iedere patiënt 
moeten verrichten alvorens er een behandeladvies gegeven kan worden. 
Dit zal waarschijnlijk niet nodig zijn. Met minder invasief onderzoek zijn we 
ook in staat te voorspellen of een patiënt een blaasuitgangsobstructie heeft 
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of niet. Reynard et al toonde dat de specificiteit en de positieve predictieve 
waarde van maximale flow voor het voorspellen van de aanwezigheid van 
een blaasuitgangsobstructie significant verbeterde na. meerdere vrije -
poliklinische - urinestraalmetingen.10 Indien de hoogste maximale flow na 3 
urinestraalmetingen lager is dan 10 ml/s, is de specificiteit en positieve 
predictieve waarde voor blaasuitgangsobstructie respectievelijk 90 en 94 
%. We zijn het met Reynard eens dat meerdere vrije urinestraalmetingen 
zeer efficiënt zijn om een nauwkeurige diagnose te stellen.10 Thuis-flowme-
trie is wat dit betreft meer geschikt om urinestraalmetingen te verzamelen 
dan de polikliniek (hoofdstuk 5). Rosier et al toonde in een retrospectieve 
studie dat met behulp van een combinatie van objectieve niet-invasieve 
metingen (totaal prostaat volume, maximale flow, volume van het urine-
residu en geplast volume), het mogelijk was om onderscheid te maken 
tussen groepen patiënten met en zonder blaasuitgangsobstructie.11 Of een 
combinatie van objectieve niet-invasieve metingen voldoende sensitiviteit 
en specificiteit heeft om nauwkeurig te voorspellen of de individuele 
patiënt een blaasuitgangsobstructie heeft of niet zal in de toekomst nog 
bevestigd moeten worden. 
Toekomstige analyses van studies zoals de International Continence 
Society - 'Benign Prostatic Hyperplasia' studie12 zouden ons de noodzake-
lijke informatie kunnen verschaffen of het in de toekomst mogelijk zal zijn 
om op grond van urodynamische of andere mictie variabelen bij de individu-
ele patiënt een gunstig resultaat van huidige en nieuwe vormen van 
behandeling te voorspellen. 
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Stellingen behorende bij het proefschrift 
Micturition variables in the assessment and treatment 
of patients with lower urinary tract symptoms 
door 
Wim P.J. Witjes 
Nijmegen, 21 mei 1997 
1 Good science is to find a problem difficult enough to attract 
the best minds, but central enough to attrack funds, and 
then to find the best people to work on it. James Watson 
2 The sympathetic nervous system plays an important etiolo-
gic role in hypertension, asthma and benign prostatic ob-
struction; the level of sympathetic drive reaches a peak in 
the morning, the time of the day at which most cardiovascu-
lar events occur, at which asthmatic patients have a decrea-
sed lung function and at which patients with benign prosta-
tic obstruction have the smallest maximum urinary flow, this 
thesis 
3 The most frequently reported lower urinary tract symptoms 
are associated with the voiding phase and the most bother-
some symptoms are associated with the storage phase or 
with incontinence, this thesis 
4 On the short term, in patients with severe bladder outlet 
obstruction, the urodynamic condition is more prone to 
improve than to deteriorate further regardless of the treat-
ment the physician institutes, this thesis 
5 The results of pressure-flow studies rather than symptom 
scores have an important role in predicting the efficacy of 
therapy and should therefore be used in the determination of 
the first choice of therapy, this thesis 
6 Aan de software van een pasgeboren kind moet langdurig 
geprogrammeerd worden voor een niveau van acceptabel 
functioneren bereikt wordt. 
7 Sublinguale toediening van bupenorfine op geleide van de 
behoefte van de patiënt is een goede methode voor post-
operatieve pijnstilling. 
8 Patiënten die deelnemen aan klinisch onderzoek, of zij nu de 
meest effectieve behandeling krijgen of niet, doen het in vele 
opzichten beter dan patiënten die dit niet doen. 
9 Met het traditionele gezegde: 
"'t Is van eiges gekomme en 't zal dus van eiges ok wer 
overgaon" (Oma Marie Derksen-Claassen, 1899-1992) 
geeft men aan te beschikken over inzicht in het natuurlijke 
beloop van de ziekte en de placebo werking van de hiervoor 
beschikbare geneesmiddelen. 
10 De effectiviteit van een experimentele behandeling in een 
fase 2 onderzoek wordt met name bepaald door de studie 
opzet en de selectie van patiënten. 
11 Als Laurent Fignon in 1989 de weg van de minste weerstand 
had gevolgd had hij zonder twijfel de Tour de France voor de 
derde keer op zijn naam gebracht. 
12 Hoe groter een nest des te agressiever de mier die daarvan 
deel uitmaakt. 
13 Omdat de steller van een ontkennende vraag een ontkenning 
van het tegendeel dat gevraagd wordt verwacht dient een 
dergelijke vraag niet correct beantwoord te worden. 
14 Het moet verboden worden om op de verpakking van allerlei 
cosmetica aan te geven dat het "dermatologisch getest" is, 
zonder dat ook de uitslag van die test genoemd wordt. 
Maarten van Al f en 
15 Aan het begin van invoegstroken van file gevoelige snelwe-
gen zou een verplicht ritspunt aangegeven moeten worden 
om voordringen via deze strook te voorkomen. Maarten van 
Alfen 
16 De samenwerking tussen clinici en wetenschappelijke onder-
zoekers dient krachtig gestimuleerd te worden. 



